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“Much of life can be understood in
rational terms if expressed in the language
of chemistry”
Arthur Kornberg
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RESUMEN
NUEVAS ESTRATEGIAS PARA EL TRATAMIENTO DE LA SENESCENCIA CELULAR
La senescencia celular es un proceso biológico irreversible que aparece después de
una etapa de estrés celular y detiene la proliferación de células disfuncionales o
dañadas. Las células senescentes se acumulan en nuestro cuerpo con la edad, por lo que
la regulación de este proceso podría tener un efecto importante en la esperanza de vida
y el envejecimiento. Con este fin, en el presente trabajo proponemos dos enfoques
diferentes para abordar el proceso de senescencia celular. En el primero de ellos
(Capítulo A), el objetivo es el desarrollo de inhibidores de la enzima isoprenilcisteína
carboxil metiltransferasa (ICMT) para el tratamiento de la progeria como un modelo de
envejecimiento acelerado. En la segunda aproximación (Capítulo B), teniendo en cuenta
la posible influencia que los metabolitos de la microbiota humana pueden tener en el
envejecimiento, proponemos una nueva estrategia para la identificación de los
metabolitos de la microbiota. En particular, se pretende la puesta a punto de dicha 
metodología para poder abordar un proyecto más amplio que permita el estudio
fenotípico en senescencia de los metabolitos identificados.
Capítulo A: Nuevos inhibidores de la enzima ICMT para el tratamiento de la progeria
El síndrome de progeria de Hutchinson-Gilford (HGPS, por sus siglas en inglés) o
progeria se describió por primera vez en 1886 y es una patología causada por una
mutación del gen LMNA que produce una versión aberrante de la proteína lámina A
llamada progerina, que se acumula en la membrana nuclear e induce anomalías
estructurales. Durante las últimas décadas, se han realizado grandes esfuerzos en la
búsqueda de tratamientos para la progeria, proporcionando hasta este momento solo
una eficacia moderada. En el presente trabajo hemos centrado nuestra atención en el
desarrollo de inhibidores de la enzima ICMT para el tratamiento de la progeria, debido a
evidencias existentes que muestran que el bloqueo genético de esta enzima mejora
  
          
 
    
     
       
     
      
         
         
    
   
       
         
      
        
      
   
 
       
    
 
 
Resumen
tanto in vitro como in vivo el fenotipo de la progeria. Con este propósito, y sobre la base
de un trabajo previo realizado en nuestro grupo de investigación dirigido al desarrollo de
inhibidores de la enzima ICMT para el tratamiento de tumores dependientes de la
proteína Ras, iniciamos un programa de química médica a partir del compuesto 3
(inhibidor de ICMT con capacidad citotóxica) con el objetivo de obtener nuevos
compuestos que conserven la capacidad de inhibir ICMT pero que carezcan de 
citotoxicidad (Figura 1). En este trabajo, hemos identificado el compuesto 59, el cual
mostró una buena capacidad para inhibir la enzima ICMT, no fue citotóxico, presentó un
buen perfil farmacocinético y, lo que es más importante, aumentó la viabilidad de las
células progeroides de un 41% a un excelente 93%. Este compuesto se seleccionó para el
estudio de su efecto sobre células progeroides humanas, en las que mostró una muy 
buena capacidad para mejorar la viabilidad celular, reducir el daño del ADN, estimular la
proliferación celular y reducir los niveles de progerina en la membrana nuclear. Estos
resultados resaltan la capacidad del compuesto 59 para mejorar las características
fenotípicas de la progeria, por lo que se están realizando actualmente en nuestro
laboratorio experimentos in vivo en un modelo progeroide de ratón para confirmar la
eficacia del compuesto 59 y por tanto, de un inhibidor de la ICMT para tratar la progeria.
Figura 1. Programa de química médica realizado a partir del compuesto 3 para la obtención del
compuesto 59, inhibidor de la enzima ICMT para el tratamiento de la progeria.
4
 
  
     
        
     
      
    
     
     
     
     
     
  
    
  
   
      
    
      
          
       
     
 
 
  
 
 
Resumen
Capítulo B: Identificación de nuevos metabolitos producidos por la microbiota humana
La microbiota humana es un complejo ecosistema de nuestro cuerpo que está
constituido por múltiples microorganismos que juegan un papel importante en la salud
debido a su interacción con el huésped a través de la secreción de metabolitos, que son
capaces de regular funciones biológicas. Investigaciones recientes han demostrado la
relación directa entre la microbiota humana y sus metabolitos con varias enfermedades
como el cáncer, la diabetes, los trastornos del sistema inmunológico e incluso con la
esperanza de vida y el envejecimiento. Sin embargo, debido a la complejidad del
metaboloma, la mayoría de estos metabolitos no se conocen, aunque se han descrito
varias estrategias en un intento de identificarlos. Estas evidencias muestran la necesidad
de desarrollar nuevas estrategias para la identificación de metabolitos. Para ello, en el
presente trabajo, hemos diseñado una nueva metodología que nos permitirá identificar
los metabolitos producidos por la microbiota humana. Esta plataforma metabolómica se
basa en el uso de precursores marcados de los metabolitos de la microbiota humana
(Figura 2). La realización de esta metodología implica varios pasos: i) incubación de
cepas seleccionadas de bacterias en presencia de precursores marcados para obtener
metabolitos marcados; ii) aislamiento del metaboloma; iii) captura de los metabolitos
marcados a través de una reacción bioortogonal con un reactivo de captura apropiado;
iv) aislamiento de los metabolitos capturados, y v) elucidación estructural de estos
metabolitos empleando técnicas de espectrometría de masas (EM) y resonancia
magnética nuclear (RMN).
Figura 2. Estrategia diseñada para la identificación de metabolitos de la microbiota humana.
5
 
  
       
    
    
       
     
     
       
    
      
       
   
   
         
         
      
      
        
   
  
 
 
Resumen
Como prueba de concepto, hemos llevado a cabo esta metodología utilizando azido
azúcares como precursores marcados. La incorporación de los azido azúcares se ha
evaluado en una variedad de cepas representativas de bacterias de la microbiota
humana empleando técnicas de 1H RMN y experimentos de citometría de flujo y análisis
por microscopía confocal. Estos experimentos nos han permitido confirmar qué azúcar
marcado era incorporado por qué cepa de bacterias. A continuación, para poder
capturar los azido metabolitos formados, se ha utilizado una reacción de cicloadición
azida-alquino catalizada por cobre (I). Para ello, se sintetizaron varias moléculas que
contienen en su estructura un alquino terminal. Estos reactivos de captura poseen,
además del alquino terminal, un fragmento de afinidad para aislar los metabolitos
capturados y una secuencia escindible para la liberación final del metabolito. Después
de optimizar el aislamiento de los diferentes metabolomas (paso 2, Figura 2), la reacción
bioortogonal con el reactivo de captura (paso 3, Figura 2) y el aislamiento de los
metabolitos marcados (paso 4, Figura 2), se ha abordado la identificación de los
metabolitos capturados (paso 5, Figura 2). Para poder llevar a cabo este objetivo final, se
ha realizado la plataforma completa a mayor escala con el fin de completar la
elucidación estructural de los compuestos aislados utilizando técnicas de RMN y EM,
experimentos que se están completando en la actualidad.
Este paso final constituirá la validación de la metodología propuesta para la 
identificación de los metabolitos producidos por la microbiota humana.
6
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SUMMARY
New strategies for the treatment of cellular senescence
Cellular senescence is a biological irreversible process that appears after cellular
stress and stops the proliferation of dysfunctional or damaged cells. Senescent cells are
accumulated in our body with aging, so the regulation of this process could have an
important effect in healthspan and aging. Towards this end, in the present work we
propose two different approaches. In the first one (Chapter A), the objective is the
development of inhibitors of isoprenylcysteine carboxyl methyltransferase (ICMT)
enzyme for targeting progeria as a model of accelerated aging. In the second approach
(Chapter B), and taking into account the possible influence that metabolites of the
human microbiota can have in aging, we propose an innovative strategy for the
identification of microbiota metabolites in the framework of a broader project aimed at
the phenotypic study of the identified metabolites in senescence.
Chapter A: New ICMT inhibitors for the treatment of progeria
Hutchinson-Gilford Progeria Syndrome (HGPS) or progeria was first described in 1886
and it is a pathology caused by a mutation of the LMNA gen that produces an aberrant
version of Lamin A protein called progerin, which accumulates in the nuclear envelope
inducing structural abnormalities. During the last decades, huge efforts have been done
in the search of treatments for progeria, providing up to this moment only a modest
benefit. In the present work we have focused our attention on the development of ICMT
inhibitors for the treatment of progeria, due to reported evidences showing that the
genetic blockade of this enzyme improves both in vitro and in vivo the phenotype of
progeria. For that purpose, and based on a previous work carried out in our 
investigation group aimed at the development of ICMT inhibitors for targeting Ras­
driven tumours, we have started a medicinal chemistry program starting from
compound 3 (ICMT inhibitor with cytotoxic properties) to obtain new compounds that
retain the ability to inhibit ICMT but are devoid of cytotoxicity (Figure 1). In this work, 
  
       
     
          
       
       
      
          
            
     
 
       
    
 
 
 
 
 
 
Summary
we have identified compound 59 that showed a good percentage of inhibition of ICMT, 
was not cytotoxic, presented a good pharmacokinetic profile, and importantly, was able
to improve the viability of progeroid cells from 41% to an excellent 93%. This compound
was selected for the study of its effect on human progeroid cells, being capable of
improving the cellular viability, reducing DNA damage, stimulating cellular proliferation,
and reducing the levels of progerin in the nuclear membrane. These results highlight the
capacity of compound 59 to ameliorate the hallmarks of progeria. Hence, its in vivo
efficacy in a mouse model of progeria is currently being performed in our laboratory in
order to confirm the efficacy of an ICMT inhibitor for treating progeria.
Figure 1. Medicinal chemistry program carried out starting from compound 3 to obtain
compound 59 as an ICMT inhibitor for treating progeria.
nce 
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Summary
Chapter B: Identification of new molecules produced by the human microbiota
The human microbiota is a complex ecosystem belonging to our body that is
constituted by multiple microorganisms that play an important role in human health due
to their interaction with the host through the secretion of metabolites, which are able to
regulate biological functions. Recent investigations showed a direct relationship
between the human microbiota and its metabolites with several diseases such as cancer,
diabetes, immune system disorders, and even with healthspan and aging. However, due
to the complexity of the metabolome, most of these metabolites still remain unknown, 
although several strategies have been performed in an attempt to identify them. This
context makes clear the need of new strategies for the identificacion of metabolites. For
that purpose, in the present work, we have designed a novel strategy which will allow us
to identify metabolites produced by the human microbiota. This metabolomic platform
is based on the use of tagged precursors of microbiota metabolites (Figure 2). The
fulfillment of this methodology implies several steps: i) incubation of selected strains of
bacteria in the presence of tagged precursors in order to obtain tagged metabolites; ii)
isolation of the metabolome; iii) capture of tagged metabolites through a bioorthogonal
reaction with an appropriate capture reagent; iv) isolation of captured metabolites, and
v) structural elucidation of these metabolites by mass spectrometry (MS) and nuclear
magnetic resonance (NMR).
Figure 2. Innovative strategy designed for the identification of metabolites of the human
microbiota.
11
 
  
      
        
    
     
   
        
       
  
        
    
      
       
      
      
    
    
      
    
 
Summary
As a proof of concept, we have set up this methodology using azido sugars as tagged
precursors. The incorporation of the azido sugars has been assessed in a variety of
representative strains of bacteria from the human microbiota. For that purpose, a 1H 
NMR-based screening, and fluorescence-activated cell sorting (FACS) and confocal
microscopy experiments have been carried out. These experiments have enabled us to
confirm which tagged sugar was metabolized for each strain of bacteria. Then, we used
the copper (I)-catalyzed azido-alkyne cycloaddition reaction to capture the azido
metabolites. For this purpose, several terminal alkyne containing molecules were
synthesized. These capture reagents contained, besides the terminal alkyne, an affinity
handle to isolate the captured metabolites and a cleavable sequence for the final
release of the metabolite. After optimizing the isolation of the different metabolomes
(step 2, Figure 2), the bioorthogonal reaction between them and the capture reagent
(step 3, Figure 2), and the isolation of tagged metabolites (step 4, Figure 2), we have
addressed the identification of captured metabolites. This final objective required to
carry out the entire platform in higher scale and complete the structural elucidation
using NMR and MS techniques, experiments that are currently being completed.
This final step will constitute the validation of the proposed methodology for the
identification of metabolites produced by the human microbiota.
12
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GENERAL INTRODUCTION
Cellular senescence is a biological irreversible process which rises up as a response to
cellular stress and stops the proliferation of dysfunctional or damaged cells. Hence, this
physiological process and, consequently, its regulation, can have an important role in
aging or pathologies such as cancer.1,2 Senescent cells are accumulated in several tissues
and organs with aging where they exert negative structural and functional effects due to
the components they secrete.3,4 Studies carried out by suppression of p16Ink4a, a cyclin­
dependent kinase inhibitor whose levels are increased by aging,5 showed delayed age­
dependent pathologies. These data confirmed the role of cellular senescence in
accelerating aging phenotypes and support the hypothesis that healthspan and tissue
dysfunction can be delayed by removal of senescent cells.6-8 Therefore, new therapeutic
approaches for the treatment of cellular senescence could represent attractive
alternatives for delaying age-related diseases and enhancing healthspan. Accordingly,
the development of senolytic drugs, which are compounds that induce apoptosis of
senescent cells, has been a focus of research in the recent years. In this context, in our
laboratory, we are following two parallel strategies towards this end (Figure 1): (i) a
target-driven approach, focused on the enzyme isoprenylcysteine carboxyl
methyltransferase (ICMT), whose inhibitors can delay aging, and (ii) an approach aimed
at the identification of new molecules produced by the human microbiota able to stop
or reverse cellular senescence. 
In the first approach our objective is the development of new ICMT inhibitors for the
treatment of progeria, a pathology characterized by the presence of aging symptons in
children (Chapter A). Considering that the genetic mouse knockout of ICMT improves
the phenotype of progeria,9 this disease can be used as a model of accelerated aging. 
Cells derived from progeria patients showed increased levels of senescence markers10 
  
       
      
  
            
      
    
       
   
     
       
     
     
       
  
 
   
 
 
 
 
General Introduction
and it is known that progerin expression is increased with aging in general population
non suffering from progeria.11 Hence, it is conceivable that ICMT inhibition cannot only
improve progeria, but also delay physiological senescence.
In the second approach, we aim to develop an innovative strategy to identify
metabolites produced by the human microbiota (Chapter B). The important role of
microbiota and its metabolites in different (patho)physiological processes has started to
emerge in the last decades including its relationship with senescence.12-14 These findings
strongly support the hypothesis that metabolites produced by the human microbiota
could represent a source of new molecules endowed with interesting biological
activities, and in particular in aging. However, the large complexity of the human
microbiome makes the identification of microbiota metabolites a daunting task that
cannot be successfully addressed by the current methodologies making necessary the
development of new strategies to carry out this objective, which could constitute the
first step for the development of new molecules able to stop senescent cells.
Figure 1. Proposed strategies for targeting cellular senescence.
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1. INTRODUCTION AND OBJECTIVES 
Hutchinson-Gilford Progeria Syndrome (HGPS) or progeria is a congenital and
lethal pathology characterized by the premature presence of aging symptoms in
children. The genetic basis of this illness were established in 20031,2 although it was first
originally described by J. Hutchinson3 and H. Gilford4 a century ago. The characteristic
physical symptoms associated to this illness include alopecia, prominent eyes and ears,
thin lips, small jaw, and low weight and height. Furthermore, patients suffer from
phalange and clavicle osteolysis and arteriosclerosis, which finally lead to the death of
the 90% of patients at the premature age of 13.5-7 
This illness is caused by mutations in the LMNA gene, which codifies for
prelamin A.1,2 Mutations in LMNA gene are responsible of a type of illnesses called
laminopathies, which include neuropathologies, muscular dystrophies,
cardiomiopathies, and most progeroid syndromes due to the structural role of lamins A,
B, and C in the nuclear lamin.8 Among the different lamins, nuclear lamin A is located in
the nuclear membrane and it is responsible for the form and size of the cellular nucleus.
Moreover, this protein is involved in the structural stability, organization, replication and
transcription of DNA.9 Lamin A belongs to the CAAX family of proteins. They are
characterized by a carboxyl terminal region that contains the CAAX box motif, where C is
cysteine, A is an aliphatic residue and X is one of several different amino acids. The
presence of the CAAX sequence is characteristic of a post-translational processing by
which the CAAX proteins turn into their active biologically form, in this case, lamin A
(Figure 1).10 These post-translational modifications consist in the attachment of a
farnesyl group to the cysteine residue by the farnesyltransferase (FTase) enzyme,
proteolysis of the –AAX tripeptide by Ras converting enzyme 1 (Rce1) endoprotease,
carboxymethylation of the C-terminal cysteine by isoprenylcysteine carboxyl
methyltransferase (ICMT) enzyme, and enzymatic cleavage of the terminal 15 amino
  
     
   
 
         
  
     
         
      
        
         
        
    
      
 
  
      
    
    
       
     
   
           
      
Introduction and objectives
acids, including the farnesylated cysteine, by Rce1 or Zinc metalloprotease STE24
(ZMPSTE24) endoprotease.
Figure 1. The nuclear prelamin A post-translational processing in normal and HGPS cells. Taken
from Annu. Rev. Genom. Hum. G. 2009, 10, 153-174.
In progeria, the majority of the cases are caused by the mutation G608G, which
is responsible for the substitution of a glycine coming from a GGC triplet by a glycine
coming from a GGT triplet. This mutation produces a mRNA 150 nucleotides shorter. Its
translation creates a mutated form of lamin A, called progerin, with 50 aminoacids less
in its terminal carboxyl group that cannot be post-translationally processed in the
correct manner due to the absence of the cleavage site of the terminal 15 amino acids. 
Therefore, this permanently farnesylated uncleaved and methylated progerin is
abnormally accumulated in the nuclear membrane triggering, by yet-to-be discovered
mechanisms, the many cellular and organismal symptoms of progeria.
Currently, there is only one available therapeutic treatment for progeria
patients, lonafarnib (Figure 2), a farnesyl transferase inhibitor (FTI) that acts by blocking
the farnesylation step, thus decreasing the levels of farnesylated mutant prelamin A.
Lonafarnib monotherapy provides some improvement in vascular stiffness, bone
structure, and audiological status, and is estimated to increase mean survival by 1.6
11-13 years. However, the use of lonafarnib was previously questioned due to the
evidences that FTI treatment resulted in alternative geranylgeranyltransferase mediated
prenylation of prelamin A and progerin,14 similar to the effect of FTIs on some
oncoproteins in cancer therapy. Then, a trial was conducted to test the efficacy of
24
 
  
      
     
    
        
      
      
  
 
    
   
        
      
 
    
         
        
    
      
      
    
  
    
 
        
       
     
     
     
Introduction and objectives
lonafarnib in combination with a statin (pravastatin) and a bisphosphonate
(zoledronate) (Figure 2). This triple-drug therapy showed an additional improvement in
bone mineral density, but there was no cardiovascular improvement compared with
lonafarnib monotherapy.15 Thus, although farnesylated progerin appears to play a major
role in progeria, current therapies to prevent progerin farnesylation appear to provide
only a modest benefit.16 Hence, finding more effective therapies is still an important
unmet need.17,18 
Figure 2. Main drugs used to treat progeria.
In this context, it has been recently described that inhibition of the post­
translational methylation step improves progeria cellular senescence in vitro and
ameliorates disease and early death in a progeroid mouse model.19 Considering that the 
methylation step is catalyzed by the enzyme ICMT, this finding suggests that inhibitors of
this enzyme could be useful for the treatment of progeria. Given that the efforts have
been focused on the role of prenylation, the influence of methylation on the toxicity or
cellular localization of progerin has not been specifically addressed. In addition, it has
been shown that extremely subtle structural changes in the carboxyl terminus of 
progerin can be associated with major differences in the toxicity of the protein,20 
bringing about the possibility that the non-methylated form of progerin did not
accumulate at the nuclear rim, was less toxic than its methylated counterpart, and
improved the symptoms of the disease. 
Then, the development of ICMT inhibitors could represent a promising strategy
for treating this illness and would allow the validation of ICMT as a bona fide therapeutic 
target for the treatment of progeria. However, its clinical validation has been hampered
by the lack of synthetic inhibitors and to date only one compound able to block ICMT
activity, cysmethynil21 (Figure 3), has been thoroughly characterized. This inhibitor
effectively blocks the anchorage independent growth in a human colon cancer cell line21 
and impairs tumor progress in mice.22,23 Nonetheless, its advancement towards clinical
25
 
  
         
         
      
       
       
     
    
  
        
   
 
  
          
 
    
            
       
       
      
       
     
     
     
          
          
    
Introduction and objectives
phases has been hindered by its limited potency in vitro in some cancer cell lines22,24 
and in vivo, where doses between 100 and 200 mg/kg are usually required to observe
inhibition of tumor growth.22,23 Further efforts in the development of more efficacious
ICMT inhibitors led to the identification of several structural scaffolds able to inhibit in
some extent ICMT (Figure 3),25-28 including indole derivatives,29,30 some of them
structurally similar to cysmethynil but with improved cellular antiproliferative
activities,24,31 farnesyl cysteine analogs,32-34 and a series of tetrahydropyrane (THP)
derivatives. Among them, one of these THP derivatives is the most potent ICMT inhibitor
described to date, with an IC50 value of 1.3 nM, although this excellent in vitro value led
only to a modest reduction in cell viability in different tumor cell lines.35 
Figure 3. Representative ICMT inhibitors.
In order to identify new ICMT inhibitors with in vivo efficacy as a promising approach
to anticancer drug development for treating challenging Ras-driven tumors, our research
group carried out a screening of our in-house library against ICMT inhibition. This
research led to the identification of compound 1 as an initial hit (Figure 4A). This
compound blocked ICMT activity, albeit with moderate potency (25% inhibition of the
IMT activity at 50 μM), making necessary further optimization; !s a first step in that 
direction, docking studies with a homology model of the human enzyme (h-ICMT) using
as template the Tribolium castaneum enzyme (Tc-ICMT),36 the only eukaryotic ICMT
described up to date (Figure 4), were carried out.37 Analysis of the complexes between
the h-ICMT with the inhibitor cysmethynil (Figure 4B), or N-acetyl-S-farnesyl-L-cysteine
(AFC), the minimal structural element recognized by ICMT (Figure 4C) showed the
possibility of adding, in compound 1, a hydrophobic tail to expand toward the
membrane through the substrate tunnel, in a similar manner to the farnesyl moiety of
AFC or the octyl chain of cysmethynil. Based on this model, derivative 2 was synthetized
26
 
  
      
        
      
    
       
          
    
        
      
         
       
    
          
       
          
     
       
          
          
  
 
 
 
 
 
 
 
 
 
 
Introduction and objectives
(Figure 4D). Remarkably, this compound displayed an enhanced capacity to inhibit ICMT
activity (55% inhibition at 50 μM); A closer look to the interaction model between
compound 2 and the protein (Figure 4D) highlighted the presence of a cluster of
aromatic amino acids in the binding site formed by Trp216 of transmembrane helix (TM) 
7 and Phe243 and Phe244 of TM8. Hence, it would be conceivable that the replacement
of the methyl and cyclohexyl substituents of compound 2 by phenyl rings, able to
establish π-π stacking interactions, allowed for an improvement of affinity towards the
protein. Consequently, we designed compound 3, which fitted perfectly in the model
(Figure 4E). One phenyl ring can fill the pocket formed by Arg174 of TM6, Tyr213 and
Trp216 of TM7 and Phe243 and Phe244 of TM8. The amide group is hydrogen bonding
Arg247 of TM8 and the octyl chain of the ligand fills the lipid site. The other phenyl 
group is placed between the TM5-TM8 crevice, while the adjacent amide group is able
to establish a hydrogen bond with Ser129 on the top of TM5 (Figure 4E). Hence,
compound 3 was synthesized and tested for ICMT activity, showing an excellent 93%
enzyme activity inhibition at 50 μM and an I50 value of 2 μM;
37,38 This compound
significantly impairs the membrane association of the four Ras isoforms, leading to a
decrease of Ras downstream signaling pathways. In addition, 3 induces cell death in a 
variety of Ras-mutated tumor cell lines and increases survival in an in vivo model of
acute myeloid leukemia, which validate ICMT as a valuable target for the treatment of
Ras-driven tumors.  
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Introduction and objectives
C)B)
Figure 4. A) Structures of cysmethynil, N-acetyl-S-farnesyl-L-cysteine (AFC), and compound 1. Tc­
ICMT-derived homology models of h-ICMT in complex with S-adenosylmethionine (SAM) cofactor 
(cyan) and cysmethynil (B); AFC (C); compound 2 (D); and compound 3 (E). All inhibitors are
represented in orange. Tc-ICMT PDB code: 5V7P.
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Introduction and objectives
Hence, compound 3 was selected as the initial hit to carry out a medicinal chemistry
program in order to obtain compounds able to inhibit ICMT but devoid of cytotoxicity so
that they can be used for improving the progeria phenotype in a cellular context and in
vivo. This overall objective involves the following steps:
1. Hit to lead process
2. Lead optimization
3. Study of selected compound(s) to improve the cellular phenotype of progeria
29
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2. RESULTS AND DISCUSSION 
2.1. Hit to lead process
As a first step in the search of compounds with good ICMT inhibitory activity but
lacking cytotoxicity, three types of structural modifications were envisioned (Figure 5): i)
modifications in the hydrophobic chain (compounds 4-13), ii) changes in the secondary
amides (compounds 14-20), and iii) modifications in the spacer between the carbonyl
groups and the central tertiary amine (21-25). 
Figure 5. Compounds 4-25.
  
    
     
    
     
      
    
       
   
   
     
    
   
 
 
         
      
  
 
 
Results and discussion
2.1.1. Modifications in the hydrophobic chain
We studied the influence of the length of the hydrophobic chain and the introduction
of heteroatoms in this chain. For that purpose, a new series of compounds was
considered where the hydrophobic n-octyl chain was substituted by shorter alkyl groups
(compound 4-6) or its polarity was increased by introduction of oxygen or nitrogen
atoms (compounds 7-13). Synthesis of compounds 4-13 was carried out following the
approach depicted in Scheme 1. Aza-Michael reaction of acrylamide 26 with the
appropriate primary amines (commercial or 27-30) in the presence of 1,8­
diazabicyclo[5.4.0]undec-7-ene (DBU) gave final compounds 4-11. The nucleophilic
substitution of bromoderivative 31 with commercial 2-(4-ethylpiperidin-1-yl)ethanamine
or synthesized piperazinyl amine 32 in the presence of triethylamine afforded
compounds 12 and 13. 
Scheme 1. Reagents and conditions: a) RNH2 (commercial or 27-30), DBU, ACN, reflux, 24 h, 21­
100%; b) 3-bromopropanoyl chloride, pyridine, DCM, rt, 2 h, 92%; c) 2-(4-ethylpiperidin-1­
yl)ethanamine or 32, Et3N, 10% KI, DCM, 60 ᵒC, 24 h, 48-54%.
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Results and discussion
This synthetic route involved the previous preparation of non-commercial amines 27­
30 and 32 (Scheme 2). Amine 27 was prepared using 2-methoxycyclohexanone as
starting material. This ketone was transformed into the corresponding oxime 33 by
reaction with hydroxylamine, and further acetylated to give intermediate 34. Later
reductive Beckman fragmentation and reduction of nitrile 35 with borane finally
provided amine 27. Synthesis of 3-(2-methoxyethoxy)propan-1-amine (28) was
performed starting from 2-methoxyethanol, by addition of acrylonitrile in the presence
of potassium hydroxide, followed by reduction of the resulting nitrile 36 with borane. 2­
(2-Ethoxyethoxy)ethanamine (29) was prepared through Mitsunobu reaction of 2-(2­
ethoxyethoxy)ethanol and phthalimide, in the presence of diisopropylazodicarboxylate
(DIAD) and triphenylphosphine, followed by deprotection of 37 with hydrazine and
sodium borohydride. 2-(3-Pentyloxetan-3-yl)ethanamine (30) was prepared by Wittig
reaction between oxetan-3-one and the appropriate phosphorane followed by
conjugate addition of pentylmagnesium bromide to the acrylonitrile 38 in the presence
of copper (I), and further reduction of nitrile 39. Finally, (4-ethylpiperazin-1­
yl)ethanamine (32) was obtained through nucleophilic substitution of 1-ethylpiperazine
and bromoacetonitrile in the presence of potassium carbonate, followed by reduction of
nitrile 40 with lithium aluminium hydride (LAH).
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Results and discussion
Scheme 2. Reagents and conditions: a) NH2OH·HCl, NaOAc, H2O, MeOH, 60 ᵒC, 24 h, 100%; b) 
Ac2O, pyridine, rt, 16 h, 85%; c) Et3SiH, CF3SO3SiMe3, DCM, 0 ᵒC, 6 h, 87%; d) BH3, THF, reflux, 3.5 
h, 66-89%; e) acrylonitrile, KOH, HCl, 0 ᵒC, 1.5 h, 94%; f) DIAD, PPh3, phthalimide, MeOH, toluene,
0 ᵒC to rt, 16 h, 58%; g) N2H4·H2O, NaBH4, MeOH, rt, 16 h, 71%; h) Ph3P=CHCN, DCM, rt, 6 h, 79%; 
i) C5H11MgBr, CuI, Et2O, 0 ᵒC, 2 h, 26%; j) LAH, Et2O, 0 ᵒC, 2 h, 59%; k) BrCH2CN, K2CO3, ACN, rt, 16
h, 100%; l) LAH, THF, 0 ᵒC, 4 h, 86%.
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Results and discussion
The ability of synthesized compounds 4-13 to inhibit ICMT enzyme was determined by
a radioactivity assay previously described by Baron et al.39 The inhibitory capacity of the
compounds is expressed as the percentage of inhibition of the methyl esterification step
by which the tritiated methyl group of the methyl donor S-adenosylmethionine ([3H]­
SAM) is transferred to the substrate biotinyl-S-farnesyl-L-cysteine (BFC). The obtained
results (Table 1) showed that a decrease in the length of the alkyl chain (compound 4) or
its substitution by cyclopropane or methylcyclopropane groups (compounds 5, 6) 
involved important reductions in the inhibitory activity of the compounds, ranging from
9% to 36% inhibition of ICMT at 50 µM. Neither the introduction of oxygen atoms in the
alkyl chain (7-11), nor the replacement of the n-octyl chain by (4-ethylpiperidin-1­
yl)ethane or (4-ethylpiperazin-1-yl)ethane (12, 13) allowed to keep good inhibition
values, compared to the 93% inhibition induced by compound 3 at the same
concentration. 
Table 1. ICMT inhibition values for compounds 3-13.
Comp. R
ICMT
Inhibition
(%)a,b 
Comp. R
3 93 9
4 9 10
5 33 11
6 36 12
7 14 13
8 30
ICMT
Inhibition
(%)a,b 
45
15
13
15
a 
ICMT inhibition values were determined at 50 µM concentration of tested compounds. 
b 
Data 
are expressed as the mean from at least two independent experiments performed in triplicate. 
The standard error of the mean (sem) in all cases is within a 10% of the mean value.
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Results and discussion
2.1.2. Changes in the secondary amides
The previous obtained data suggested that a long hydrophobic chain attached to the
nitrogen atom was needed, so we decided to keep the n-octyl group and continue with
the structural exploration of the amide groups. Hence, the secondary amides of
compound 3 were replaced by tertiary amides (14, 15), sulfonamides (16-19) or an
oxadiazole heterocycle (20), considering that the two later moieties have been reported
as bioisosters of the amide group (Schemes 3 and 4).40 For the obtention of derivatives
14, 16, and 17, acrylamides 41-43 were treated with octylamine in the presence of DBU
(Scheme 3). Synthesis of final compounds 15, 18, and 19 was assessed by reaction of
acrylamide 26 with octylamine followed by aza-Michael reaction of the resulting
secondary amine 44 with acrylamides 41-43. The nucleophilic substitution of 2­
(chloromethyl)-5-phenyl-1,3,4-oxadiazole with amine 44 afforded compound 20
(Scheme 4).
Scheme 3. Reagents and conditions: a) DBU, ACN, reflux, 24 h, 44-81%.
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Results and discussion
Scheme 4. Reagents and conditions: a) octylamine, DBU, ACN, 60 ᵒC, 5 h, 76 %; b) DBU, ACN,
reflux, 24 h, 12-64%; c) Et3N, ACN, 60 ᵒC, 24 h, 62%.
The biological evaluation of compounds 14-20 as ICMT inhibitors indicated that none
of the modifications introduced in the amide groups improved the inhibitory capacity of
these derivatives in comparison to the reference compound 3 (Tables 2 and 3) and only
methylamides 14 and 15 showed moderate activity (68% and 65% inhibition,
respectively).
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Results and discussion
Table 2. ICMT inhibition values for compounds 3, 14, 16, and 17.
Comp. X
ICMT Inhibition
(%)a,b 
3 NHCO 93
14 NCH3CO 65
16 SO2NH 34
17 SO2NCH3 12
a 
ICMT inhibition values were determined at 50 µM concentration of tested compounds. 
b 
Data 
are expressed as the mean from at least two independent experiments performed in triplicate. 
The sem in all cases is within a 10% of the mean value.
Table 3. ICMT inhibition values for compounds 3, 15, 18-20.
Comp. Y
ICMT Inhibition
(%)a,b 
3 NHCO 93
15 NCH3CO 68
18 SO2NH 22
19 SO2NCH3 10
20 13
a 
ICMT inhibition values were determined at 50 µM concentration of tested compounds. 
b 
Data 
are expressed as the mean from at least two independent experiments performed in triplicate. 
The sem in all cases is within a 10% of the mean value.
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Results and discussion
2.1.3. Modifications in the spacer between the two carbonyl groups
Finally, we studied the distance between the two carbonyl groups with derivatives 21­
25 (Scheme 5). Final compounds 21 and 22 were obtained from 2-bromo-N­
phenylacetamide as starting material by nucleophilic substitution with octylamine. The
regioselectivity of the reaction in order to obtain the dialkylated product 21 or the
intermediate 45 was achieved by controlling the reaction conditions. The treatment of
secondary amine 45 with 3-bromo-N-phenylpropanamide (31) provided derivative 22. 
Synthesis of compounds 23-25 was carried out by reaction of amine 44 with the
corresponding commercial haloketone (compounds 23 and 24) or benzoic acid (diamide
25) (Scheme 5).
Scheme 5. Reagents and conditions: a) octylamine, DIPEA, ACN, 60 ᵒC, 16 h, 93%; b) octylamine, 
DCM, rt, 16 h, 40%; c) 3-bromo-N-phenylpropanamide (31), DIPEA, DCM, reflux, 16 h, 25%; d) 3­
chloropropiophenone, NaHCO3, ACN, H2O, rt, 16 h, 43%; e) 2-bromoacetophenone, K2CO3, ACN,
rt, 16 h, 56%; f) benzoic acid, EDC, HOBt, DCM, rt, 16 h, 72%.
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Results and discussion
Once synthesized, the ability of compounds 21-25 to inhibit ICMT enzyme was
determined (Tables 4 and 5). Compounds 23 and 24 did not show enough stability for
their ICMT inhibition determination. However, compound 25 showed a good percentage
of ICMT inhibition (it blocked the 80% of ICMT activity at 50 µM).
Table 4. ICMT inhibition values for compounds 3, 21, and 22.
Comp. m n
ICMT Inhibition
(%)a,b 
3 2 2 93
21 1 1 62
22 2 1 68
a 
ICMT inhibition values were determined at 50 µM concentration of tested compounds. 
b 
Data 
are expressed as the mean from at least two independent experiments performed in triplicate. 
The sem in all cases is within a 10% of the mean value. 
Table 5. ICMT inhibition values for compounds 3, 23-25.
Comp. X m
ICMT Inhibition
(%)a,b 
3 CONH 2 93
23 CO 2 NDc 
24 CO 1 NDc
25 CO 0 80
a 
ICMT inhibition values were determined at 50 µM concentration of tested compounds. 
b 
Data 
are expressed as the mean from at least two independent experiments performed in triplicate. 
The sem in all cases is within a 10% of the mean value. 
c 
Not determined.
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Results and discussion
In order to determine if any of the identified ICMT inhibitors could be a candidate for
the treatment of progeria, those compounds with a percentage of ICMT inhibition
higher than 60% at 50 µM were selected and their cytotoxicity was determined in AF3
fibroblasts. The evaluation of the cellular cytotoxicity was carried out by a colorimetric
assay based on the metabolic reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5­
diphenyltetrazolium bromide (MTT) by the dehydrogenase succinate mitochondrial
enzyme. After incubation of the desired compound for 48 h, the cells which remain
functional are able to reduce the MTT forming a colored precipitated (formazan), which
is quantified by measuring its absorbance at 570 nm. The cellular viability is expressed as
the percentage of viable cells after treatment with the compound under study respect
to the viability in the absence of compound. Only compound 25 showed low cytotoxicity
with a percentage of cell viability of 85% with respect to 100% viability obtained in
vehicle-treated cells (0.1% DMSO). Hence, we selected derivative 25 as a lead in order to
continue with its optimization in the search of derivatives with improved cell viability
and good capacity to inhibit ICMT enzyme.
2.2. Lead optimization
Then, we decided to introduce substituents in one phenyl ring (compounds 46-52) 
and replace a phenyl ring by different heterocycles (compounds 53-61) (Figure 6). All
these compounds were synthesized by coupling of amine 44 with the corresponding
carboxylic acids (Scheme 6). 
Figure 6. Compounds 46-61.
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Results and discussion
Scheme 6. Reagents and conditions: a) Ar-COOH, EDC, HOBt, DCM, rt, 16 h, 66-73%; b) Het-
COOH, EDC, HOBt, DCM, rt, 16 h, 36-100%.
The ICMT inhibition data obtained for compounds 46-48 (Table 6), with a methoxy
group at ortho, meta, and para position of one of the phenyl ring, indicated that the
introduction of the substituent in para position yielded the best results in terms of
enzymatic inhibition, so this position was kept for the rest of the studied compounds 49­
52. Nonetheless, none of the new substituents introduced in the phenyl ring improved
the inhibitory capacity of initial compound 25 (80% of inhibition at 50 μM). In
relationship with compounds 53-61, their percentage of inhibition of ICMT showed that
the replacement of a phenyl group by a 3-furyl ring or a pyrrol moiety (compounds 54
and 56-58) kept the inhibitory capacity of these compounds, which showed similar ICMT
inhibition percentages to the parent compound 25 (75-81% inhibition at 50 µM) (Table
7). 
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Results and discussion
Table 6. ICMT inhibition values of compounds 25, 46-52.
Comp. X
ICMT Inhibition
(%)a,b 
Comp. X
ICMT Inhibition
(%)a,b 
25 H 80 49 p-CN 59
46 o-OMe 32 50 p-F 42
47 m-OMe 26 51 p-CF3 18
48 p-OMe 58 52 p-NHCOMe 10
a 
ICMT inhibition values were determined at 50 µM concentration of tested compounds. 
b 
Data 
are expressed as the mean from at least two independent experiments performed in triplicate. 
The sem in all cases is within a 10% of the mean value.
Table 7. ICMT inhibition values of compounds 53-61.
Comp. Het
ICMT Inhibition
(%)a,b 
Comp. Het
ICMT Inhibition
(%)a,b 
53 49 57 81
54 81 58 75
55 62 59 63
(R)-55 61 60 38
(S)-55 64 61 30
56 75
a 
ICMT inhibition values were determined at 50 µM concentration of tested compounds. 
b 
Data 
are expressed as the mean from at least two independent experiments performed in triplicate. 
The sem in all cases is within a 10% of the mean value.
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Results and discussion
Then, those compounds with a percentage of inhibition over 60% at 50 µM were
selected for the assessment of their cytotoxicity in wild type AF3 and G609G progeroid
mouse fibroblasts, the cellular model of progeria as they come from the mouse model
with the mutation in the LMNA gene.41 We have also studied the pharmacokinetic
profile of the selected compounds. We determined the in vitro stability of the
compounds in mouse and human serum and microsomes as a model of first pass
metabolism. Also, the binding to human serum albumin (HSA) was assessed. These
experiments were carried out by incubation of the compounds in the presence of the
corresponding serum, microsomes, or HSA and, after the appropriate incubation, the
remaining compound was quantified by high performance liquid chromatography
coupled to mass spectrometry (HPLC-MS) to obtain half-life values (t1/2) in the case of
serum and microsomes stabilities or affinity values in terms of dissociation constant (Kd) 
and bounded fraction (Fb) in the case of HSA. Also, the theoretical calculated values of
the logarithm of the partition coefficient between n-octanol and water (clogP) and the
topological polar surface area (TPSA) were determined using the ACDLabs Percepta
Software as a predicted value of the lypophilicity and cellular permeability, respectively. 
In terms of cellular viability, the obtained results (Table 8) showed that all compounds 
were not cytotoxic in wild type AF3 fibroblasts and were able to enhance the viability of
progeroid cells, with the best results obtained for compound 59, which was able to
increase the viability of the progeroid cells up to 93%, compared to the 41% viability
observed in the vehicle-treated cells. Regarding the pharmacokinetic profile, selected
compounds exhibited moderate pharmacokinetic properties (Table 9), with t1/2 values
higher than 24 h and between 14 and 243 min in human and mouse serum, respectively, 
or HSA bound fractions from 72 to 100%. Furthermore, the lypophilicity and cellular
permeability values were approximately in the range of expected drug-like compounds
(clogP < 5, 60 < TPSA < 120 Å2).42 
Taking into account all the results obtained up to this moment, the inhibitor with the
best efficacy to improve the cellular progeroid phenotype was 59. However, their
pharmacokinetic properties were slightly worse compared to the rest of compounds.
Then, in an attempt to obtain an improved compound, we replaced one of the carbonyl
groups by a methylene, as it has been reported that the amide bond can be, in some
cases, a hydrolysis-prone group. Hence, compound 62 was synthesized by reductive
amination of the intermediate secondary amine 44 with 2-pyridinecarboxaldehyde
followed by treatment with sodium triacetoxyborohydride (Scheme 7). 
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Results and discussion
Scheme 7. Reagents and conditions: a) 2-pyridinecarboxaldehyde, NaBH(OAc)3, DCE, rt, 16 h,
16%.
Then, we determined the cytotoxicity, effect on progeroid mouse cells, and
pharmacokinetic properties of this new compound (Tables 8 and 9). The obtained results
showed that the replacement of the carbonyl group next to the heterocycle by a
methylene unit did not improve the viability of progeroid cells (93% viability of 59 vs
60% viability of 62) nor the pharmacokinetic profile (t1/2 in human microsomes
decreased from 14 min for compound 59 to 2 min for derivative 62).
Table 8. Effect of compounds 54-59 and 62 on the viability of AF3 wild type and
G609G progeroid mouse fibroblasts.
Viability (%)a 
Compound AF3 wild type G609G progeroid
mouse fibroblasts mouse fibroblasts
Vehicle-treated 100 41 ± 3
54 116 ± 2 77 ± 5
55 121 ± 11 60 ± 10
(R)-55 114 ± 6 80 ± 7
(S)-55 124 ± 10 70 ± 5
56 107 ± 5 45 ± 6
57 109 ± 4 53 ± 13
58 99 ± 5 74 ± 9
59 123 ± 9 93 ± 9
62 103 ± 8 60 ± 9
a 
Cellular viability was determined by the MTT assay. Data are expressed as the means ± sem
from three independent experiments performed in triplicate at a compound concentration of 2 
µM. The percentage of viability is expressed considering 100% viability in vehicle-treated AF3 
wild type mouse fibroblasts.
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Results and discussion
Table 9. Pharmacokinetic profile of compounds 54-59 and 62.
Comp.
Stability (t1/2, min)
a
HSA bindinga,b
Fb (Kd, µM)
clogPc TPSA (Å2)cSerum Microsomes
Human Mouse Human Mouse
54 > 1440 14 ± 1 8 ± 3 7 ± 2 98.1 (11) 5.1 62.6
55 >1440 243 ± 64 30 ± 17 17 ± 7 72.4 (240) 3.9 61.4
(R)-55 > 1440 112 ± 8 12 ± 1 9 ± 1 80.5 (140) 4.5 61.4
(S)-55 > 1440 38 ± 13 21 ± 12 4 ± 1 90.5 (62) 4.5 61.4
56 > 1440 41 ± 9 15 ± 3 4 ± 1 99.0 (1.5) 3.5 65.2
57 > 1440 58 ± 21 16 ± 2 2 ± 1 99.0 (1.6) 3.9 65.2
58 > 1440 47 ± 1 22 ± 6 11 ± 2 98.7 (8) 4.0 54.3
59 > 1440 17 ± 1 14 ± 7 3 ± 1 98.1 (7.2) 4.5 62.3
62 > 1440 26 ± 8 2 ± 1 5 ± 1 100 (1.7 · 10 -6) 5.3 45.2
a 
Data are expressed as the means ± sem from five independent experiments performed in
duplicate.
b 
Binding to human serum albumin (HSA) is expressed as the bound fraction (Fb).
Dissociation constants (Kd) are given between parentheses. Sem is in all cases within a 10% of the
mean value.
c 
Values obtained with the ACDLabs Percepta Software.
Taken together, these results suggested that compound 59 showed the best
combination of ICMT inhibitory activity (63%), viability of progeroid cells (93%), and
pharmacokinetic profile, so it was selected for further biological studies. Moreover, its
excellent capacity to improve viability of progeroid cells made 59 a good candidate to
confirm, as a proof of concept, the efficacy of an ICMT inhibitor to improve the progeria
phenotype. 
2.3. Study of the efficacy of compound 59 in human progeroid cells
As human progeroid cells are characterized by reduced viability, damaged DNA,
impaired cellular proliferation, and high levels of progerin localized in the nuclear
membrane, we studied whether compound 59 was able to improve or even reverse
these cellular hallmarks of progeria. Hence, we determined the capacity of compound
59 to: i) increase viability of human progeroid fibroblasts; ii) reduce DNA damage; iii)
stimulate cellular proliferation; and iv) delocalize progerin.
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Results and discussion
Hence, HGADFN167 fibroblasts from a progeria patient and HGFDFN168 cells from a
healthy donor were obtained from The Progeria Research Foundation in order to carry
out these experiments. The effect of compound 59 in the cellular viability of
HGADFN167 progeroid fibroblasts was assessed by incubating the cells for 24 days in the 
presence of compound 59 (2 µM) or vehicle and counting the number of viable cells
(Figure 7). We can observe that the cellular viability was improved around a 20% when
using compound 59 in comparison with vehicle-treated cells. Next, in order to
determine the efficacy of the compound in the reduction of damaged DNA, the
stimulation of cellular proliferation and the delocalization of progerin, western blot or
immunofluorescence experiments were carried out. Hence, HGADFN167 progeroid
fibroblasts were incubated with compound 59 (2 µM) and cells analyzed at different
times. In relationship with the reduction of DNA damage, the levels of phosphorylated
histone 2AX (pH2AX) were measured, observing a decrease when treating with
compound 59 (Figure 8A). Stimulation of the cellular proliferation pathways was assesed
by determining the levels of phosphorylated Akt protein. In this case, we observed an
increase when progeroid fibroblasts were treated with the compound (Figure 8B).
Finally, we confirmed that selected compound 59 was able not only to delocalize
progerin from the nuclear membrane but also to reduce its overall levels (Figure 9).
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Figure 7. Viability curve at 24 days for healthy HGFDFN168 (blue) and progeroid HGADFN167 cells
treated with vehicle (0.1% DMSO, red) or with compound 59 at 2 µM (purple). Data represent the
mean ± sem of two independent experiments.
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Figure 8. Representative western blots of the levels of pH2AX (A) and pAkt (B). Lysates were
obtained for healthy (HGFDFN168, 168 in the figure) and progeroid (HGADFN167, 167 in the
figure) cells treated with vehicle or with compound 59 after 17 and 10 days of culture for pH2AX
and pAkt, respectively. The bar graphs are the mean ± sem of three different experiments and
represent the optical density of the immunoreactive phosphorylated protein normalized to ERK 
1/2 used as loading control, and it is expressed as relative to healthy cells treated with vehicle. 
50
 
  
 
 
         
          
          
             
             
             
   
 
 
Results and discussion
Hoeschst
Progerin
HGADFN167 + vehicle HGADFN167 + 59
P
ro
ge
ri
n
 le
ve
ls
in
 H
G
A
D
FN
1
6
7
  c
el
ls
(%
)
***
0
20
40
60
80
100
120
A)
B)
Figure 9. A) Representative confocal images of HGADFN167 fibroblasts treated with 0.1% DMSO 
(vehicle) or with compound 59 (2 µM) for 17 days. Cells were immunostained with an antibody
against progerin (green) and imaged with an Olympus IX83 confocal microscope. Nuclei were
visualized with Hoechst stain in blue. Similar results were obtained in three independent assays.
B) The bar graphs represent progerin levels measured in terms of fluorescence intensity. Data
correspond to the mean ± sem of two independent experiments (50 cells quantified). ***, p <
0.0005 (Student´s t test).
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Results and discussion
All in sum, the results obtained up to this moment indicate that compound 59 
remarkably improves the viability of progeroid mouse fibroblasts. Furthemore, in human
cells coming from progeria patients, this compound is able not only to increase cell
viability but also to stimulate pro-proliferation pathways and to reduce DNA damage
and progerin levels, and to delocalize progerin from the nuclear membrane. Accordingly,
59 is a promising compound to assay its in vivo efficacy in a mouse model of progeria,
experiments that are currently ongoing in our laboratory. 
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3. CONCLUSIONS
In this work we have validated the enzyme ICMT as a new therapeutic target for the
treatment of progeria. After a medicinal chemistry program starting from initial hit 3, we
have identified compound 59, which shows the best combination of ICMT inhibitory
activity (63%), viability of progeroid cells (93%), and pharmacokinetic profile. 
Furthermore, this compound is able to increase the viability and cellular proliferation of
progeroid human fibroblasts, reduce their DNA damage and the levels of progerin,
inducing its delocalization from nuclear membrane. In summary, compound 59 is an
excellent candidate for in vivo efficacy testing, experiments that are currently ongoing in
our laboratory.  
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4. EXPERIMENTAL SECTION
4.1. Synthesis
Unless stated otherwise, starting materials, reagents and solvents were purchased as
high-grade commercial products from Sigma-Aldrich, Acros, ABCR, Fluorochem,
Scharlab, Honeywell or Panreac, and were used without further purification.
Tetrahydrofuran (THF), Et2O, and dichloromethane (DCM) were dried using a Pure Solv™
Micro 100 Liter solvent purification system. Pyridine (py) and Et3N were dried over KOH
and distilled before using. All reactions in organic solvents were performed under an
argon atmosphere in dry glassware. Analytical thin-layer chromatography (TLC) was run
on Merck silica gel plates (Kieselgel 60 F-254) with detection by UV light (254 nm),
ninhydrin solution, or 10% phosphomolybdic acid solution in ethanol. Flash
chromatography was performed on a Varian 971-FP flash purification system using silica
gel cartridges (Varian, particle size 50 μm) or on glass columns using silica gel type 60
(Merck, particle size 230 μm, 400 mesh); All compounds were obtained as oils, except
for those whose melting points (mp) are indicated, which were solids. 
Melting points (mp, uncorrected) were determined on a Stuart Scientific
electrothermal apparatus. Infrared (IR) spectra were measured on a Bruker Tensor 27
instrument equipped with a Specac ATR accessory of 5200-650 cm-1 transmission range;
frequencies (ν) are expressed in cm-1. Optical rotation [α] was measured on an Anton
Paar MCP 100 modular circular polarimeter using a sodium lamp (λ = 589 nm) with a 1
dm path length; concentrations (c) are given as g/100 mL. NMR spectra were recorded
at room temperature on a Bruker DPX 300 (1H, 300 MHz; 13C, 75 MHz) spectrometer at
the Universidad omplutense de Madrid (UM) NMR facilities; hemical shifts (δ) are
expressed in parts per million relative to internal tetramethylsilane; coupling constants
  
     
        
     
     
    
 
      
 
  
        
       
  
     
      
    
      
    
     
 
   
  
    
    
    
    
    
    
    
 
 
 
Experimental section
(J) are in hertz (Hz). The following abbreviations were used to describe peak patterns
when appropriate: s (singlet), d (doublet), t (triplet), q (quadruplet), m (multiplet), br
(broad), and app (apparent). 2D NMR experiments (HMQC and HMBC) of representative
compounds were carried out to assign protons and carbons of the new structures. High
resolution mass spectrometry (HRMS) was carried out on a FTMS Bruker APEX Q IV
spectrometer in electrospray ionization (ESI) mode at UM’s spectrometry facilities;
For all final compounds, purity was determined by high-performance liquid
chromatography coupled to mass spectrometry (HPLC-MS) using an Agilent 1200LC-MSD
VL instrument, and satisfactory chromatograms confirmed a purity of at least 95% for all
tested compounds. LC separation was achieved with an Eclipse XDB-18 column (5 μm,
4.6 mm x 150 mm), together with a guard column (5 μm, 4;6 mm x 12;5 mm) with a flow
of 0.5 mL/min. The gradient mobile phase consisted of A (95:5 water/acetonitrile) and B 
(5:95 water/acetonitrile) with 0.1% formic acid as solvent modifier, indicating the
gradients in Table 10. Spectra were acquired in positive or negative ionization mode
from 100 to 1000 m/z and in UV-mode at four different wavelengths (210, 230, 254, and
280 nm). MS analysis was performed with an ESI source. The capillary voltage was set to
3.0 kV and the fragmentor voltage was set at 72 eV. The drying gas temperature was 350
ᵒC, the drying gas flow was 10 L/min, and the nebulizer pressure was 20 psi.
Table 10. HPLC gradients.
Method A Method B
t (min) % B t (min) % B
0 0 0 0
5 0 2 0
15 90 8 80
22 100 25 100
26 100 30 0
30 0
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Experimental section
The enantiomeric excess (ee) was determined by HPLC using a chiral column in
reversed-phase chromatography. Chiralpak® IA (5 µm, 4.6 mm x 15.0 mm) was used as
the stationary phase, equipped with an Eclipse XDC-C18 precolumn (5 µm, 4.6 mm x
12.5 mm) using a flow of 0.5 mL/min. The mobile phase consisted of A (20 mM
NH4HCO3, pH 9) and B (acetonitrile) using an isocratic method of 80% B for 10 (chiral
HPLC method A) or 30 min (chiral HPLC method B), indicated in the particular cases. 
HPLC traces were compared to racemic samples obtained by mixing equal amounts of
the enantiopure compounds independently obtained.
4.1.1. General Procedures
4.1.1.1. Amide formation through acid chlorides
To a solution of the corresponding aniline (1 equiv) in anhydrous DCM (1 mL/mmol),
acryloyl chloride (1.1 equiv) and pyridine (1.1 equiv) were added, consecutively, at 0 ᵒC.
Then, the reaction mixture was stirred for 2 h at rt and then, the reaction crude was
washed with saturated aqueous solutions of NaHCO3, CuSO4 and NaCl, subsenquently. 
The organic layer was dried over Na2SO4, filtered, and the solvent was evaporated in
vacuo to yield the corresponding compounds.
4.1.1.2. Aza-Michael reaction
A mixture of the corresponding acrylamide or sulfonamide (1.5-3 equiv), the desired
amine (1.0 equiv), and DBU (1.5 equiv) in anhydrous ACN (1 mL/mmol) was heated at
reflux for 24 h. Then, the solvent was removed under reduced pressure and the residue
was purified by column chromatography.
4.1.1.3. Amide formation with coupling reagents
To a solution of the corresponding carboxylic acid (1.0 equiv) in anhydrous DCM (4
mL/mmol), EDC (1.0 equiv) and HOBt (1.0 equiv) were added. The reaction mixture was
stirred at rt for 1 h. Then, a solution of the secondary amine 44 (1.0 equiv) in anhydrous
DCM (2.0 mL/mmol) was added and the reaction mixture was stirred at rt for 16 h. The 
reaction crude was washed with saturated aqueous solutions of NaHCO3 and NaCl, 
consecutively. The organic extracts were dried over Na2SO4, filtered, and the solvent
removed under reduced pressure. The residue was purified by column chromatography
obtaining the desired amides.
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Experimental section
4.1.2. Synthesis of final compounds 4-13
● N-Phenylacrylamide (26). Obtained following the general procedure 4.1.1.1. from
aniline (500 µL, 5.0 mmol) and acryloyl chloride (500 mg, 5.5 mmol) in 63% yield (465
mg). The spectroscopic data are in agreement with those previously described.43 
Rf (DCM/MeOH, 95:5): 0.57. Mp: 107-108 ᵒC. (Lit.
43 105-106 ᵒC). 1H-NMR (CDCl3, δ): 5.71
(dd, J = 9.6, 2.0 Hz, 1H, ½CH2), 6.31 (dd, J = 16.9, 9.7 Hz, 1H, CHCO), 6.42 (dd, J = 16.9, 1.9
Hz, 1H, ½CH2), 7.10 (t, J = 7.4 Hz, 1H, H4), 7.30 (t, J = 7.9 Hz, 2H, H3, H5), 7.60 (d, J = 7.9
Hz, 2H, H2, H6), 8.16 (br s, 1H, NH). MS (ESI, m/z): 148.1 [M+H]
+.
● Amines 27-30, 32
N-Hydroxy-2-methoxycyclohexylimine (33). To a solution of sodium acetate (192 mg,
2.3 mmol) and hydroxylamine hydrochloride (163 mg, 2.3 mmol) in H2O (5.8 mL)
previously heated at 60 ᵒC, a solution of 2-methoxycyclohexanone (150 µL, 1.1 mmol) in
methanol (0.6 mL) was added. The reaction mixture was stirred overnight at 60 ᵒC, and
the crude was washed with H2O (5.5 mL) and extracted with Et2O. The organic phase was
washed with saturated aqueous solutions of NaHCO3 and NaCl, consecutively, dried over
Na2SO4, filtered, and the solvent was removed under reduced pressure. The crude was
purified by chromatography (hexane/EtOAc, 7:3) to obtain the title compound in
quantitative yield (329 mg). The spectroscopic data are in agreement with those
previously described.44 
Rf (hexane/EtOAc, 7:3): 0.40. 
1H NMR (CDCl3, δ): 1.35-1.94 (m, 5H, 2CH2, ½CH2), 2.03­
2.14 (m, 2H, CH2), 3.01-3.05 (m, 1H, ½CH2), 3.27 (s, 3H, CH3), 3.75 (m, 1H, CH), 6.05 (br s,
1H, OH). MS (ESI, m/z): 143.9 [M+H]+. 
2-Methoxycyclohexanone oxime acetate (34). A solution of ketoxime 33 (166 mg, 1.2
mmol), pyridine (340 µL, 4.2 mmol) and acetic anhydride (0.7 mL, 7.2 mmol) was stirred
overnight at rt. The excess of reagents was removed under reduced pressure and
coevaporated with toluene. The crude was purified by chromatography (hexane/EtOAc,
7:3) to obtain the title compound in 85% yield (189 mg). 
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Experimental section
Rf (hexane/EtOAc, 7:3): 0.42. IR (ATR, cm
-1): 1769 (COO), 1702 (CN), 1193 (COC). 1H NMR 
(CDCl3, δ): 1.34-1.70 (m, 5H, 2CH2, ½CH2), 1.73-2.02 (m, 2H, CH2), 2.07-2.26 (m, 5H, CH2, 
CH3CO), 3.03-3.08 (m, 1H, ½CH2), 3.30 (s, 3H, OCH3), 3.95 (m, 1H, CH). 
13C NMR (CDCl3, 
δ): 19.3 (CH3CO diastereomer), 19.4 (CH2 diastereomer), 19.4 (CH3CO diastereomer),
19.6, 23.2, 25.5, 26.8, 28.0, 31.8, 32.7 (7CH2 diastereomers), 56.0, 56.2 (CH3O
diastereomers), 70.1, 77.0 (CH diastereomers), 166.9, 167.4, 168.3, 168.5 (CN, CO
diastereomers). MS (ESI, m/z): 125.9 [M-OCOCH3]
+.
6-Methoxyhexanenitrile (35). A solution of 34 (120 mg, 0.7 mmol), trimethylsilane
(120 μL, 0.8 mmol) and trimethylsilyl trifluoromethanesulfonate (TMSOTf) (12 μL, 70
nmol) was stirred at 0 ᵒC for 6 h. Then, the solvent was removed under reduced pressure
and the crude was purified by chromatography (hexane/EtOAc, 8:2) to give the title
compound in 87% yield (77 mg). The spectroscopic data are in agreement with those
previously described.45 
Rf (hexane/EtOAc, 8:2): 0.33.
1H NMR (CDCl3, δ): 1.47-1.75 (m, 6H, (CH2)3CH2CN), 2.36 (t,
J = 7.1 Hz, 2H, CH2CN), 3.34 (s, 3H, CH3), 3.39 (t, J = 6.1 Hz, 2H, CH2O). MS (ESI, m/z):
113.0 [M-CH3+H]
+.
6-Methoxyhexan-1-amine (27). To a solution of nitrile 35 (100 mg, 0.8 mmol) in
anhydrous THF (1 mL), a solution of BH3 (1 M in THF, 3.2 mL) was added dropwise and
the mixture was stirred at reflux for 3.5 h. Once at rt, the reaction was quenched by slow
addition of MeOH (1.8 mL) and concentrated HCl (0.2 mL). The product was extracted
with DCM and the organic layer was dried over Na2SO4 and filtered. The solvent was
removed under reduced pressure and the residue was purified by chromatography
(EtOAc/MeOH, 9:1) to afford the title amine in 66% yield (70 mg). 
Rf (hexane/EtOAc, 1:1): 0.13. IR (ATR, cm
-1): 3332 (NH). 1H NMR (CDCl3, δ): 1.34-1.49 (m,
4H, 2CH2), 1.56 (qt, J = 6.6 Hz, 2H, CH2), 1.79 (qt, J = 7.4 Hz, 2H, CH2), 2.99 (t, J = 7.7 Hz,
2H, CH2N), 3.32 (s, 3H, CH3), 3.37 (t, J = 6.4 Hz, 2H, CH2O). 
13C NMR (CDCl3, δ): 25.7, 26.4,
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27.6, 29.4 ((CH2)4CH2N) 40.0 (CH2N), 58.6 (CH3), 72.6 (CH2O). MS (ESI, m/z): 132.0
[M+H]+.
3-(2-Methoxyethoxy)propanenitrile (36). A solution of 2-methoxyethanol (2 mL, 26
mmol) in acrylonitrile (15 mL, 229 mmol) was stirred at 0 ᵒC for 10 min. Then, KOH (133
mg, 2.4 mmol) was added and the mixture was stirred at 0 ᵒC for 1.5 h. Concentrated
HCl was added and the mixture was evaporated under reduced pressure. The residue
was dissolved in chloroform, filtered and the solvent was removed under reduced
pressure to obtain the title nitrile in 94% yield (291 mg). The spectroscopic data are in
agreement with those previously described.46 
Rf (hexane/EtOAc, 7:3): 0.28. 
1H NMR (CDCl3, δ): 2.64 (t, J = 6.5 Hz, 2H, CH2CN), 3.40 (s,
3H, CH3), 3.55-3.58 (m, 2H, CH2O), 3.66-3.69 (m, 2H, CH2O), 3.73 (t, J = 6.5 Hz, 2H, CH2O). 
MS (ESI, m/z): 130.0 [M+H]+ .
3-(2-Methoxyethoxy)propyl-1-amine (28). To a solution of nitrile 36 (440 mg, 31.8
mmol) in anhydrous THF (41.6 mL), a solution of BH3 (1 M in THF, 7.7 mL) was added
dropwise and the mixture was stirred at reflux for 3.5 h. Once at rt, the reaction was
quenched by slow addition of MeOH (73 mL) and concentrated HCl (8 mL). The product
was extracted with DCM and the organic layer was dried over Na2SO4, filtered, and
evaporated under reduced pressure to obtain the title amine in 89% yield (912 mg). The
spectroscopic data are in agreement with those previously described.46 
Rf (hexane/EtOAc, 9:1): 0.25. 
1H NMR (CDCl3, δ): 1.74 (qt, J = 6.5 Hz, 2H, CH2CH2N), 2.78
(t, J = 6.8 Hz, 2H, CH2N), 3.38 (s, 3H, CH3), 3.52-3.60 (m, 6H, 3CH2O). MS (ESI, m/z): 134.1
[M+H]+. 
2-[2-(2-Ethoxyethoxy)ethyl]-1H-isoindol-1,3(2H)-dione (37). To a solution of 2-(2­
ethoxyethoxy)ethanol (0.5 mL, 3.7 mmol), phthalimide (549 mg, 3.7 mmol) and
triphenylphosphine (977 mg, 3.7 mmol) in anhydrous toluene (11 mL), DIAD (0.8 mL, 4
mmol) was added at 0 ᵒC. The reaction mixture was stirred at 0 ᵒC for 50 min and at rt
for an additional 1 h. Then, methanol was added (2.9 mL), the mixture was stirred on at
rt and the solvents were removed under reduced pressure. Hexane was added and the
64
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precipitate was filtered and washed with hexane (3x). The solvent was removed under
reduced pressure and the residue was purified by chromatography (hexane/EtOAc, 7:3) 
to obtain the title compound in 58% yield (565 mg). The spectroscopic data are in
agreement with those previously described.47 
Rf (hexane/EtOAc, 7:3): 0.22. 
1H NMR (CDCl3, δ): 1.13 (t, J = 7.0 Hz, 3H, CH3), 3.45 (q, J = 
7.0 Hz, 2H, CH3CH2O), 3.52-3.55 (m, 2H, CH2N), 3.62-3.65 (m, 2H, CH2O), 3.74 (t, J = 5.8
Hz, 2H, CH2O), 3.90 (t, J = 5.8 Hz, 2H, CH2O), 7.70 (m, 2H, 2HAr), 7.84 (m, 2H, 2HAr). MS 
(ESI, m/z): 264.0 [M+H]+. 
2-(2-Ethoxyethoxy)ethanamine (29). To a solution of 37 (295 mg, 1.1 mmol) in dry
methanol (4.9 mL), hydrazine (0.1 mL, 2.2 mmol) was added and the reaction mixture
was stirred at rt for 2 h. Then, NaBH4 (42 mg, 1.1 mmol) and a second portion of
hydrazine (0.1 mL, 2.2 mmol) were added and the mixture was stirred at rt for 16 h. The
suspension was filtered and the solvent was removed under reduced pressure. The
residue was dissolved in EtOAc (20 mL), warmed to 50 °C, sonicated, and filtered. The
filtrate was evaporated, redissolved in Et2O (20 mL), filtered, and the solvent was
removed under reduced pressure to afford the title compound in 71% yield (104 mg).
The spectroscopic data are in agreement with those previously described.47 
Rf (EtOAc/MeOH, 9:1): 0.35. 
1H NMR (CDCl3, δ): 1.20 (t, J = 7.0 Hz, 3H, CH3), 1.95 (br s,
2H, NH2 ), 2.85 (t, J = 5.2 Hz, 2H, CH2N), 3.42-3.53 (m, 4H, 2CH2O), 3.56-3.62 (m, 4H,
2CH2O). MS (ESI, m/z): 134.1 [M+H]
+.
(Oxetan-3-ylidene)acetonitrile (38). To a solution of oxetan-3-one (0.7 mL, 10.4
mmol) in dry DCM (3 mL), a solution of Ph3P=CHCN (3.10 g, 10.4 mmol) in dry DCM (15
mL) was added dropwise. The mixture was stirred for 6 h at rt and the solvent was
evaporated under reduced pressure. The residue was dissolved in hexane/Et2O (3:2),
filtered over a plug of silica gel and washed with Et2O. The solvents were removed under
reduced pressure and the residue was purified by chromatography (hexane/EtOAc, 8:2) 
to give nitrile 38 in 79% yield (780 mg). The spectroscopic data are in agreement with
those previously described.48 
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Rf (hexane/EtOAc, 7:3): 0.40.
1H NMR (CDCl3, δ): 5.30 (m, 1H, CH), 5.25-5.28 (m, 2H,
CH2O), 5.29-5.32 (m, 2H, CH2O). MS (ESI, m/z): 96.0 [M+H]
+.
(3-Pentyloxetan-3-yl)acetonitrile (39). To a suspension of CuI (200 mg, 1 mmol) in
anhydrous Et2O (1 mL), pentylmagnesium bromide (2 M in Et2O, 1.3 mL) was added
dropwise. The mixture was cooled to 0 ᵒC before a solution of nitrile 38 (210 mg, 2.2
mmol) in Et2O (4 mL) was added 15 min. The reaction mixture was stirred at this
temperature for 2 h, quenched with a saturated aqueous solution of NH4Cl, and
extracted with EtOAc. The organic layers were washed with a saturated aqueous
solution of NaCl, dried over Na2SO4 and filtered. The solvent was removed under
reduced pressure and the residue was purified by chromatography (hexane/EtOAc, 8:2)
to give the title compound in 26% yield (43 mg). 
Rf (hexane): 0.20. IR (ATR, cm
-1): 2245 (CN). 1H NMR (CDCl3, δ): 0.84 (t, J = 6.7 Hz, 3H,
CH3), 1.16-1.29 (m, 6H, (CH2)3CH3), 1.74 (m, 2H, CH2C), 2.75 (s, 2H, CH2CN), 4.43 (d, J = 
6.4 Hz, 2H, CH2O), 4.51 (d, J = 6.4 Hz, 2H, CH2O). 
13C NMR (CDCl3, δ): 14.0 (CH3), 22.5,
23.9, 25.0 ((CH2)3CH3), 31.9 (CH2CN), 35.7 (CH2C), 41.1 (C), 79.9 (2CH2O), 118.3 (CN). MS 
(ESI, m/z): 168.1 [M+H]+.
2-(3-Pentyloxetan-3-yl)ethanamine (30). To a suspension of LAH (96 mg, 2.5 mmol) in
anhydrous Et2O, nitrile 39 (200 mg, 1.2 mmol) was added dropwise at 0 ᵒC. The reaction
was stirred for 2 h and the crude was quenched by adding H2O (2.5 mL), NaOH 1 M (2.5
mL), and H2O (5 mL). The reaction mixture was extracted with EtOAc and the organic
layers were washed with a saturated aqueous solution of NaCl, dried over Na2SO4 and
filtered. Then, the solvent was removed under reduced pressure to obtain the amine in
59% yield (121 mg).
Rf (EtOAc/MeOH, 85:15): 0.10. IR (ATR, cm
-1): 3360 (NH). 1H NMR (CDCl3, δ): 0.90 (t, J = 
6.7 Hz , 3H, CH3), 1.18-1.35 (m, 6H, (CH2)3CH3), 1.54 (br s, 2H, NH2), 1.65 (app t, J = 7.3
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Hz, 2H, CH2C), 1.84 (app t, J = 8.1 Hz, 2H, CH2CH2N), 2.69 (t, J = 7.3 Hz, 2H, CH2N), 4.40
(AB system, J = 5.7 Hz, 4H, 2CH2O); 
13C-NMR (CDCl3, ): 14.1 (CH3), 22.6, 23.7, 31.0
((CH2)3CH3), 32.3 (C), 34.3 (CH2CH2N), 35.9 (CH2C), 41.5 (CH2N), 81.9 (2CH2O). MS (ESI, 
m/z): 172.1 [M+H]+.
(4-Ethylpiperazin-1-yl)acetonitrile (40). A mixture of 1-ethylpiperazine (0.7 mL, 5.4 
mmol), bromoacetonitrile (0.4 mL, 6.0 mmol) and K2CO3 (1.70 g, 12 mmol) in anhydrous
ACN (12 mL) was stirred overnight at rt. The crude was filtered through celite washing
with ACN, and the solvent was evaporated under reduced pressure to give the title
compound in quantitative yield (827 mg).
Rf (EtOAc/MeOH, 8:2): 0.28. IR (ATR, cm
-1): 2231 (CN). 1H NMR (CDCl3, δ): 1.08 (t, J = 7.2
Hz, 3H, CH3), 2.42 (q, J = 7.2 Hz, 2H, CH3CH2), 2.51 (m, 4H, 2CH2N), 2.64 (t, J = 4.6 Hz, 4H,
2CH2N), 3.50 (s, 2H, CH2CN).
13C NMR (CDCl3, δ): 11.9 (CH3), 45.7 (CH2N), 51.7 (2CH2cycN),
52.0 (CH2N), 52.1 (2CH2cycN), 114.7 (CN). MS (ESI, m/z): 154.1 [M+H]
+.
(4-Ethylpiperazin-1-yl)ethanamine (32). A mixture of nitrile 40 (465 mg, 3 mmol) in
THF (9 mL) was treated with a solution of LAH (242 mg, 6 mmol) in THF (18 mL) at 0 ᵒC 
for 4 h. After completion, the reaction was quenched with Na2SO4·10H2O (8.40 g, excess)
and stirred for 30 min. The product was isolated by filtration through celite washing with 
THF. The crude was evaporated under reduced pressure to give the title compound in
86% yield (405 mg). 
IR (ATR, cm-1): 3311 (NH2).
1H NMR (CDCl3, δ): 1.07 (t, J = 7.2 Hz, 3H, CH3), 2.36-2.48 (m,
12H, CH2CH3, 4CH2N, CH2CH2NH2), 2.78 (t, J = 6.3 Hz, 2H, CH2NH2).
13C NMR (CDCl3, δ):
12.1 (CH3), 38.9 (CH2NH2), 52.4 (CH2CH3), 52.9 (2CH2N), 53.3 (2CH2N), 61.3 (CH2CH2NH2).
MS (ESI, m/z): 158.2 [M+H]+. 
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● 3-Bromo-N-phenylpropanamide (31). Obtained following the general procedure
4.1.1.1. from aniline (0.4 mL, 4.5 mmol) and 3-bromopropanoyl chloride (0.5 mL, 5
mmol) in 92% yield (939 mg). The spectroscopic data are in agreement with those
previously described.49 
Rf (DCM/MeOH, 95:5): 0.56. Mp: 118-122 ᵒC (Lit.
49 123-124 ᵒC). 1H NMR (CDCl3, δ): 2.96
(t, J = 6.5 Hz, 2H, CH2CO), 3.65 (t, J = 6.5 Hz, 2H, CH2Br), 7.10 (t, J = 7.4 Hz, 1H, H4), 7.27
(t, J = 7.8 Hz, 2H, H3, H5), 7.55 (d, J = 7.8 Hz, 2H, H2, H6), 8.63 (br s, 1H, NH). MS (ESI, m/z):
143.9 [M+H]+.
● Synthesis of final compounds 4-13
N3-(3-Anilino-3-oxopropyl)-N3-hexyl-N1-phenyl-β-alaninamide (4). Obtained
following the general procedure 4.1.1.2. from acrylamide 26 (500 mg, 3.4 mmol) and
hexylamine (111 mg, 1.1 mmol) in 76% yield (344 mg). 
Chromatography: EtOAc/MeOH, 9:1. Rf (EtOAc/MeOH, 9:1): 0.21. IR (ATR, cm
-1): 3298
(NH), 1660 (CO), 1601, 1547, 1498, 1443 (Ar). 1H NMR (CDCl3, δ): 0.82 (t, J = 6.9 Hz, 3H,
CH3), 1.20-1.28 (m, 6H, (CH2)3CH3), 1.50-1.54 (m, 2H, CH2(CH2)3CH3), 2.52 (t, J = 6.2 Hz,
6H, 2CH2CO, (CH2)4CH2N), 2.83 (t, J = 6.2 Hz, 4H, 2NCH2CH2CO), 7.02 (t, J = 7.4 Hz, 2H,
2H4), 7.19 (t, J = 7.8 Hz, 4H, 2H3, 2H5), 7.44 (d, J = 7.9 Hz, 4H, 2H2, 2H6), 9.08 (br s, 2H,
2NH). 13C NMR (CDCl3, δ): 14.4 (CH3), 23.0, 27.1, 27.7, 32.1 ((CH2)4CH3), 34.7 (2CH2CO), 
50.1 (2CH2N), 54.0 ((CH2)4CH2N), 120.2 (2C2, 2C6), 124.4 (2C4), 129.3 (2C3, 2C5), 138.5
(2C1), 170.9 (2CO). HRMS (ESI, m/z): Calculated for C24H34N3O2 [M+H]
+: 396.2646. Found:
369.2648.
N3-(3-Anilino-3-oxopropyl)-N3-cyclopropyl-N1-phenyl-β-alaninamide (5). Obtained
following the general procedure 4.1.1.2. from acrylamide 26 (100 mg, 0.7 mmol) and
cyclopropylamine (16 μL, 0.2 mmol) in 27% yield (19 mg). 
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Chromatography: EtOAc/MeOH, 9:1. Rf (EtOAc/MeOH, 9:1): 0.51. IR (ATR, cm
-1): 3296 
(NH), 1659 (CO), 1598, 1546, 1498, 1443 (Ar). 1H NMR (CDCl3, δ): 0.50-0.55 (m, 2H,
CH2cyc), 0.58-0.61 (m, 2H, CH2cyc), 1.78-1.83 (m, 1H, CHcyc), 2.63 (t, J = 6.2 Hz, 4H, 
2CH2CO), 3.02 (t, J = 6.2 Hz, 4H, 2 NCH2CH2CO), 7.03 (t, J = 7.4 Hz, 2H, 2H4), 7.19 (t, J = 
7.8 Hz, 4H, 2H3, 2H5), 7.41 (d, J = 7.7 Hz, 4H, 2H2, 2H6), 8.70 (br s, 2H, 2NH).
13C NMR
(CDCl3, δ): 6.9 (2CH2cyc), 34.5 (2CH2CO), 37.2 (CH), 51.7 (CH2N), 119.6 (2C2, 2C6), 124.1
(2C4), 129.0 (2C3, 2C5), 138.1 (2C1), 170.6 (2CO). HRMS (ESI, m/z): Calculated for
C21H25N3O2Na [M+Na]
+: 374.18445. Found: 374.17157.
N3-(3-Anilino-3-oxopropyl)-N3-(cyclopropylmethyl)-N1-phenyl-β-alaninamide (6).
Obtained following the general procedure 4.1.1.2. from acrylamide 26 (100 mg, 0.7
mmol) and aminomethylcyclopropane (20 μL, 0.2 mmol) in quantitative yield (73 mg). 
Chromatography: EtOAc/MeOH, 9:1. Rf (EtOAc/MeOH, 9:1): 0.42. IR (ATR, cm
-1): 3306
(NH), 1658 (CO), 1599, 1548, 1498, 1444 (Ar). 1H NMR (CDCl3, δ): 0.13 (q, J = 5.0 Hz, 2H,
CH2cyc), 0.49-0.55 (m, 2H, CH2cyc), 0.88-0.94 (m, 1H, CHcyc), 2.43 (d, J = 6.7 Hz, 2H,
CHCH2N), 2.52 (t, J = 6.3 Hz, 4H, 2CH2CO), 2.90 (t, J = 6.3 Hz, 4H, 2NCH2CH2CO), 7.01 (t, J
= 7.4 Hz, 2H, 2H4), 7.18 (t, J = 7.8 Hz, 4H, 2H3, 2H5), 7.46 (d, J = 7.7 Hz, 4H, 2H2, 2H6), 9.53
(br s, 2H, 2NH). 13C NMR (CDCl3, δ): 4.3 (2CH2cyc), 8.6 (CH), 34.3 (2CH2CO), 49.7 (2CH2N),
58.5 (CH2N), 119.9 (2C2, 2C6), 124.1 (2C4), 128.9 (2C3, 2C5), 138.3 (2C1), 170.7 (2CO).
HRMS (ESI, m/z): Calculated for C22H27N3O2Na [M+Na]
+: 388.20010. Found: 388.19619.
N3-(3-Anilino-3-oxopropyl)-N3-(3-butoxypropyl)-N1-phenyl-β-alaninamide (7).
Obtained following the general procedure 4.1.1.2. from acrylamide 26 (336 mg, 2.3
mmol) and 3-butoxypropan-1-amine (0.1 mL, 0.8 mmol) in 25% yield (81 mg). 
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Chromatography: EtOAc. Rf (EtOAc): 0.30. IR (ATR, cm
-1): 3287 (NH), 1661 (CO), 1600,
1547, 1498, 1443 (Ar). 1H NMR (CDCl3, δ): 0.76 (t, J = 7.3 Hz, 3H, CH3), 1.10-1.37 (m, 4H,
(CH2)2CH3), 1.64 (qt, J = 6.6 Hz, 2H, NCH2CH2CH2O), 2.44-2.52 (m, 6H, 2CH2CO,
NCH2(CH2)2O), 2.75 (t, J = 6.3 Hz, 4H, 2NCH2CH2CO), 3.13 (t, J = 6.6 Hz, 2H, CH2O), 3.30 (t,
J = 6.4 Hz, 2H, CH2O), 6.93 (t, J = 7.4 Hz, 2H, 2H4), 7.10 (t, J = 7.9 Hz, 4H, 2H3, 2H5), 7.37
(dd, J = 8.8, 1.0 Hz, 4H, 2H2, 2H6). 
13C NMR (CDCl3, δ): 14.4 (CH3), 20.4, 28.3, 32.9
((CH2)2CH3, NCH2CH2CH2O), 35.6 (2CH2CO), 51.2 (2CH2N), 51.3 (CH2N), 69.8, 71.7
(2CH2O), 121.3 (2C2, 2C6), 125.1 (2C4), 129.8 (2C3, 2C5), 139.7 (2C1), 173.4 (2CO). HRMS 
(ESI, m/z): Calculated for C25H35N3O3Na [M+Na]
+: 448.25761. Found: 448.25641.
N3-[6-(Methoxyhexyl)]-N1-phenyl-N3-[3-(phenylamino)-3-oxopropyl]-β-alaninamide
(8). Obtained following the general procedure 4.1.1.2. from acrylamide 26 (168 mg, 1.1
mmol) and amine 27 (60 mg, 0.5 mmol) in 21% yield (133 mg).
Chromatography: EtOAc/MeOH, 9:1. Rf (EtOAc/MeOH, 9:1): 0.42. IR (ATR, cm
-1): 3238
(NH), 1678, 1645 (CO), 1601, 1548, 1495, 1443 (Ar). 1H NMR (CDCl3, δ): 1.18-1.58 (m,
8H, OCH2(CH2)4), 2.51 (t, J = 7.1 Hz, 2H, (CH2)5CH2N), 2.53 (t, J = 5.9 Hz, 4H, 2CH2CO), 2.83
(t, J = 6.1 Hz, 4H, 2NCH2CH2CO), 3.29-3.33 (m, 5H, CH2OCH3), 7.02 (t, J = 7.4 Hz, 2H, 2H4),
7.18 (t, J = 7.8 Hz, 4H, 2H3, 2H5), 7.44 (d, J = 7.8 Hz, 4H, 2H2, 2H6), 9.20 (br s, 2H, 2NH).
13C 
NMR (CDCl3, δ): 25.9, 26.6, 27.2, 29.5 ((CH2)4CH2O), 34.6 (2CH2CO), 50.0 (2CH2N), 53.4
((CH2)5CH2N), 58.6 (CH3), 72.8 (CH2O), 119.9 (2C2, 2C6), 124.0 (2C4), 128.9 (2C3, 2C5),
138.3 (2C1), 170.7 (2CO). HRMS (ESI, m/z): Calculated for C25H34N3O3 [M-H] 
-: 424.26001. 
Found: 424.26106.
N3-(3-Anilino-3-oxopropyl)-N3-[3-(2-methoxyethoxy)propyl]-N1-phenyl-β­
alaninamide (9). Obtained following the general procedure 4.1.1.2. from acrylamide 26
(332 mg, 2.3 mmol) and amine 28 (100 mg, 0.8 mmol) in 39% yield (133 mg).
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Chromatography: EtOAc/MeOH, 8:2. Rf (EtOAc/MeOH, 9:1): 0.29. IR (ATR, cm
-1): 3305
(NH), 1662, 1545 (CO), 1600, 1497, 1443 (Ar). 1H NMR (CDCl3, δ): 1.59 (qt, J = 5.7 Hz, 2H,
NCH2CH2CH2O), 2.51 (app t, 4H, 2CH2CO), 2.54 (t, J = 5.4 Hz, 2H, NCH2CH2CH2O), 2.75 (t, J
= 5.4 Hz, 4H, 2NCH2CH2CO), 3.28 (t, J = 5.5 Hz, 2H, NCH2CH2CH2O), 3.39-3.42 (m, 2H,
CH2O), 3.45 (s, 3H, CH3), 3.60-3.63 (m, 2H, CH2O), 6.98 (t, J = 7.3 Hz, 2H, 2H4), 7.11 (t, J = 
7.7 Hz, 4H, 2H3, 2H5), 7.39 (d, J = 8.1 Hz, 4H, 2H2, 2H6), 8.89 (br s, 2H, 2NH).
13C NMR
(CDCl3, δ): 27.1 (CH2), 35.5 (2CH2CO), 49.3 (CH2N), 50.6 (2CH2N), 58.9 (CH3), 67.2, 69.4,
72.5 (3CH2O), 119.8 (2C2, 2C6), 123.6 (2C4), 128.7 (2C3, 2C5), 138.4 (2C1), 171.9 (2CO).
HRMS (ESI, m/z): Calculated for C24H34N3O4 [M+H]
+: 428.25493. Found: 428.25429.
N3-(3-Anilino-3-oxopropyl)-N3-[2-(2-ethoxyethoxy)ethyl]-N1-phenyl-β-alaninamide
(10). Obtained following the general 4.1.1.2. from acrylamide 26 (332 mg, 2.3 mmol) and
amine 29 (100 mg, 0.8 mmol) in 53% yield (181 mg). 
Chromatography: EtOAc/MeOH, 8:2. Rf (EtOAc/MeOH, 9:1): 0.30. IR (ATR, cm
-1): 3303
(NH), 1660, 1547 (CO), 1601, 1496, 1443 (Ar). 1H NMR (CDCl3, δ): 1.14 (t, J = 7.0 Hz, 3H,
CH3), 2.53 (t, J = 6.0 Hz, 4H, 2CH2CO), 2.74 (t, J = 4.9 Hz, 2H, NCH2CH2O), 2.87 (t, J = 6.0
Hz, 4H, 2NCH2CH2CO), 3.44-3.49 (m, 4H, NCH2CH2O, OCH2CH3), 3.54-3.59 (m, 4H,
O(CH2)2O), 6.98 (t, J = 7.4 Hz, 2H, 2H4), 7.13 (t, J = 7.8 Hz, 4H, 2H3, 2H5), 7.43 (d, J = 7.7
Hz, 4H, 2H2, 2H6), 9.24 (br s, 2H, 2NH).
13C NMR (CDCl3, δ): 15.0 (CH3), 35.2 (2CH2CO),
51.4 (2CH2N), 54.7 (CH2N), 66.6, 69.3, 69.6, 70.3 (4CH2O), 120.0 (2C2, 2C6), 123.8 (2C4),
128.7 (2C3, 2C5), 138.3 (2C1), 171.0 (2CO). HRMS (ESI, m/z): Calculated for C24H33N3O4Na
[M+Na]+: 450.23688. Found: 450.23663.
N3-(3-Anilino-3-oxopropyl)-N3-[(3-pentyloxetan-3-yl)ethyl]-N1-phenyl-β-alaninamide
(11). Obtained following the general procedure 4.1.1.2. from acrylamide 26 (275 mg, 1.9
mmol) and amine 30 (98 mg, 0.6 mmol) in 21% yield (63 mg). 
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Chromatography: EtOAc/MeOH, 9:1. Rf (EtOAc/MeOH, 95:5): 0.60. IR (ATR, cm
-1): 3304
(NH), 1657 (CO), 1598, 1542, 1498, 1442 (Ar). 1H NMR (CDCl3, δ): 0.88 (t, J = 7.1 Hz, 3H,
CH3), 1.15-1.31 (m, 6H, (CH2)3CH3), 1.56 (app t, J = 7.3 Hz, 2H, CH2C), 1.78 (t, J = 7.1 Hz, 
2H, CCH2CH2N), 2.56 (t, J = 5.8 Hz, 4H, 2CH2CO), 2.63 (t, J = 7.1 Hz, 2H, CCH2CH2N), 2.87
(t, J = 5.8 Hz, 4H, 2CH2N), 4.30 (d, J = 5.9 Hz, 2H, CH2O), 4.45 (d, J = 5.9 Hz, 2H, CH2O), 
7.02 (t, J = 7.5 Hz, 2H, 2H4), 7.16 (t, J = 7.5 Hz, 4H, 2H3, 2H5), 7.38 (d, J = 8.1 Hz, 4H, 2H2, 
2H6), 8.63 (br s, 2H, 2NH).
13C NMR (CDCl3, δ): 14.1 (CH3), 22.6, 23.8 ((CH2)2CH3), 31.6
(CCH2CH2N), 32.2 (CH2(CH2)2CH3), 35.1 (2CH2CO), 36.9 (CH2C), 41.4 (C), 49.2 (CCH2CH2N), 
50.1 (2CH2N), 80.9 (2CH2O), 119.8 (2C2, 2C6), 124.0 (2C4), 128.8 (2C3, 2C5), 138.0 (2C1),
170.6 (2CO). HRMS (ESI, m/z): Calculated for C28H39N3O2 [M+H]
+: 466.3025. Found:
466.3050.
● General procedure for the synthesis of final compounds 12 and 13. To a solution of
bromo derivative 31 (3 equiv) and the corresponding amine (1 equiv) in DCM (0.5
mL/mmol), Et3N (2.5 equiv) and KI (0.01 equiv) were added, and the reaction mixture
was stirred for 24 h at 60 ᵒC. The solvent was removed under reduced pressure and the 
crude was purified by column chromatography to give the title compounds.
N3-(3-Anilino-3-oxopropyl)-N3-[2-(4-ethylpiperidin-1-yl)ethyl]-N1-phenyl-β­
alaninamide (12). Obtained from 31 (218 mg, 0.9 mmol) and 2-(4-ethylpiperidin-1­
yl)ethanamine (42 mg, 0.3 mmol) in 48% yield (65 mg). 
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Chromatography: EtOAc/MeOH/NH3, 9:1:0.2. Rf (EtOAc/MeOH/NH3, 9:1:0.2): 0.43. IR
(ATR, cm-1): 3310 (NH), 1675 (CO), 1602, 1551, 1498, 1445 (Ar). 1H NMR (CDCl3, δ): 0.76
(t, J = 7.3 Hz, 3H, CH3), 1.04-1.12 (m, 5H, CH2CH3, CH, 2x½CH2cyc), 1.48 (d, J = 11.2 Hz, 2H,
2x½CH2cyc), 1.92 (t, J = 11.1 Hz, 2H, 2x½CH2cycN), 2.52-2.54 (m, 6H, NcycCH2CH2N, 2CH2CO), 
2.71 (t, J = 6.1 Hz, 2H, NcycCH2CH2N), 2.85 (t, J = 6.0 Hz, 4H, 2NCH2CH2CO), 2.95 (d, J = 
11.3 Hz, 2H, 2x½CH2cycN), 7.01 (t, J = 7.4 Hz, 2H, 2H4), 7.17 (t, J = 7.8 Hz, 4H, 2H3, 2H5),
7.44 (d, J = 7.9 Hz, 4H, 2H2, 2H6), 8.84 (br s, 2H, 2NH).
13C NMR (CDCl3, δ): 14.3 (CH3),
29.2 (CH2CH3), 31.6 (2CH2cyc), 35.2 (2CH2CO), 37.3 (CH), 50.8 (2NCH2CH2CO), 51.5
(NcycCH2CH2N), 54.9 (2CH2N), 56.8 (NcycCH2CH2N), 120.2 (2C2, 2C6), 124.1 (2C4), 128.9
(2C3, 2C5), 138.2 (2C1), 170.8 (2CO). HRMS (ESI, m/z): Calculated for C27H39N4O2 [M+H]
+: 
451.30730. Found: 451.30714.
N3-(3-Anilino-3-oxopropyl)-N3-[2-(4-ethylpiperazin-1-yl)ethyl]-N1-phenyl-β­
alaninamide (13). Obtained from 31 (218 mg, 0.9 mmol) and amine 32 (50 mg, 0.3
mmol) in 54% yield (73 mg). 
Chromatography: EtOAc/MeOH/NH3, 7:3:0.2. Rf (EtOAc/MeOH/NH3, 8:2:0.2): 0.22. Mp:
70-72 ᵒC. IR (ATR, cm-1): 3276 (NH), 1664 (CO), 1601, 1548, 1498, 1445 (Ar). 1H NMR
(CDCl3, δ): 0.96 (t, J = 7.2 Hz, 3H, CH3), 2.23 (q, J = 7.2 Hz, 2H, CH2CH3), 2.19-2.53 (m, 14H,
2CH2CO, 4CH2cyc, NcycCH2CH2N), 2.64 (t, J = 5.9 Hz, 2H, NcycCH2CH2N), 2.80 (t, J = 6.1 Hz,
4H, 2NCH2CH2CO), 7.00 (t, J = 7.4 Hz, 2H, 2H4), 7.16 (t, J = 7.8 Hz, 4H, 2H3, 2H5), 7.44 (d, J 
= 7.7 Hz, 4H, 2H2, 2H6), 9.24 (br s, 2H, 2NH).
13C NMR (CDCl3, δ): 11.9 (CH3), 34.8
(2CH2CO), 50.6 (2NCH2CH2CO), 50.8 (NcycCH2CH2N), 52.2 (CH2CH3), 52.4 (2CH2cyc), 53.8
(2CH2cyc), 56.3 (NcycCH2CH2N), 120.3 (2C2, 2C6), 124.1 (2C4), 128.9 (2C3, 2C5), 138.3 (2C1),
170.7 (2CO). HRMS (ESI, m/z): Calculated for C26H38N5O2 [M+H
+]: 452.30255. Found:
452.30104.
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Experimental section
4.1.3. Synthesis of final compounds 14, 16, and 17
● Synthesis of acrylamides 41-43
N-Methyl-N-phenylacrylamide (41). Obtained using the general procedure 4.1.1.1.
from acryloyl chloride (268 µL, 3.3 mmol), pyridine (268 µL, 3.3 mmol) and N­
methylaniline (317 µL, 3.0 mmol) in quantitative yield (484 mg). The spectroscopic data
are in agreement with those previously described.43 
Rf (hexane/EtOAc, 7:3): 0.26. Mp: 75-76 ᵒC. (Lit.
43 74-76 ᵒC). 1H-NMR (CDCl3, δ): 3.37 (s,
3H, CH3N), 5.52 (dd, J = 10.3, 2.0 Hz, 1H, ½CH2=), 6.08 (dd, J = 16.8, 10.4 Hz, 1H, CH=),
6.37 (dd, J = 16.8, 2.0 Hz, 1H, ½CH2=), 7.19 (d, J = 7.1 Hz, 2H, H2, H6), 7.34 (t, J = 7.3 Hz,
1H, H4), 7.42 (t, J = 7.4 Hz, 2H, H3, H5). MS (ESI, m/z): 162.1 [M+H]
+.
General procedure for the obtention of sulfonamides 42, 43. Over a solution of the 
corresponding aniline (1 equiv) and pyridine (1.1 equiv) in anhydrous acetone (2.5
mL/mmol), 2-chloroethane sulfonyl chloride (1.1 equiv) was added dropwise at 0 ᵒC. The
reaction mixture was stirred overnight at 0-10 ᵒC and then, the solvent was removed
under reduced pressure. The obtained residue was redissolved in DCM and washed with
saturated aqueous solutions of NaHCO3, CuSO4 and NaCl, subsequently. The organic
extract was dried over Na2SO4, filtered, and the solvent was removed under reduced
pressure. The crude was purified by column chromatography to yield desired
sulfonamides.
N-Phenylethylensulfonamide (42). Obtained from aniline (245 μL, 2.7 mmol),
pyridine (238 μL, 3.0 mmol), and 2-chloroethanesulfonyl chloride (309 μL, 3.0 mmol) in
30% yield (148 mg). The spectroscopic data are in agreement with those previously
reported.50 
Chromatography: hexane/EtOAc, 6:4; Rf (hexane/EtOAc, 7:3): 0.29. Mp: 67-68 ᵒC.
1H­
NMR (CDCl3, δ): 5.94 (d, J = 10.0 Hz, 1H, ½CH2=), 6.09 (d, J = 16.5 Hz, 1H, ½CH2=), 6.66
(dd, J = 16.5, 10.0 Hz, 1H, CH=), 7.06 (tt, J = 6.9, 1.8 Hz, 1H, H4), 7.21-7.32 (m, 4H, H2, H3, 
H5, H6), 8.69 (br s, 1H, NH). MS (ESI, m/z): 184.1 [M+H]
+.
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Experimental section
N-Methyl-N-phenylethylensulfonamide (43). Obtained from N-methylaniline (300
µL, 2.3 mmol), pyridine (0.2 mL, 2.6 mmol), and 2-chloroethanesulfonyl chloride (300 µL, 
2.3 mmol) in 70% yield (321 mg). The spectroscopic data are in agreement with those
previously described.50 
Rf (hexane/EtOAc, 8:2): 0.32. Mp: 73-74 ᵒC. 
1H-NMR (CDCl3, ): 3.25 (s, 3H, CH3), 6.02 (d,
J = 9.9 Hz, 1H, ½CH2=), 6.20 (d, J = 16.6 Hz, 1H, ½CH2=), 6.46 (dd, J = 16.6, 9.9 Hz, 1H,
CH=), 7.29-7.41 (m, 5H, H2-H6). MS (ESI, m/z): 198.1 [(M+H)
+].
● Synthesis of diamides 14, 16, and 17
N1-Methyl-N3-octyl-N1-phenyl-N3-{3-[phenyl(methyl)amino]-3-oxopropyl}-β­
alaninamide (14). Obtained using the procedure 4.1.1.2. from acrylamide 41 (325 mg,
2.0 mmol) and octylamine (111 µL, 0.7 mmol) in 64% yield (202 mg).
Chromatography: EtOAc. Rf (EtOAc/methanol, 9:1): 0.37. IR (ATR, cm 
-1): 1651 (CON),
1595, 1495, 1454 (Ar). 1H-NMR (CDCl3, δ): 0.88 (t, J = 6.9 Hz, 3H, CH3CH2), 1.06-1.29 (m,
12H, (CH2)6CH3), 2.09 (m, 2H, (CH2)6CH2N), 2.14 (t, J = 7.6 Hz, 4H, 2CH2CO), 2.60 (t, J = 7.3
Hz, 4H, 2COCH2CH2N), 3.23 (s, 6H, 2CH3N), 7.15 (d, J = 7.4 Hz, 4H, 2H2, 2H6), 7.33 (t, J = 
7.4 Hz, 2H, 2H4), 7.40 (t, J = 7.3 Hz, 4H, 2H3, 2H5).
13C-NMR (CDCl3, δ): 14.5 (CH3CH2), 
23.1, 27.3, 27.8, 29.7, 29.8, 32.1 ((CH2)6CH3), 32.2 (2CH2CO), 37.7 (2CH3N), 50.1 (2CH2N),
54.1 ((CH2)6CH2N), 127.7 (2C2, 2C6), 128.2 (2C4), 130.2 (2C3, 2C5), 144.4 (2C1), 172.3
(2CO). HRMS (ESI, m/z): Calculated for C28H42N3O2 [M+H]
+: 452.3271. Found: 452.3286.
2-2´-(Octylimino)bis(N-phenylethanesulfonamide) (16). Obtained using the
procedure 4.1.1.2. from sulfonamide 42 (140 mg, 0.8 mmol) and octylamine (42 µL, 0.3
mmol) in 44% yield (65 mg).
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Chromatography: hexane/EtOAc, 6:4. Rf (hexane/EtOAc, 6:4): 0.50. IR (ATR, cm
-1): 3247
(NH), 1600, 1496 (Ar), 1340, 1148 (SO2).
1H-NMR (CDCl3, δ): 0.88 (t, J = 6.9 Hz, 3H, CH3), 
1.02-1.37 (m, 12H, (CH2)6CH3), 2.41 (app t, J = 8.0 Hz, 2H, (CH2)6CH2N), 2.99 (t, J = 5.3 Hz,
4H, 2CH2SO2), 3.33 (t, J = 5.6 Hz, 4H, 2CH2N), 7.11-7.19 (m, 2H, 2H4), 7.28-7.37 (m, 8H,
2H2, 2H3, 2H5, 2H6), 7.95 (br s, 2H, 2NH).
13C-NMR (CDCl3, δ): 14.1 (CH3), 22.6, 23.0, 27.4,
29.2, 29.3, 31.8 ((CH2)6CH3), 48.3 (2CH2N), 49.4 (2CH2SO2), 50.7 (CH2N), 119.5 (2C2, 2C6),
124.6 (2C4), 129.5 (2C3, 2C5), 137.3 (2C1). HRMS (ESI, m/z): Calculated for C24H36N3O4S2 
[M-H] -: 494.2152. Found: 494.2173.
2,2'-(Octylimino)bis(N-methyl-N-phenylethanesulfonamide) (17). Obtained using
the procedure 4.1.1.2. from sulfonamide 43 (140 mg, 0.8 mmol) and octylamine (42 µL,
0.3 mmol) in 81% yield (127 mg).
Chromatography: EtOAc. Rf (hexane/EtOAc, 7:3): 0.30. IR (ATR, cm
-1): 1597, 1493, 1454
(Ar), 1341, 1142 (SO2). 
1H-NMR (CDCl3, ) 0.88 (t, J = 6.8 Hz, 3H, CH3CH2), 1.24-1.41 (m,
12H, (CH2)6CH3), 2.35 (app t, J = 7.4 Hz, 2H, (CH2)6CH2N), 2.85-2.90 (m, 4H, 2CH2SO2), 
3.07-3.12 (m, 4H, 2CH2N), 3.31 (s, 6H, 2CH3N), 7.25-7.32 (m, 2H, 2H4), 7.34-7.40 (m, 8H,
2H2, 2H3, 2H5, 2H6). 
13C-NMR (CDCl3, ): 14.2 (CH3CH2), 22.7, 27.1, 27.2, 29.3, 29.4, 31.8
((CH2)6CH3), 38.3 (2CH3N), 46.8 (2CH2N), 47.4 (2CH2SO2), 53.9 ((CH2)6CH2N), 126.2 (2C2, 
2C6), 127.4 (2C4), 129.4 (2C3, 2C5), 141.2 (2C1). HRMS (ESI, m/z): Calculated for
C26H42N3O4S2 [M+H]
+: 524.26112. Found: 524.25981.
4.1.4. Synthesis of final compounds 15, 18-20
N3-Octyl-N1-phenyl-β-alaninamide (44). A mixture of acrylamide 26 (200 mg, 1.4
mmol), octylamine (674 µL, 4.1 mmol) and DBU (610 µL, 4.1 mmol) in anhydrous ACN
(20 mL) was stirred for 5 h at 60 ᵒC. Then, the solvent was removed under reduced
pressure and the residue was purified by chromatography (hexane/EtOAc, 1:1) to obtain
the desired secondary amide in 76% yield (294 mg).
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Rf (EtOAc): 0.12. IR (ATR, cm
-1): 3297 (NH), 1667, 1551 (CON), 1601, 1497, 1444 (Ar). 1H­
NMR (CDCl3, δ): 0.86-0.88 (m, 3H, CH3), 1.29 (m, 10H, (CH2)5CH3), 1.54-1.58 (m, 2H,
CH2(CH2)5CH3), 2.48 (t, J = 5.2 Hz, 2H, CH2CO), 2.69 (t, J = 6.8 Hz, 2H, (CH2)6CH2N), 2.97 (t,
J = 5.4 Hz, 2H, COCH2CH2N), 3.48 (br s, 1H, NH), 7.06 (t, J = 7.3 Hz, 1H, H4), 7.29 (t, J = 7.7
Hz, 2H, H3, H5), 7.53 (d, J = 7.8 Hz, 2H, H2, H6).
13C-NMR (CDCl3, δ): 14.1 (CH3), 22.7, 27.5,
29.3, 29.5, 30.1, 31.8 ((CH2)6CH3), 36.1 (CH2CO), 45.5 (CH2N), 49.3 ((CH2)6CH2N), 119.7
(C2, C6), 123.6 (C4), 128.9 (C3, C5), 138.8 (C1), 171.1 (CO). MS (ESI, m/z): 277.2 [M+H]
+.
N3-{3-[Methyl(phenyl)amino]-3-oxopropyl}-N3-octyl-N1-phenyl-β-alaninamide (15).
Obtained following the general procedure 4.1.1.2. from acrylamide 41 (87 mg, 0.5
mmol), DBU (81 µL, 0.5 mmol), and amine 44 (100 mg, 0.2 mmol) in 58% yield (102 mg).
Chromatography: EtOAc/MeOH, 9:1. Rf (EtOAc/MeOH, 9:1): 0.31. IR (ATR, cm
-1): 3306
(NH), 1658 (CO), 1599, 1547, 1497 (Ar). 1H NMR (CDCl3, δ): 0.88 (t, J = 6.8 Hz, 3H, 
CH3CH2), 1.23 (m, 10H, (CH2)5CH3), 1.47 (m, 2H, CH2(CH2)5CH3), 2.30 (t, J = 6.8 Hz, 2H,
CH2CO), 2.39 (t, J = 7.5 Hz, 2H, (CH2)6CH2N), 2.46 (app t, 2H, CH2CO), 2.63 (app t, 2H,
NCH2CH2CO), 2.84 (t, J = 6.8 Hz, 2H, NCH2CH2CO), 3.18 (s, 3H, CH3N), 7.07 (t, J = 7.4 Hz,
1H, H4), 7.10 (d, J = 6.7 Hz, 2H, H2´, H6´), 7.27-7.42 (m, 5H, H3, H5, H3´-H5´), 7.50 (d, J = 7.9
Hz, 2H, H2, H6), 10.40 (br s, 1H, NH). 
13C NMR (CDCl3, δ): 14.1 (CH3CH2), 22.6, 26.6, 27.6,
29.3, 29.5 (5CH2), 31.5 (CH2CONCH3), 31.8 (CH2), 33.9 (CH2CONH), 37.3 (CH3N), 49.1, 50.3
(2CH2N), 53.4 ((CH2)6CH2N), 119.8 (C2, C6), 123.5 (C4), 127.1 (C2´, C6´), 128.0 (C4´), 128.8
(C3, C5), 129.9 (C3´, C5´), 138.7 (C1), 143.7 (C1´), 170.9, 171.2 (2CO). HRMS (ESI, m/z):
Calculated for C27H39N3O2 [M+H]
+: 437.3042. Found: 437.3041.
N3-[2-(Anilinosulfonyl)ethyl]-N3-octyl-N1-phenyl-β-alaninamide (18). Obtained
following the general procedure 4.1.1.2. from sulfonamide 42 (150 mg, 0.8 mmol), DBU
(122 µL, 0.8 mmol), and amine 44 (151 mg, 0.8 mmol) in 12% yield (44 mg).
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Chromatography: hexane/EtOAc, 7:3. Rf (hexane/EtOAc, 7:3): 0.35. IR (ATR, cm
-1): 3253 
(NH), 1661, 1545 (CO), 1599, 1498, 1466 (Ar), 1376, 1148 (SO2). 
1H NMR (CDCl3, δ): 0.81
(t, J = 6.8 Hz, 3H, CH3), 1.04-1.29 (m, 10H, (CH2)5CH3), 1.36 (m, 2H, CH2(CH2)5CH3), 2.35
(app t, J = 7.7 Hz, 2H, (CH2)6CH2N), 2.44 (t, J = 5.8 Hz, 2H, CH2CO), 2.71 (t, J = 5.7 Hz, 2H, 
NCH2CH2CO), 2.96 (t, J = 6.5 Hz, 2H, CH2SO2), 3.21 (t, J = 6.5 Hz, 2H, NCH2CH2SO2), 6.99­
7.12 (m, 4H, H4, H2´, H4´, H6´), 7.19-7.32 (m, 5H, H3, H5, H3´, H5´, NH), 7.48 (d, J = 7.7 Hz, 2H,
H2, H6), 9.12 (br s, 1H, NH). 
13C NMR (CDCl3, δ): 14.1 (CH3), 22.6, 26.3, 27.5, 29.2, 29.4,
31.8 ((CH2)6CH3), 34.6 (CH2CO), 47.4 (CH2SO2), 48.1 (SO2CH2CH2N), 50.5 (COCH2CH2N), 
53.7 ((CH2)6CH2N), 119.9, 120.5 (C2, C6, C2´, C6´), 124.1, 125.0 (C4, C4´), 128.9, 129.6 (C3, C5,
C3´, C5´), 136.9 (C1´), 138.1 (C1), 170.8 (CO). HRMS (ESI, m/z): Calculated for C25H38N3O3S
[M+H]+: 460.26284. Found: 460.26383.
N3-(2-{[Methyl(phenyl)amino]sulfonyl}ethyl)-N3-octyl-N1-phenyl-β-alaninamide (19).
Obtained following the general procedure 4.1.1.2. from sulfonamide 43 (103 mg, 0.5
mmol), DBU (0.1 mL, 0.5 mmol) and amine 44 (96 mg, 0.4 mmol) in 39% yield (64 mg). 
Chromatography: hexane/EtOAc, 4:6. Rf (hexane/EtOAc, 1:1): 0.38. IR (ATR, cm
-1): 3322
(NH), 1664, 1543 (CON), 1598, 1494, 1443 (Ar), 1342, 1143 (SO2). 
1H-NMR (CDCl3, ):
0.79 (t, J = 6.8 Hz, 3H, CH3CH2), 1.15-1.22 (m, 10H, (CH2)5CH3), 1.38-1.43 (m, 2H,
CH2(CH2)5CH3), 2.39 (t, J = 5.4 Hz, 2H, CH2CO), 2.42 (t, J = 7.4 Hz, 2H, (CH2)6CH2N), 2.69 (t,
J = 5.8 Hz, 2H, CH2SO2), 2.93-2.98 (m, 2H, CH2N), 3.08-3.12 (m, 2H, CH2N), 3.25 (s, 3H,
CH3N), 7.01 (t, J = 7.4 Hz, 1H, H4), 7.18-7.33 (m, 7H, H3, H5, H2´-H6´), 7.45 (d, J = 7.7 Hz, 2H,
H2, H6), 9.63 (br s, 1H, NH).
13C-NMR (CDCl3, ): 14.1 (CH3CH2), 22.6, 26.8, 27.5, 29.2,
29.4, 31.8 ((CH2)6CH3), 34.4 (CH2CO), 38.3 (CH3N), 46.1, 47.0 (2CH2N), 50.5 (CH2SO2), 53.6
((CH2)6CH2N), 119.7 (C2, C6), 123.8 (C4), 126.2 (C2´, C6´), 127.5 (C4´), 128.9 (C3, C5), 129.5
(C3´, C5´), 138.4 (C1), 141.1 (C1´), 170.4 (CONH). HRMS (ESI, m/z): Calculated for
C26H40N3O3S [M+H]
+: 474.27849. Found: 474.27701.
N3-Octyl-N1-phenyl-N3-[(5-phenyl-1,3,4-oxadiazol-2-yl)methyl]-β-alaninamide (20).
To a solution of 2-(chloromethyl)-5-phenyl-1,3,4-oxadiazole (117 mg, 0.6 mmol) in
anhydrous ACN (2.4 mL), amine 44 (200 mg, 0.7 mmol) and Et3N (0.1 mL, 0.7 mmol)
were added and the reaction mixture was stirred for 24 h at 60 ᵒC. Once at rt, the
solvent was evaporated under reduced pressure and the crude was suspended in water
and extracted with DCM. The organic layers were dried over Na2SO4, filtered, and the 
78
 
  
   
       
 
        
      
            
    
         
   
    
    
      
    
    
 
 
    
      
     
    
        
   
 
 
        
      
       
      
         
 
     
 
Experimental section
solvent was removed under reduced pressure. The residue was purified by
chromatography (DCM/EtOAc, 8:2) to yield final compound 20 in 62% yield (162 mg).
Rf (DCM/EtOAc, 8:2): 0.40. IR (ATR, cm
-1): 3304 (NH), 1728 (CO), 1599, 1550, 1499, 1444
(Ar). 1H NMR (CDCl3, δ): 0.85 (t, J = 6.9 Hz, 3H, CH3), 1.25-1.30 (m, 10H, (CH2)5CH3), 1.50­
1.60 (m, 2H, CH2(CH2)5CH3), 2.63 (t, J = 6.3 Hz, 2H, CH2CO), 2.70 (app t, J = 7.3 Hz, 2H,
NCH2), 3.00 (t, J = 6.3 Hz, 2H, NCH2CH2CO), 4.10 (s, 2H, NCH2Chet), 7.07 (tt, J = 7.7 Hz, 1.8,
1H, H4), 7.28 (t, J = 7.2 Hz, 2H, H3, H5), 7.44 (t, J = 7.7 Hz, 2H, H3´, H5´), 7.50 (d, J = 7.3 Hz,
1H, H4´), 7.57 (d, J = 8.6 Hz, 2H, H2, H6), 7.93 (d, J = 8.6 Hz, 2H, H2´, H6´), 10.17 (br s, 1H, 
NH). 13C NMR (CDCl3, δ): 14.5 (CH3), 23.0, 27.2, 27.8, 29.6, 29.8, 32.1 ((CH2)6CH3), 34.2
(CH2CO), 47.7 (NCH2Chet), 51.0 (COCH2CH2N), 54.4 ((CH2)6CH2N), 120.3 (C2, C6), 123.8 (C4),
124.3 (C4´), 127.3 (C2´, C6´), 129.3 (C3, C5), 129.5 (C3´, C5´), 132.3 (C1´), 138.8 (C1), 163.8
(CH2CN), 165.9 (C1´CN), 170.4 (CO). HRMS (ESI, m/z): Calculated for C26H35N4O2 [M+H]
+: 
435.2755. Found: 435.2752.
4.1.5. Synthesis of final compounds 21-25
N2-(2-Anilino-2-oxoethyl)-N2-octyl-N1-phenylglycinamide (21). To a solution of 2­
bromo-N-phenylacetamide (575 mg, 2.7 mmol) and octylamine (200 µL, 1.2 mmol) in
anhydrous ACN (12 mL), DIPEA (600 µL, 3.5 mmol) was added at rt. The reaction mixture
was stirred at 60 ᵒC for 16 h. The solvent was evaporated under reduced pressure and
the residue was purified by chromatography (hexane/EtOAc, 1:1) to yield diamide 21 in
93% yield (441 mg).
Rf (EtOAc): 0.75. IR (ATR, cm
-1): 3274 (NH), 1666 (CO), 1601, 1542, 1444 cm-1 (Ar). 1H 
NMR (CDCl3, δ): 0.85 (t, J = 6.7 Hz, 3H, CH3), 1.23-1.28 (m, 10H, (CH2)5CH3), 1.44-1.51 (m,
2H, CH2(CH2)5CH3), 2.66 (t, J = 7.4 Hz, 2H, NCH2CH2), 3.36 (s, 4H, 2NCH2CO), 7.10 (t, J = 
7.4 Hz, 2H, 2H4), 7.32 (app t, J = 7.9 Hz, 4H, 2H3, 2H5), 7.62 (d, J = 7.7 Hz, 4H, 2H2, 2H6), 
9.07 (br s, 2H, 2NH). 13C NMR (CDCl3, δ): 14.1 (CH3), 22.6, 27.2, 27.6, 29.3, 29.4, 31.8
((CH2)6CH3), 56.4 (NCH2CH2), 59.8 (2NCH2CO), 119.9 (2C2, 2C6), 124.4 (2C4), 129.0 (2C3, 
2C5), 137.7 (2C1), 169.4 (2CO). HRMS (ESI, m/z): Calculated for C24H33N3O2Na [M+Na]
+: 
418.2465. Found: 418.2449.
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Experimental section
N2-Octyl-N1-phenylglycinamide (45). To a solution of octylamine (3.4 mL, 21 mmol) in
dry DCM (20 mL), a solution of 2-bromo-N-phenylacetamide (2.20 g, 10 mmol) in dry
DCM (10 mL) was added dropwise at rt. The reaction mixture was stirred at rt for 16 h.
The crude was washed with saturated solutions of NaHCO3 and NaCl, subsequently. The
organic layer was dried over Na2SO4, filtered, and evaporated under reduced pressure. 
The residue was purified by chromatography (hexane/EtOAc, 1:1) to yield secondary
amine 45 in 40% yield (1.05 g).
Rf (EtOAc): 0.24. IR (ATR, cm
-1): 3349 (NH), 1713 (CO), 1598, 1444 (Ar). 1H NMR (CDCl3, 
δ): 0.88 (t, J = 6.8 Hz, 3H, CH3), 1.28-1.38 (m, 10H, (CH2)5CH3), 1.51 (qt, J = 6.9 Hz, 2H,
CH2(CH2)5CH3), 1.74 (br s, 1H, NH), 2.66 (t, J = 6.9 Hz, 2H, NCH2CH2), 3.36 (s, 2H, NCH2CO),
7.09 (tt, J = 7.4, 1.1 Hz, 1H, H4), 7.32 (app t, J = 7.9 Hz, 2H, H3, H5), 7.58 (dd, J = 8.7, 1.1
Hz, 2H, H2, H6), 9.38 (br s, 1H, NH).
13C NMR (CDCl3, δ): 14.1 (CH3), 22.7, 27.2, 29.3, 29.5,
30.1, 31.8 ((CH2)6CH3), 50.3, 53.1 (2CH2N), 119.4 (2C2, 2C6), 124.1 (C4), 129.0 (2C3, 2C5),
137.8 (C1), 170.0 (CO). MS (ESI, m/z): 263.2 [M+H]
+.
N3-(2-Anilino-2-oxoethyl)-N3-octyl-N1-phenyl-β-alaninamide (22). To a suspension
of amine 45 (195 mg, 0.7 mmol) and 3-bromo-N-phenylpropanamide (31) (340 mg, 1.5
mmol) in dry DCM (1.5 mL), DIPEA (0.40 mL, 2.4 mmol) was added and the reaction
mixture was stirred at reflux for 16 h. Once at rt, the crude was washed with saturated
solutions of NaHCO3 and NaCl, subsequently. The organic layer was dried over Na2SO4, 
filtered and evaporated under reduced pressure. The residue was purified by
chromatography (hexane/EtOAc, 1:1) to yield compound 22 in 25% yield (76 mg). 
Rf (hexane/EtOAc, 6:4): 0.16. IR (ATR, cm-
1): 3274 (NH), 1664 (CO), 1601, 1540, 1444
(Ar). 1H NMR (CDCl3, δ): 0.83 (t, J = 6.8 Hz, 3H, CH3), 1.18-1.23 (m, 10H, (CH2)5CH3), 1.44
(m, 2H, CH2(CH2)5CH3), 2.47-2.54 (m, 4H, NCH2(CH2)6, COCH2CH2N), 2.91 (t, J = 6.3 Hz, 2H,
NCH2CH2CO), 3.15 (s, 2H, NCH2CO), 7.08 (m, 2H, H4, H4´), 7.18 (t, J = 7.8 Hz, 2H, H3, H5), 
7.24 (t, J = 7.9 Hz, 2H, H3´, H5´), 7.48 (d, J = 7.6 Hz, 2H, H2, H4), 7.53 (d, J = 7.6 Hz, 2H, H2´, 
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Experimental section
H4´), 8.87 (br s, 1H, NH), 9.45 (br s, 1H, NH). 
13C NMR (CDCl3, δ): 14.0 (CH3), 22.6, 27.2,
27.5, 29.3, 29.5, 31.8 ((CH2)6CH3), 35.0 (COCH2CH2N), 51.1, 55.7 (2NCH2CH2), 58.9
(NCH2CO), 119.7, 119.9 (C2, C6, C2´, C6´), 124.1, 124.2 (C4, C4´), 128.8, 128.9 (C3, C5, C3´, C5´), 
137.5, 138.3 (C1, C1´), 170.4 (2CO). HRMS (ESI, m/z): Calculated for C25H35N3O2Na 
[M+Na]+: 432.2622. Found: 432.2615.
N2-Octyl-N2-(3-oxo-3-phenylpropyl)-N1-phenyl-β-alaninamide (23). Over a solution of
3-chloropropiophenone (98 mg, 0.6 mmol) in ACN (3.0 mL), NaHCO3 (1 M in H2O, 0.6 mL) 
and a solution of amine 44 (160 mg, 0.6 mmol) in ACN (1.0 mL) were added. The mixture
was stirred on at rt and then, washed with a saturated solution of NaCl. The organic
extract was dried over Na2SO4, filtered, the solvent removed under reduced pressure
and the residue was purified by chromatography (hexane/EtOAc, 1:1) to yield desired
product in 43% yield (105 mg).
Rf (hexane/EtOAc, 1:1): 0.25. IR (ATR, cm
-1): 3308 (NH), 1681, 1543 (CO, CON), 1598,
1498, 1443 (Ar). 1H-NMR (CDCl3, δ): 0.86 (t, J = 6.8 Hz, 3H, CH3), 1.21-1.27 (m, 10H,
(CH2)5CH3), 1.55 (m, 2H, CH2(CH2)5CH3), 2.53 (t, J = 5.5 Hz, 2H, CH2CON), 2.60 (t, J = 7.5
Hz, 2H, (CH2)6CH2N), 2.84 (t, J = 5.8 Hz, 2H, NCOCH2CH2N), 3.08 (t, J = 6.4 Hz, 2H, CH2CO),
3.22 (t, J = 6.6 Hz, 2H, COCH2CH2N), 7.06 (t, J = 7.4 Hz, 1H, H4), 7.28 (t, J = 7.9 Hz, 2H, H3, 
H5), 7.46 (t, J = 7.6 Hz, 2H, H3´, H5´), 7.51 (d, J = 7.5 Hz, 2H, H2, H6), 7.58 (t, J = 7.4 Hz, 1H,
H4´), 7.93 (d, J = 7.1 Hz, 2H, H2´, H6´), 10.29 (br s, 1H, NH).
13C-NMR (CDCl3, δ): 14.2 (CH3),
22.7, 26.8, 27.7, 29.3, 29.6, 31.9 ((CH2)6CH3), 34.1, 35.4 (2CH2CO), 48.2, 50.8, 53.6
(3CH2N), 119.8 (C2, C6), 123.7 (C4), 128.1 (C2´, C6´), 128.8 (C3´, C5´), 128.9 (C3, C5), 133.4
(C4´), 136.7 (C1´), 138.6 (C1), 170.9 (CON), 199.0 (CO). HRMS (ESI, m/z): Calculated for
C26H36N2O2Na [M+Na]
+: 431.2674. Found: 431.2666.
N2-Octyl-N2-(2-oxo-2-phenylethyl)-N1-phenyl-β-alaninamide (24). Over a solution of
2-bromoacetophenone (110 mg, 0.6 mmol) and K2CO3 (229 mg, 1.7 mmol) in anhydrous
ACN (2.5 mL), a solution of amine 44 (145 mg, 0.6 mmol) in anhydrous ACN (1.0 mL) was
added and the mixture stirred on at rt. Then, the crude was washed with an aqueous
solution of NaOH 0.1 M and the aqueous phase was extracted with EtOAc. The organic
extracts were dried over Na2SO4, filtered, and the solvent removed under reduced
pressure. The residue was purified by chromatography (hexane/EtOAc, 1:1) to give
compound 24 in 56% yield (133 mg).
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Experimental section
Rf (hexane/EtOAc, 1:1): 0.37. IR (ATR, cm
-1): 3269 (NH), 1660, 1547 (CO, CON), 1599,
1496, 1444 (Ar). 1H-NMR (CDCl3, δ): 0.85 (t, J = 6.8 Hz, 3H, CH3), 1.20-1.27 (m, 10H,
(CH2)5CH3), 1.55 (m, 2H, CH2(CH2)5CH3), 2.60 (t, J = 5.8 Hz, 2H, CH2CO), 2.72 (t, J = 7.6 Hz,
2H, (CH2)6CH2N), 2.98 (t, J = 5.8 Hz, 2H, COCH2CH2N), 4.10 (s, 2H, NCH2CO), 7.08 (t, J = 6.9
Hz, 1H, H4), 7.33 (t, J = 7.9 Hz, 2H, H3, H5), 7.49 (t, J = 7.5 Hz, 2H, H3´, H5´), 7.61 (t, J = 7.4
Hz, 1H, H4´), 7.77 (d, J = 8.2 Hz, 2H, H2, H6), 7.98 (d, J = 7.1 Hz, 2H, H2´, H6´), 10.81 (br s,
1H, NH). 13C-NMR (CDCl3, δ): 14.2 (CH3), 22.7, 26.8, 27.4, 29.5, 29.8, 31.9 ((CH2)6CH3), 
34.3 (CH2CO), 50.9 (COCH2CH2N), 54.4 ((CH2)6CH2N), 60.0 (NCH2CO), 120.2 (C2, C6), 123.7
(C4), 128.0 (C2´, C6´), 128.9 (C3, C5), 129.0 (C3´, C5´), 133.9 (C4´), 134.4 (C1´), 139.0 (C1), 170.4
(CON), 197.3 (CO). HRMS (ESI, m/z): Calculated for C25H35N2O2 [M+H]
+: 395.2698. Found:
395.2680.
N2-Benzoyl-N2-octyl-N1-phenyl-β-alaninamide (25). Obtained using the procedure
4.1.1.3 from amine 44 (167 mg, 0.6 mmol), benzoic acid (74 mg, 0.6 mmol), EDC (94 mg,
0.6 mmol) and HOBt (81 mg, 0.6 mmol) in 72% yield (164 mg).
Chromatography: hexane/EtOAc, 9:1. Rf (hexane/EtOAc, 7:3): 0.28. Mp: 65-67 ᵒC. IR
(ATR, cm-1): 3307 (NH), 1686 (CON), 1607, 1546, 1498, 1439 (Ar). 1H-NMR (CDCl3, δ): 
0.85 (t, J = 6.9 Hz, 3H, CH3), 1.09-1.15 (m, 10H, (CH2)5CH3), 1.50 (m, 2H, CH2(CH2)5CH3), 
2.75 (m, 2H, CH2CO), 3.25 (m, 2H, (CH2)6CH2N), 3.81 (m, 2H, COCH2CH2N), 7.04 (t, J = 7.4
Hz, 1H, H4), 7.21-7.27 (m, 2H, H3´, H5´), 7.32-7.40 (m, 5H, H3, H5, H2´, H4´, H6´), 7.51 (d, J = 
7.7 Hz, 2H, H2, H6), 9.35 (br s, 1H, NH). 
13C-NMR (CDCl3, δ): 14.0 (CH3), 22.6, 26.4, 28.8,
29.0 (2C), 31.7 ((CH2)6CH3), 36.2 (CH2CO), 42.6 (CH2N), 50.6 ((CH2)6CH2N), 119.9 (C2, C6),
123.9 (C4), 126.4 (C2´, C6´), 128.5 (C3´, C5´), 128.8 (C3, C5), 129.5 (C4´), 136.4 (C1´), 138.6 (C1),
169.8, 172.7 (2CO). MS (ESI, m/z): 381.2 [M+H]+. 
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Experimental section
4.1.6. Synthesis of final compounds 46-61
N2-(2-Methoxyphenylcarbonyl)-N2-octyl-N1-phenyl-β-alaninamide (46). Obtained
using the procedure 4.1.1.3 from amine 44 (85 mg, 0.3 mmol), 2-methoxybenzoic acid
(46 mg, 0.3 mmol), EDC (47 mg, 0.3 mmol) and HOBt (41 mg, 0.3 mmol) in 70% yield (86
mg).
Chromatography: hexane/EtOAc, 1:1. Rf (hexane/EtOAc, 1:1): 0.42. IR (ATR, cm
-1): 3270
(NH), 1686, 1547 (CON), 1599, 1498, 1441 (Ar). 1H-NMR (CDCl3, δ): Mixture of rotamers
A:B, 9:1; 0.86 (t, J = 7.0 Hz, 3H, CH3CH2), 1.08-1.31 (m, 10H, (CH2)5CH3), 1.44-1.51 (m, 2H,
CH2(CH2)5CH3 rotamer A), 1.52-1.73 (m, 2H, CH2(CH2)5CH3 rotamer B), 2.17 (m, 2H,
CH2CO rotamer B), 2.39-2.48 (m, 2H, (CH2)6CH2N rotamer B), 2.80-2.85 (m, 2H, CH2CO 
rotamer A), 3.13-3.20 (m, 2H, (CH2)6CH2N rotamer A), 3.42-3.57 (m, 2H, COCH2CH2N 
rotamer B), 3.67 (s, 3H, CH3O rotamer A), 3.72-4.06 (m, 5H, COCH2CH2N rotamer A, CH3O 
rotamer B), 6.86 (d, J = 8.3 Hz, 1H, H3´), 6.95 (t, J = 7.4 Hz, 1H, H5´), 7.04 (t, J = 7.4 Hz, 1H,
H4), 7.19 (dd, J = 7.4, 1.7 Hz, 1H, H6´), 7.24 (t, J = 8.1 Hz, 2H, H3, H5), 7.32 (td, J = 7.1, 1.7
Hz, 1H, H4´), 7.53 (d, J = 7.7 Hz, 2H, H2, H6), 9.47 (br s, 1H, NH).
13C-NMR (CDCl3, δ): 14.2
(CH3CH2), 22.7, 26.5, 28.6, 29.1 (2C), 31.8 ((CH2)6CH3), 36.3 (CH2CO), 42.0 (CH2N), 49.9
((CH2)6CH2N), 55.4 (CH3O), 110.9 (C3´), 120.0 (C2, C6), 120.8 (C5´), 123.7 (C4), 125.9 (C1´),
127.6 (C6´), 128.7 (C3, C5), 130.5 (C4´), 138.8 (C1), 155.2 (C2´), 170.0, 170.5 (2CO). HRMS
(ESI, m/z): Calculated for C25H34N2O3Na [M+Na]
+: 433.2467. Found: 433.2466.
N2-(3-Methoxyphenylcarbonyl)-N2-octyl-N1-phenyl-β-alaninamide (47). Obtained
using the procedure 4.1.1.3 from amine 44 (85 mg, 0.3 mmol), 3-methoxybenzoic acid
(46 mg, 0.3 mmol), EDC (47 mg, 0.3 mmol) and HOBt (41 mg, 0.3 mmol) in 67% yield (83
mg).
Chromatography: hexane/EtOAc, 1:1. Rf (hexane/EtOAc, 1:1): 0.48. IR (ATR, cm
-1): 3273
(NH), 1687, 1547 (CON), 1601, 1498, 1442 (Ar). 1H-NMR (CDCl3, δ): Mixture of rotamers
A:B, 9:1; 0.86 (t, J = 6.9 Hz, 3H, CH3CH2), 1.12-1.27 (m, 10H, (CH2)5CH3), 1.52 (m, 2H,
CH2(CH2)5CH3), 2.48 (m, 2H, CH2CO rotamer B), 2.77 (t, J = 6.0 Hz, 2H, CH2CO rotamer A),
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3.27 (t, J = 7.5 Hz, 2H, (CH2)6CH2N rotamer A), 3.45 (m, 2H, (CH2)6CH2N rotamer B), 3.69
(s, 3H, CH3O), 3.81-3.92 (m, 2H, COCH2CH2N), 6.83 (s, 1H, H2´), 6.90 (t, J = 7.4 Hz, 1H, H5´),
6.91 (d, J = 8.6 Hz, 1H, H4´), 7.06 (t, J = 7.4 Hz, 1H, H4), 7.23-7.29 (m, 3H, H3, H5, H6´), 7.54
(d, J = 7.9 Hz, 2H, H2, H6), 9.39 (br s, 1H, NH). 
13C-NMR (CDCl3, δ): 14.2 (CH3CH2), 22.7,
26.5, 28.9, 29.1, 29.2, 31.8 ((CH2)6CH3), 36.2 (CH2CO), 42.7 (CH2N), 50.7 ((CH2)6CH2N), 
55.3 (CH3O), 111.7 (C2´), 115.6 (C6´), 118.6 (C5´), 120.0 (C2, C6), 124.0 (C4), 128.9 (C3, C5), 
129.8 (C4´), 137.6 (C1´), 138.6 (C1), 159.7 (C3´), 169.9, 172.6 (2CO). HRMS (ESI, m/z):
Calculated for C25H33N2O3 [M-H] 
-: 409.2496. Found: 409.2491.
N2-(4-Methoxyphenylcarbonyl)-N2-octyl-N1-phenyl-β-alaninamide (48). Obtained
using the procedure 4.1.1.3 from amine 44 (50 mg, 0.2 mmol), 4-methoxybenzoic acid
(30 mg, 0.2 mmol), EDC (20 mg, 0.2 mmol) and HOBt (23 mg, 0.2 mmol) in 73% yield (60
mg).
Chromatography: hexane/EtOAc, 7:3 to 3:7. Rf (hexane/EtOAc, 7:3): 0.31. IR (ATR, cm
-1):
3309 (NH), 1688, 1547 (CON), 1607, 1504, 1441 (Ar). 1H-NMR (CDCl3, δ): 0.86 (t, J = 6.9
Hz, 3H, CH3CH2), 1.14-1.26 (m, 10H, (CH2)5CH3), 1.53 (m, 2H, CH2(CH2)5CH3), 2.77 (m, 2H,
CH2CO), 3.32 (m, 2H, (CH2)6CH2N), 3.81-3.86 (m, 5H, COCH2CH2N, CH3O), 6.86 (d, J = 8.8
Hz, 2H, H3´, H5´), 7.07 (t, J = 7.4 Hz, 1H, H4), 7.29 (t, J = 9.2 Hz, 2H, H3, H5), 7.30 (m, 2H, H2´, 
H6´), 7.56 (d, J = 7.7 Hz, 2H, H2, H6), 9.31 (br s, 1H, NH).
13C-NMR (CDCl3, δ): 14.2 (CH3CH2), 
22.7, 26.6, 28.9, 29.2 (2C), 31.8 ((CH2)6CH3), 36.4 (CH2CO), 42.8 (CH2N), 50.9
((CH2)6CH2N), 55.4 (CH3O), 113.8 (C3´, C5´), 120.0 (C2, C6), 124.0 (C4), 128.5 (C3, C5), 128.9
(C2´, C6´), 138.6 (C1), 143.0 (C1´), 160.7 (C4´), 169.9, 172.9 (2CO). HRMS (ESI): Calculated for
C25H34N2O3Na [M+Na]
+: 433.2467. Found: 433.2450.
N2-(4-Cyanophenylcarbonyl)-N2-octyl-N1-phenyl-β-alaninamide (49). Obtained
using the procedure 4.1.1.3 from amine 44 (50 mg, 0.2 mmol), 4-cyanobenzoic acid (22
mg, 0.2 mmol), EDC (20 mg, 0.2 mmol) and HOBt (23 mg, 0.2 mmol) in 68% yield (55
mg).
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Experimental section
Chromatography: hexane/EtOAc, 1:1. Rf (hexane/EtOAc, 1:1): 0.30. Mp: 90-91 ᵒC. IR
(ATR, cm-1): 3311 (NH), 2232 (CN), 1686, 1611, 1545 (CON), 1498, 1439 (Ar). 1H-NMR
(CDCl3, δ): Mixture of rotamers A:B, 9:1; 0.87 (t, J = 6.9 Hz, 3H, CH3), 1.10-1.27 (m, 10H,
(CH2)5CH3), 1.50 (m, 2H, CH2(CH2)5CH3 rotamer A), 1.66 (m, 2H, CH2(CH2)5CH3 rotamer B),
2.49 (m, 2H, CH2CO rotamer B), 2.78 (t, J = 6.4 Hz, 2H, CH2CO rotamer A), 3.22 (t, J = 7.8
Hz, 2H, (CH2)6CH2N rotamer A), 3.50 (m, 2H, (CH2)6CH2N rotamer B), 3.60 (m, 2H,
COCH2CH2N rotamer B), 3.84 (t, J = 6.4 Hz, 2H, COCH2CH2N rotamer A), 7.01 (t, J = 7.3 Hz,
1H, H4), 7.28 (t, J = 7.8 Hz, 2H, H3, H5), 7.42 (d, J = 8.1 Hz, 2H, H3´, H5´), 7.49 (d, J = 8.0 Hz,
2H, H2, H6), 7.65 (d, J = 8.1 Hz, 2H, H2´, H6´), 8.13 (br s, 1H, NH rotamer B), 9.02 (br s, 1H,
NH rotamer A). 13C-NMR (CDCl3, δ): 14.1 (CH3), 22.6, 26.4, 28.8, 29.0 (2C), 31.7
((CH2)6CH3), 35.8 (CH2CO), 42.6 (CH2N), 50.6 ((CH2)6CH2N), 113.4 (C4´), 118.0 (CN), 119.9
(C2, C6), 124.2 (C4), 127.2 (C3´, C5´), 128.9 (C3, C5), 132.5 (C2´, C6´), 138.2 (C1), 140.7 (C1´), 
169.3, 170.6 (2CO). MS (ESI): 406.3 [M+H]+.
N2-(4-Fluorophenylcarbonyl)-N2-octyl-N1-phenyl-β-alaninamide (50). Obtained
using the procedure 4.1.1.3 from amine 44 (85 mg, 0.3 mmol), 4-fluorobenzoic acid (42
mg, 0.3 mmol), EDC (47 mg, 0.3 mmol) and HOBt (41 mg, 0.3 mmol) in 72% yield (86
mg).
Chromatography: hexane/EtOAc, 7:3 to 3:7. Rf (hexane/EtOAc, 1:1): 0.42. Mp: 76-77 ᵒC.
IR (ATR, cm-1): 3306, 3136 (NH), 1688, 1666, 1546 (CON), 1602, 1499, 1442 (Ar). 1H-NMR
(CDCl3, δ): 0.86 (t, J = 6.9 Hz, 3H, CH3), 1.11-1.26 (m, 10H, (CH2)5CH3), 1.51 (m, 2H,
CH2(CH2)5CH3), 2.75 (t, J = 5.9 Hz, 2H, CH2CO), 3.26 (t, J = 7.2 Hz, 2H, (CH2)6CH2N), 3.82 (t,
J = 6.0 Hz, 2H, COCH2CH2N), 7.03 (t, J = 8.6 Hz, 2H, H2´, H6´), 7.07 (t, J = 7.4 Hz, 1H, H4),
7.27 (t, J = 7.9 Hz, 2H, H3, H5), 7.32 (dd, J = 8.4, 5.5 Hz, 2H, H3´, H5´), 7.52 (d, J = 7.9 Hz, 2H,
H2, H6), 9.29 (br s, 1H, NH).
13C-NMR (CDCl3, δ): 14.2 (CH3), 22.7, 26.5, 28.9, 29.1 (2C),
31.8 ((CH2)6CH3), 36.1 (CH2CO), 42.8 (CH2N), 50.8 ((CH2)6CH2N), 115.7 (C3´, C5´), 119.9 (C2, 
C6), 124.1 (C4), 128.7 (d, J = 8.4 Hz, C2´, C6´), 128.9 (C3, C5), 132.5 (C1´), 138.2 (C1), 163.3
(C4´), 169.7, 171.8 (2CO). MS (ESI): 399.1 [(M+H)
+].
N2-[4-(Trifluoromethyl)phenylcarbonyl]-N2-octyl-N1-phenyl-β-alaninamide (51).
Obtained using the procedure 4.1.1.3 from amine 44 (85 mg, 0.3 mmol), 4­
(trifluoromethyl)benzoic acid (57 mg, 0.3 mmol), EDC (47 mg, 0.3 mmol) and HOBt (41
mg, 0.3 mmol) in 66% yield (89 mg).
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Chromatography: hexane/EtOAc, 7:3 to 1:1. Rf (hexane/EtOAc, 1:1): 0.53. Mp: 80-81 ᵒC.
IR (ATR, cm-1): 3307 (NH), 1688, 1666, 1615, 1546 (CON), 1499, 1443 (Ar). 1H-NMR
(CDCl3, δ): Mixture of rotamers A:B, 9:1; 0.88 (t, J = 6.9 Hz, 3H, CH3), 1.12-1.28 (m, 10H,
(CH2)5CH3), 1.53 (m, 2H, CH2(CH2)5CH3 rotamer A), 1.69 (m, 2H, CH2(CH2)5CH3 rotamer B),
2.51 (m, 2H, CH2CO rotamer B), 2.83 (t, J = 6.4 Hz, 2H, CH2CO rotamer A), 3.26 (t, J = 7.5
Hz, 2H, (CH2)6CH2N rotamer A), 3.53 (m, 2H, (CH2)6CH2N rotamer B), 3.64 (m, 2H,
COCH2CH2N rotamer B), 3.88 (t, J = 6.4 Hz, 2H, COCH2CH2N rotamer A), 7.10 (t, J = 7.4 Hz,
1H, H4), 7.28 (t, J = 7.8 Hz, 2H, H3, H5), 7.45 (d, J = 8.0 Hz, 2H, H2´, H6´ rotamer A), 7.50 (d,
J = 8.0 Hz, 2H, H2, H6), 7.64 (d, J = 8.1 Hz, 2H, H3´, H5´ rotamer A), 7.72 (d, J = 8.2 Hz, 2H,
H2´, H6´ rotamer B), 8.17 (d, J = 8.1 Hz, 2H, H3´, H5´ rotamer B), 9.25 (br s, 1H, NH).
13C­
NMR (CDCl3, δ): 14.1 (CH3), 22.6, 26.4, 28.8, 29.0, 29.1, 31.7 ((CH2)6CH3), 35.9 (CH2CO),
42.8 (CH2N), 50.7 ((CH2)6CH2N), 120.0 (C2, C6), 124.2 (C4), 125.7 (q, J = 3.6 Hz, C3´, C5´),
126.9 (C2´, C6´), 127.3 (CF3), 128.9 (C3, C5), 131.7 (C4´), 138.3 (C1), 139.9 (C1´), 169.6, 171.3
(2CO). MS (ESI): 449.2 [(M+H)+].
N2-(4-Acetamidophenylcarbonyl)-N2-octyl-N1-phenyl-β-alaninamide (52). Obtained
using the procedure 4.1.1.3 from amine 44 (85 mg, 0.3 mmol), 4-acetamidobenzoic acid
(54 mg, 0.3 mmol), EDC (47 mg, 0.3 mmol) and HOBt (41 mg, 0.3 mmol) in 70% yield (92
mg).
Chromatography: hexane/EtOAc, 2:8. Rf (hexane/EtOAc, 2:8): 0.19. IR (ATR, cm
-1): 3300
(NH), 1669, 1535 (CON), 1602, 1468, 1438 (Ar). 1H-NMR (CDCl3, δ): Mixture of rotamers
A:B, 8:2; 0.85 (t, J = 6.8 Hz, 3H, CH3CH2), 1.16-1.29 (m, 10H, (CH2)5CH3), 1.49-1.62 (m, 2H,
CH2(CH2)5CH3 rotamers A and B), 1.97 (s, 3H, CH3CO rotamer B), 2.15 (s, 3H, CH3CO
rotamer A), 2.22 (m, 2H, CH2CO rotamer B), 2.76 (m, 2H, CH2CO rotamer A), 3.26 (m, 2H,
(CH2)6CH2N rotamer A), 3.45 (m, 2H, (CH2)6CH2N rotamer B), 3.60 (m, 2H, COCH2CH2N 
rotamer B), 3.83 (m, 2H, COCH2CH2N rotamer A), 7.07 (t, J = 7.4 Hz, 1H, H4), 7.20 (d, J = 
7.6 Hz, 2H, H2´, H6´), 7.27 (t, J = 7.8 Hz, 2H, H3, H5), 7.44 (d, J = 7.4 Hz, 2H, H3´, H5´), 7.53 (d,
J = 7.7 Hz, 2H, H2, H6), 8.15 (br s, 1H, NH), 9.19 (br s, 1H, NH).
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13C-NMR (CDCl3, δ): 14.2 (CH3CH2), 22.7 (CH2), 24.6 (CH3CO), 26.6, 26.7, 29.0, 29.2, 31.8
(5CH2), 36.3 (CH2CO), 42.6 (CH2N), 50.8 ((CH2)6CH2N), 119.7 (C3´, C5´), 120.1 (C2, C6), 124.2
(C4), 127.6 (C2´, C6´), 129.0 (C3, C5), 131.8 (C1´), 138.4 (C1), 139.5 (C4´), 169.0, 169.1, 169.9
(3CO). HRMS (ESI): Calculated for C26H35N3O3Na [(M+Na)
+]: 460.2570. Found: 460.25833.
N2-(2-Furoyl)-N2-octyl-N1-phenyl-β-alaninamide (53). Obtained using the procedure
4.1.1.3 from amine 44 (85 mg, 0.3 mmol), 2-furoic acid (34 mg, 0.3 mmol), EDC (47 mg,
0.3 mmol) and HOBt (41 mg, 0.3 mmol) in 95% yield (106 mg).
Chromatography: hexane/EtOAc, 1:1. Rf (hexane/EtOAc, 1:1): 0.40. IR (ATR, cm
-1): 3315
(NH), 1668 (CON), 1605 (Ar). 1H-NMR (CDCl3, δ): 0.87 (t, J = 6.6 Hz, 3H, CH3), 1.25 (m,
10H, (CH2)5CH3), 1.65 (m, 2H, CH2(CH2)5CH3), 2.75 (t, J = 6.3 Hz, 2H, CH2CO), 3.61 (m, 2H,
(CH2)6CH2N), 3.83 (m, 2H, COCH2CH2N), 6.43 (m, 1H, H4´), 6.95 (m, 1H, H3´), 7.06 (t, J = 7.4
Hz, 1H, H4), 7.27 (t, J = 7.8 Hz, 2H, H3, H5), 7.41 (m, 1H, H5´), 7.49-7.60 (m, 2H, H2, H6), 
9.29 (br s, 1H, NH). 13C-NMR (CDCl3, δ): 14.1 (CH3), 22.6, 26.8, 29.2, 29.3, 29.7, 31.8
((CH2)6CH3), 36.2 (CH2CO), 44.3 (CH2N), 49.6 ((CH2)6CH2N), 111.4, 116.5 (C3´, C4´), 119.9
(C2, C6), 123.9 (C4), 128.8 (C3, C5), 138.5 (C1), 144.0 (C5´), 147.9 (C2´), 160.5 (CON), 169.6
(CONH). MS (ESI): 371.2 [(M+H)+].
N2-(3-Furoyl)-N2-octyl-N1-phenyl-β-alaninamide (54). Obtained using the procedure
4.1.1.3 from amine 44 (85 mg, 0.3 mmol), 3-furoic acid (34 mg, 0.3 mmol), EDC (47 mg,
0.3 mmol) and HOBt (41 mg, 0.3 mmol) in quantitative yield (111 mg).
Chromatography: hexane/EtOAc, 7:3. Rf (hexane/EtOAc, 7:3): 0.14. IR (ATR, cm
-1): 3281
(NH), 1685 (CON), 1605, 1547, 1501, 1441 (Ar). 1H-NMR (CDCl3, δ): 0.88 (t, J = 6.7 Hz, 3H,
CH3), 1.25 (m, 10H, (CH2)5CH3), 1.61 (m, 2H, CH2(CH2)5CH3), 2.76 (m, 2H, CH2CO), 3.44 (t, J
= 7.9 Hz, 2H, (CH2)6CH2N), 3.82 (t, J = 6.6 Hz, 2H, COCH2CH2N), 6.55 (m, 1H, H4´), 7.08 (t, J
= 7.4 Hz, 1H, H4), 7.29 (t, J = 8.3 Hz, 2H, H3, H5), 7.41 (t, J = 1.7 Hz, 1H, H5´), 7.55 (d, J = 7.8 
Hz, 2H, H2, H6), 7.68 (m, 1H, H2´).
13C-NMR (CDCl3, δ): 14.1 (CH3), 22.6, 26.6, 29.2 (3C),
31.7 ((CH2)6CH3), 36.5 (CH2CO), 43.2 (CH2N), 50.1 ((CH2)6CH2N), 110.1 (C4´), 119.8 (C2, C6), 
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121.3 (C3´), 124.1 (C4), 128.9 (C3, C5), 138.3 (C1), 143.1, 143.2 (C2´, C5´), 165.6 (CON), 169.4
(CONH). MS (ESI): 371.2 [(M+H)+].
N2-Octyl-N1-phenyl-N2-(pyrrolidin-2-ylcarbonyl)-β-alaninamide (55). Following the
procedure 4.1.1.3 from amine 44 (72 mg, 0.3 mmol), N-(tert-butoxycarbonyl)-proline
(109 mg, 0.5 mmol), EDC (47 mg, 0.3 mmol), and HOBt (41 mg, 0.3 mmol), N2-octyl-N1­
phenyl-N2-(N-Boc-pyrrolidin-2-ylcarbonyl)-β-alaninamide was obtained in 44% yield (75
mg). 
Chromatography: hexane/EtOAc, 1:1. Rf (hexane/EtOAc, 1:1): 0.27. IR (ATR, cm
-1): 3312
(NH), 1685, 1667 (CO), 1604, 1546, 1441 (Ar). 1H-NMR (CDCl3, δ): (Mixture of rotamers
A:B, 2:1): 0.80-0.88 (m, 3H, CH3CH2), 1.17-1.28 (m, 10H, (CH2)5CH3), 1.44-1.67 (m, 11H,
CH2(CH2)5CH3, C(CH3)3), 1.74-1.95 (m, 2H, CH2CH2CH), 2.06-2.19 (m, 2H, CH2CH), 2.31­
2.51 (m, 2H, CH2CO), 2.60-2.79 (m, 2H, CH2NBoc, rotamer A), 3.00-3.32 (m, 2H,
NCH2(CH2)6), 3.52-3.65 (m, 2H, NCH2CH2CO), 3.67-3.87 (m, 2H, CH2NBoc, rotamer B),
4.41-4.57 (m, 1H, CH), 7.01 (t, J = 7.3 Hz, 1H, H4), 7.26 (d, J = 7.9 Hz, 2H, H3, H5), 7.55 (d, J
= 7.7 Hz, 2H, H2, H6, rotamer A), 7.74 (d, J = 7.7 Hz, 2H, H2, H6, rotamer B), 9.13 (br s, 1H,
NH, rotamer A), 9.34 (br s, 1H, NH, rotamer B). 13C-NMR (CDCl3, δ): 14.0 (CH3CH2), 22.6
(2C), 24.4, 24.7, 26.7, 27.7 (4CH2, rotamers A and B), 28.5, 28.6 (C(CH3)3, rotamers A and
B), 29.1, 29.3, 30.0, 30.1, 30.2, 31.7 (2C) (4CH2, rotamers A and B), 37.1, 37.9 (CH2CO,
rotamers A and B), 44.9, 46.0, 47.2, 47.3, 47.9, 50.0 (3CH2N, rotamers A and B), 56.1,
56.5 (CH, rotamers A and B), 80.0, 80.1 (C(CH3)3, rotamers A and B), 120.1, 120.2 (C2, C6, 
rotamers A and B), 123.8, 124.0 (C4, rotamers A and B), 128.7 (C3, C5), 138.5, 139.0 (C1, 
rotamers A and B), 154.7, 154.9 (NCOO, rotamers A and B), 169.6, 171.2, 172.5, 173.1
(2CO, rotamers A and B). MS (ESI): 474.3 [M+H]+, 374.0 [M-Boc+H]+.
To a solution of the previous N-Boc pyrrolidine derivative (63 mg, 0.1 mmol) in
anhydrous DCM (0.5 mL), TFA (200 µL, 2.7 mmol) was added. The mixture of the
reaction was stirred at rt for 1 h, basified with NaHCO3 until pH ≈ 8 and extracted with
DCM. The organic extract was washed with a saturated solution of NaCl, dried over
Na2SO4, filtered, and the solvent was removed under reduced pressure, obtaining the
desired final compound 55 in quantitative yield (49 mg).
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Rf (EtOAc/methanol, 7/3): 0.19. IR (ATR, cm
-1): 3269 (NH), 1644 (CO), 1605, 1548, 1494,
1444 (Ar). 1H-NMR (CDCl3, δ): (Mixture of rotamers A:B, 2:1): 0.83-0.88 (m, 3H, CH3),
1.21-1.24 (m, 10H, (CH2)5CH3), 1.45-2.30 (m, 6H, CH2(CH2)5CH3, (CH2)2CH), 2.56-3.05 (m,
4H, CH2CO, CH2NH), 3.15-3.34 (m, 2H, NCH2(CH2)6), 3.55-3.76 (m, 2H, NCH2CH2CO), 3.91
(t, J = 7.5 Hz, 1H, CH, rotamer A), 4.37 (t, J = 7.5 Hz, 1H, CH, rotamer B), 5.10 (br s, 1H,
NH), 7.05 (t, J = 7.3 Hz, 1H, H4), 7.23-7.30 (m, 2H, H3, H5), 7.56 (d, J = 7.7 Hz, 2H, H2, H6,
rotamer A), 7.61 (d, J = 7.7 Hz, 2H, H2, H6, rotamer B), 8.97 (br s, 1H, NH, rotamer A),
9.58 (br s, 1H, NH, rotamer B). 13C-NMR (CDCl3, δ): 14.1 (CH3), 22.6, 25.8, 26.3, 26.8,
27.6, 29.1, 29.2 (2C), 29.3 (2C), 29.7, 30.6, 31.1, 31.7 ((CH2)6CH3, (CH2)2CH, rotamers A
and B), 36.3, 37.2 (CH2CO, rotamers A and B), 43.2, 44.0 (NCH2CH2CO, rotamers A and B),
46.8, 46.9, 47.4, 48.3 (NCH2(CH2)6, CH2NH, rotamers A and B), 57.8, 58.2 (CH, rotamers A
and B), 119.9 (C2, C6), 124.1 (C4), 128.8, 128.9 (C3, C5), 138.4 (C1), 168.7, 169.5, 171.4,
173.9 (2CO, rotamers A and B). HRMS (ESI, m/z): Calculated for C22H36N3O2 [M+H]
+: 
374.2796. Found: 374.2802.
N2-Octyl-N1-phenyl-N2-(R-pyrrolidin-2-ylcarbonyl)-β-alaninamide (R-55). Following
the procedure 4.1.1.3 from amine 44 (72 mg, 0.3 mmol), N-(tert-butoxycarbonyl)-D­
proline (109 mg, 0.5 mmol), EDC (47 mg, 0.3 mmol), and HOBt (41 mg, 0.3 mmol), N2­
octyl-N1-phenyl-N2-(N-Boc-R-pyrrolidin-2-ylcarbonyl)-β-alaninamide was obtained in
74% yield (102 mg). Spectroscopic data were in agreement with those described for its
racemic counterpart.
Chiral HPLC-MS, rt (min): 6.66 (Chiral HPLC method A). ee> 99%
To a solution of the previous N-Boc-(R)-pyrrolidine derivative (63 mg, 0.1 mmol) in
anhydrous DCM (0.5 mL), TFA (200 µL, 2.7 mmol) was added. The mixture of the
reaction was stirred at rt for 1 h, basified with NaHCO3 until pH ≈ 8 and extracted with
DCM. The organic extract was washed with NaCl, dried over Na2SO4, filtered, and the
solvent removed under reduced pressure, obtaining the desired final compound (R)-55
in quantitative yield (49 mg). Spectroscopic data were in agreement with those
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described for racemic compound 55.
Chiral HPLC-MS, rt (min): 5.99 (Chiral HPLC method B). ee> 99%
[α\D20: -103.2 ᵒ (c = 0.4, methanol)
N2-Octyl-N1-phenyl-N2-(S-pyrrolidin-2-ylcarbonyl)-β-alaninamide (S-55). Following
the procedure 4.1.1.3 from amine 44 (72 mg, 0.3 mmol), N-(tert-butoxycarbonyl)-L­
proline (109 mg, 0.5 mmol), EDC (47 mg, 0.3 mmol), and HOBt (41 mg, 0.3 mmol), N2­
octyl-N1-phenyl-N2-(N-Boc-S-pyrrolidin-2-ylcarbonyl)-β-alaninamide was obtained in 78% 
yield (107 mg). Spectroscopic data were in agreement with those described for its
racemic counterpart.
Chiral HPLC-MS, rt (min): 7.45 (Chiral HPLC method A). ee> 99%
To a solution of the corresponding N-Boc-(S)-pyrrolidine derivative (63 mg, 0.1
mmol) in anhydrous DCM (0.5 mL), TFA (200 µL, 2.7 mmol) was added. The mixture of
the reaction was stirred at rt for 1 h, basified with NaHCO3 until pH ≈ 8 and extracted
with DCM. The organic extract was washed with NaCl, dried over Na2SO4, filtered, and
the solvent removed under reduced pressure, obtaining the desired final compound (S)­
55 in quantitative yield (49 mg). Spectroscopic data were in agreement with those
described for racemic compound 55.
Chiral HPLC-MS, rt (min): 10.18 (Chiral HPLC method B). ee> 99%
[α\D20: + 99.8 ᵒ (c = 0.4, methanol)
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N2-Octyl-N1-phenyl- N2-(1H-pyrrol-2-ylcarbonyl)-β-alaninamide (56). Obtained using
the procedure 4.1.1.3 from amine 44 (85 mg, 0.3 mmol), 1H-2-pyrrolcarboxylic acid (34
mg, 0.3 mmol), EDC (47 mg, 0.3 mmol) and HOBt (41 mg, 0.3 mmol) in 76% yield (84
mg).
Chromatography: hexane/EtOAc, 7:3. Rf (hexane/EtOAc, 1:1): 0.40. Mp: 105-107 ᵒC. IR
(ATR, cm-1): 3264 (NH), 1666 (CON), 1599, 1548, 183, 1445 (Ar). 1H-NMR (CDCl3, δ): 0.88
(t, J = 6.7 Hz, 3H, CH3), 1.28-1.31 (m, 10H, (CH2)5CH3), 1.71 (m, 2H, CH2(CH2)5CH3), 2.74 (t,
J = 6.7 Hz, 2H, CH2CO), 3.58 (m, 2H, (CH2)6CH2N), 3.87 (m, 2H, COCH2CH2N), 6.25-6.28 (m,
1H, H4´), 6.54 (m, 1H, H3´), 6.90 (m, 1H, H5´), 7.07 (t, J = 7.3 Hz, 1H, H4), 7.28 (t, J = 7.8 Hz,
2H, H3, H5), 7.55 (d, J = 7.8 Hz, 2H, H2, H6), 8.84 (br s, 1H, NH), 9.84 (br s, 1H, NH).
13C­
NMR (CDCl3, δ): 14.1 (CH3), 22.6, 26.8, 28.6, 29.2, 29.4, 31.8 ((CH2)6CH3), 36.7 (CH2CO),
44.3 (CH2N), 49.3 ((CH2)6CH2N), 110.3, 112.2 (C3´, C4´), 119.9 (C2, C6), 121.3 (C5´), 124.1
(C4), 124.4 (C2´), 128.9 (C3, C5), 138.3 (C1), 162.5 (CON), 169.4 (CONH). MS (ESI): 370.2
[M+H]+.
N2-Octyl-N1-phenyl-N2-(1H-pyrrol-3-ylcarbonyl)-β-alaninamide (57). Obtained using
the procedure 4.1.1.3 from amine 44 (85 mg, 0.3 mmol), 1H-3-pyrrolcarboxilic acid (34
mg, 0.3 mmol), EDC (47 mg, 0.3 mmol) and HOBt (41 mg, 0.3 mmol) in 54% yield (60
mg).
Chromatography: hexane/EtOAc, 3:7. Rf (EtOAc): 0.25. Mp: 99-101 ᵒC. IR (ATR, cm
-1):
3250 (NH), 1598 (CON), 1548 (Ar). 1H-NMR (CDCl3, δ): 0.79 (t, J = 6.7 Hz, 3H, CH3), 1.16
(m, 10H, (CH2)5CH3), 1.54 (m, 2H, CH2(CH2)5CH3), 2.61 (m, 2H, CH2CO), 3.41 (t, J = 7.2 Hz,
2H, (CH2)6CH2N), 3.74 (t, J = 6.6 Hz, 2H, COCH2CH2N), 6.26 (m, 1H, H4´), 6.56 (m, 1H, H5´), 
6.92 (m, 1H, H2´), 6.97 (t, J = 7.4 Hz, 1H, H4), 7.18 (t, J = 7.8 Hz, 2H, H3, H5), 7.49 (d, J = 7.9
Hz, 2H, H2, H6), 9.37 (br s, 2H, 2NH).
13C-NMR (CDCl3, δ): 14.1 (CH3), 22.6, 26.7, 28.9,
29.2, 29.3, 31.8 ((CH2)6CH3), 36.6 (CH2CO), 43.4 (CH2N), 49.8 ((CH2)6CH2N), 108.6 (C4´),
118.3 (C5´), 118.4 (C3´), 120.0 (C2, C6), 121.1 (C2´), 123.9 (C4), 128.8 (C3, C5), 138.5 (C1),
168.4 (CON), 170.0 (CONH). MS (ESI): 370.2 [M+H]+.
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N2-[(1-Methyl-1H-pyrrol-2-yl)carbonyl]-N2-octyl-N1-phenyl-β-alaninamide (58).
Obtained using the procedure 4.1.1.3 from amine 44 (163 mg, 0.59 mmol) and 1-methyl­
1H-pyrrol-2-carboxylic acid (150 mg, 1.2 mmol) in 49% yield (111 mg).
Chromatography: hexane/EtOAc, 7:3. Rf (hexane/EtOAc, 7:3): 0.44. IR (ATR, cm
-1): 3277
(NH), 1684 (C=O), 1602, 1543, 1473, 1439 (Ar). 1H-NMR (CDCl3, δ): 0.87 (t, J = 6.7 Hz, 3H, 
CH3CH2), 1.23-1.30 (m, 10H, (CH2)5CH3), 1.58-1.65 (m, 2H, CH2(CH2)5CH3), 2.73 (t, J = 6.8
Hz, 2H, CH2CO), 3.54 (t, J = 7.6 Hz, 2H, NCH2(CH2)6), 3.67 (s, 3H, CH3N), 3.80 (t, J = 6.8 Hz,
2H, NCH2CH2CO), 6.06 (dd, J = 3.7, 2.7 Hz, 1H, H4´), 6.30 (dd, J = 3.7, 1.4 Hz, 1H, H3´), 6.66
(t, J = 2.9 Hz, 1H, H5´), 7.07 (t, J = 7.4 Hz, 1H, H4), 7.28 (t, J = 7.8 Hz, 2H, H3, H5), 7.55 (d, J = 
8.1 Hz, 2H, H2, H6), 9.11 (br s, 1H, NH). 
13C-NMR (CDCl3, δ): 14.5 (CH3CH2), 23.0, 26.9,
29.2, 29.6 (2C), 32.1 ((CH2)6CH3), 35.9 (CH3N), 36.8 (CH2CO), 43.5 (NCH2CH2CO), 50.6
(NCH2(CH2)6), 107.5, 112.5 (C3´, C4´), 120.2 (C2, C6), 124.4 (C4), 125.7 (C2´), 126.6 (C5´),
129.2 (C3, C5), 138.8 (C1), 165.6 (CON), 170.1 (CONH). HRMS (ESI, m/z): Calculated for
C23H34N3O2 [M+H]
+: 384.2646. Found: 384.2655.
N2-Octyl-N1-phenyl-N2-(pyridin-2-ylcarbonyl)-β-alaninamide (59). Obtained using
the procedure 4.1.1.3 from amine 44 (85 mg, 0.3 mmol), picolinic acid (37 mg, 0.3
mmol), EDC (47 mg, 0.3 mmol) and HOBt (41 mg, 0.3 mmol) in 92% yield (105 mg).
Chromatography: hexane/EtOAc, 2:8. Rf (hexane/EtOAc, 3:7): 0.30. IR (ATR, cm
-1): 3309
(NH), 1685 (CON), 1615, 1547, 1495, 1443 (Ar). 1H-NMR (CDCl3, δ): Mixture of rotamers
A:B, 2:1; 0.85 (t, J = 6.7 Hz, 3H, CH3), 1.11-1.25 (m, 10H, (CH2)5CH3), 1.57 (m, 2H,
CH2(CH2)5CH3), 2.81 (t, J = 6.4 Hz, 2H, CH2CO), 3.37 (t, J = 7.4 Hz, 2H, (CH2)6CH2N, rotamer
A), 3.46-3.47 (m, 2H, (CH2)6CH2N, rotamer B), 3.69-3.75 (m, 2H, COCH2CH2N, rotamer B),
3.87 (t, J = 6.3 Hz, 2H, COCH2CH2N, rotamer A), 7.05 (t, J = 7.1 Hz, 1H, H4), 7.24-7.32 (m,
3H, H3, H5, H5´), 7.54-7.56 (m, 3H, H2, H6, H4´), 7.71-7.76 (m, 1H, H3´), 8.55 (d, J = 4.4 Hz,
1H, H6´), 8.64 (br s, 1H, NH, rotamer B), 8.92 (br s, 1H, NH, rotamer A).
13C-NMR (CDCl3, 
δ): 14.0 (CH3), 22.6, 26.5, 28.8, 29.0 (2C), 31.7 ((CH2)6CH3), 36.5 (CH2CO), 43.2 (CH2N), 
50.0 ((CH2)6CH2N), 119.9 (C2, C6), 123.1, 123.9, 124.4 (C4, C3´, C5´), 128.8 (C3, C5), 137.0
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(C4´), 138.4 (C1), 148.5 (C6´), 154.5 (C2´), 169.5, 169.7 (CONH, CON). HRMS (ESI, m/z):
Calculated for C23H31N3O2Na [M+Na]
+: 404.2308. Found: 404.2276.
N2-Octyl-N1-phenyl-N2-(pyridin-3-ylcarbonyl)-β-alaninamide (60). Obtained using
the procedure 4.1.1.3 from amine 44 (85 mg, 0.3 mmol), nicotinic acid (37 mg, 0.3
mmol), EDC (47 mg, 0.3 mmol) and HOBt (41 mg, 0.3 mmol) in 36% yield (41 mg).
Chromatography: hexane/EtOAc, 2:8. Rf (EtOAc): 0.28. IR (ATR, cm
-1): 3312 (NH), 1685
(CON), 1612, 1546, 1495, 1440 (Ar). 1H-NMR (CDCl3, δ): Mixture of rotamers A:B, 6:1;
0.87 (t, J = 6.8 Hz, 3H, CH3), 1.13-1.18 (m, 10H, (CH2)5CH3), 1.53 (m, 2H, CH2(CH2)5CH3), 
2.50 (m, 2H, CH2CO, rotamer B), 2.79 (t, J = 5.7 Hz, 2H, CH2CO, rotamer A), 3.28 (t, J = 7.0
Hz, 2H, (CH2)6CH2N, rotamer A), 3.49 (m, 2H, (CH2)6CH2N, rotamer B), 3.64 (m, 2H,
COCH2CH2N, rotamer B), 3.86 (m, 2H, COCH2CH2N, rotamer A), 7.07 (t, J = 7.3 Hz, 1H, H4),
7.24-7.32 (m, 3H, H3, H5, H5´), 7.53 (d, J = 7.6 Hz, 2H, H2, H6), 7.67 (d, J = 7.7 Hz, 1H, H4´),
8.64 (d, J = 1.4 Hz, 2H, H2´, H6´), 9.27 (br s, 1H, NH).
13C-NMR (CDCl3, δ): 14.0 (CH3), 22.5,
26.4, 28.9, 29.0 (2C), 31.6 ((CH2)6CH3), 35.8 (CH2CO), 42.7 (CH2N), 50.7 ((CH2)6CH2N),
119.9 (C2, C6), 123.4 (C5´), 124.1 (C4), 128.8 (C3, C5), 132.4 (C3´), 134.2 (C4´), 138.3 (C1),
147.3, 150.6 (C2´, C6´), 169.5, 169.8 (CONH, CON). HRMS (ESI, m/z): Calculated for
C23H31N3O2Na [M+Na]
+: 404.2308. Found: 404.2302.
N2-Octyl-N1-phenyl-N2-(pyridin-4-ylcarbonyl)-β-alaninamide (61). Obtained using
the procedure 4.1.1.3. from amine 44 (85 mg, 0.3 mmol), isonicotinic acid (37 mg, 0.3
mmol), EDC (47 mg, 0.3 mmol) and HOBt (41 mg, 0.3 mmol) in 41% yield (47 mg).
Chromatography: hexane/EtOAc, 2:8. Rf (EtOAc): 0.19. IR (ATR, cm
-1): 3310 (NH), 1624
(CON), 1547 (Ar). 1H-NMR (CDCl3, δ): (Mixture of rotamers A:B, 4:1): 0.76 (t, J = 6.9 Hz,
3H, CH3), 1.02-1.07 (m, 10H, (CH2)5CH3), 1.41 (qt, J = 6.9 Hz, 2H, CH2(CH2)5CH3), 2.40 (m,
2H, CH2CO, rotamer B), 2.70 (t, J = 6.5 Hz, 2H, CH2CO, rotamer A), 3.12 (t, J = 7.6 Hz, 2H,
(CH2)6CH2N, rotamer A), 3.41 (m, 2H, (CH2)6CH2N, rotamer B), 3.50 (m, 2H, COCH2CH2N, 
rotamer B), 3.74 (t, J = 6.5 Hz, 2H, COCH2CH2N, rotamer A), 7.00 (t, J = 7.3 Hz, 1H, H4), 
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7.11 (d, J = 5.8 Hz, 2H, H3´, H5´), 7.16-7.21 (m, 2H, H3, H5), 7.41 (d, J = 7.9 Hz, 2H, H2, H6),
8.55 (d, J = 5.7 Hz, 2H, H2´, H6´), 8.78 (br s, 1H, NH).
13C-NMR (CDCl3, δ): 14.0 (CH3), 22.5,
26.4, 28.8, 29.0 (2C), 31.6 ((CH2)6CH3), 35.9 (CH2CO), 42.4 (CH2N), 50.4 ((CH2)6CH2N),
119.8 (C2, C6), 120.8 (C3´, C5´), 124.2 (C4), 128.9 (C3, C5), 138.2 (C1), 144.1 (C4´), 150.3 (C2´, 
C6´), 169.2, 169.9 (CON, rotamers A and B), 171.1 (CONH). HRMS (ESI, m/z): Calculated
for C23H31N3O2Na [M+Na]
+: 404.2308. Found: 404.2311.
4.1.7. Synthesis of N2-octyl-N-phenyl-N2-[(pyridin-2-yl)methyl)]-β-alaninamide (62). To
a solution of the secondary amine 44 (85 mg, 0.3 mmol) in anhydrous DCE (3 mL), a
solution of 2-pyridinecarboxaldehyde (50 μL, 0.5 mmol) was added and the mixture
stirred for 20 min at rt. Then, the reaction mixture was cooled to 0 ᵒC and treated with a
solution of NaBH(OAc)3 (135 mg, 0.6 mmol) in anhydrous DCE (5 mL), followed by
stirring at rt for 16 h. The solvent was removed under reduced pressure, the residue
was redissolved in EtOAc and washed with saturated solutions of NaHCO3 and NaCl,
consecutively. The organic extract was dried over Na2SO4, filtered, and the solvent was
removed under reduced pressure. The residue was purified by chromatography
(hexane/EtOAc, 1:1) to yield compound 62 in 16% yield (18 mg).
Rf: 0.15 (hexane/EtOAc, 3:7). IR (ATR, cm
-1): 3309 (NH), 1685 (CO), 1615, 1547, 1495,
1443 (Ar). 1H-NMR (CDCl3, δ): 0.85 (t, J = 7.0 Hz, 3H, CH3), 1.11-1.25 (m, 10H, (CH2)5CH3), 
1.57 (m, 2H, CH2(CH2)5CH3), 2.54-2.61 (m, 4H, CH2CO, (CH2)6CH2N), 2.85 (t, J = 5.6 Hz, 2H,
COCH2CH2N), 3.81 (s, 2H, CH2pyr), 7.06 (t, J = 7.4 Hz, 1H, H4), 7.15 (dd, J =7.2, 5.3 Hz, 1H,
H5´), 7.24-7.33 (m, 3H, H3, H5, H3´), 7.59 (td, J = 7.6, 1.7 Hz, 1H, H4´), 7.63 (d, J = 7.7 Hz, 2H,
H2, H6), 8.50 (d, J = 4.2 Hz, 1H, H6´), 10.8 (br s, 1H, NH).
13C-NMR (CDCl3, δ): 14.0 (CH3),
22.8, 26.6, 27.7, 29.3, 29.8, 32.1 ((CH2)6CH3), 34.2 (CH2CO), 50.4 (CH2N), 54.1
((CH2)6CH2N), 60.1 (CH2pyr), 120.4 (C2, C6), 122.6 (C5´), 123.6 (C3´), 123.7 (C4), 128.9 (C3, C5), 
136.7 (C4´), 139.1 (C1), 149.9 (C6´), 157.9 (C2´), 171.0 (CO). HRMS (ESI, m/z): Calculated for
C23H33N3O [M+H]
+: 368.2657. Found: 368.2108.
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Table 11. HPLC-MS for final compounds.*
Comp. rt (min) Comp. rt (min)
4 19.6 24 13.9
5 6.7 25 16.5
6 6.7 46 10.7
7 16.3 47 10.8
8 8.4 48 10.8
9 19.0 49 10.7
10 20.3 50 10.9
11 11.5 51 11.6
12 13.0 52 9.9
13 17.4 53 12.7
14 8.7 54 10.6
15 9.6 55 18.7
16 9.1 56 11.9
17 14.2 57 8.6
18 8.9 58 24.5
19 10.3 59 22.9
20 10.2 60 23.2
21 29.1 61 23.5
22 25.4 62 18.0
23 9.7
* All compounds have been analyzed using HPLC gradient method A with exception of
compounds 16-19 that were analyzed with method B.
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4.2. Biology
4.2.1. ICMT activity assay
The ability of synthesized compounds to inhibit ICMT enzyme was determined by a
radioactivity assay previously described by Baron et al.39 Briefly, membranes that
overexpress ICMT enzyme were incubated in the presence of the compounds under
study and the substrates BFC and [3H]-SAM with shaking at rt. Compounds were tested
at 50 µM concentration in a final volume of 50 µL of incubation buffer [Hepes 70 mM,
NaCl 100 mM, MgCl2 5 mM, 1,4-dithiotreitol (DTT) 3 mM, pH 7.5] and both substrates
BFC and [3H]-SAM at final concentration of 5 and 2 µM, respectively. Then, the mixture
was incubated for 30 min at 37 ᵒC and the enzymatic reaction was stopped by adding 10
µL of streptavidin beads (Thermo Scientific, 10 µL of beads in 500 µL of PBS). The
samples were stirred at 4 ᵒC overnight and later filtered through fiberglass filters
(Filtermat A, PerkinElmer), using a multiple filtration equipment FilterMate Unifilter 96­
Harvester (PerkinElmer). The inhibition of the methylesterification reaction, in which the
tritiated methyl group of [3H]-SAM is transferred to the substrate BFC, was quantified by
measuring the radioactivity by liquid scintillation spectrometry (Microbeta TopCount,
Perkin Elmer). The percentage of this inhibition was determined with respect to the
100% activity obtained in the absence of compounds.
4.2.2. Cell lines and culture
AF3 wild type and G690G mouse fibroblasts (kindly donated by Prof. Carlos López-
Otín, Oviedo University) were grown in Dulbecco´s Modified Eagle Medium (DMEM,
Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum (FBS, HyClone),
1% L-glutamine (Invitrogen), 1% sodium pyruvate (Invitrogen), 50 U/mL penicillin and 50
µg/mL streptomycin (Invitrogen). HGADFN167 and HGFDFN168 human fibroblasts
(obtained from The Progeria Research Foundation) were grown in 15% DMEM, 50 U/mL
penicillin and 50 µg/mL streptomycin. Cells were incubated in a humidified atmosphere
at 37 ᵒC in the presence of 5% CO2.
4.2.3. MTT assay
Cells were seeded in 96-well plates at a density of 5 x 102 cells per well in the 
corresponding medium with 10% FBS for 24 h prior to treatments. The medium was
then replaced by fresh medium containing different concentrations of compounds or
the equivalent volume of DMSO. Cells were treated for 48 h and the medium was
replaced by fresh medium with 2 mg/mL of MTT (Sigma Aldrich) and cells were
incubated for 4 h at 37 ᵒC in the dark. Then, supernatants were removed and formazan
crystals formed by viable cells were dissolved in DMSO (100 µL/well) and absorbance
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Experimental section
was measured at 570 and at 630 nm using an Asys UVM 340 microplate reader. Then,
absorbance at 630 nm (background) was substracted from the absorbance at 570 nm
and the cytotoxicity values were calculated from the percentage of viable cells with
respect to the 100% viability of the vehicle-treated cells. 
4.2.4. In vitro pharmacokinetic assays
4.2.4.1. HSA binding assay
Determination of the binding of the compound to HSA was performed by incubating a 
fixed concentration of the compound with different concentrations of immobilized HSA,
using the TRANSILXL HSA Binding Kit (TMP-0210-2096, Sovicell). An eightwell unit of the
TRANSIL assay plate was used for each compound; six wells contain increasing
concentrations of HSA immobilized on silica beads suspended in PBS at pH 7.4, and two
wells contain buffer only and serve as references to account for non-specific binding.
The TRANSIL assay plate was thawed for 3 h at rt and centrifuged at 750g for 5 s. Then,
15 μL of an 80 μM stock solution of the compound in PBS (for a final concentration of 5
μM) was added to each well of the eight-well unit, and the plate was incubated on a
plate shaker at 1000 rpm for 12 min at rt. After this time, the plate was centrifuged at
750g for 10 min, and 50 μL of the supernatants were transferred for analytical
quantification by HPLC-MS using selected ion monitoring (SIM) and quantification was
estimated by measuring the area under the peak ([M+H]+) normalized with an internal
standard. The binding percentage was calculated from the remaining free compound
concentration in the supernatant of each well, using the spreadsheet and algorithms
supplied with the kit.
4.2.4.2. Stability assay in mouse and human serum
Stability for selected compounds was assayed by adding 625 μL of a 2 mM solution of
test compound in PBS (pH 7.4) to 1875 µL of mouse or human serum (Europa
Bioproducts, EQSM-0100) pre-warmed at 37 ᵒC. Next, solutions were incubated at 37 ᵒC 
for 24 h, taking aliquots of 125 μL at different time points (0, 1, 4, 8 and 24 h). Each
aliquot was quenched with 500 μL of cold ACN, vortexed, incubated for 10 min in ice and
centrifuged at 39000g for 10 min. Supernatants were then analyzed by HPLC-MS using
SIM mode. Concentrations were quantified by measuring the area under the peak
([M+H]+) normalized with an internal standard and converted to the percentage of
compound remaining, using the time zero peak area value as 100%. 
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4.2.4.3. Stability assay in mouse and human liver microsomes
Compounds were incubated at 37 °C at a final concentration of 1 or 5 μM in PS
together with a solution of nicotinamide adenine dinucleotide phosphate (NADPH) in
PBS (final concentration of 2 mM) and a solution of MgCl2 in PBS (final concentration of
5 mM). Reactions were initiated by the addition of a suspension of mouse liver
microsomes (MLMs) (male CD-1 mice pooled, Sigma-Aldrich) or human liver microsomes
(HLMs) (male human pooled, Sigma-Aldrich), respectively, at a final protein
concentration of 1 mg/mL. The solutions were vortexed and incubated at 37 °C. Aliquots
of 100 μL were quenched at time zero and at seven points ranging to 1 h (MLM) or 2 h
(HLM) by pouring into 100 μL of ice-cold ACN. Quenched samples were centrifuged at
10000g for 5 min, and the supernatants were filtered through a polytetrafluoroethylene
(PTFE) membrane syringe filter (pore size of 0;2 μm, 13 mm of diameter, GE Healthcare
Life Sciences). The relative disappearance of the compound under study over the course
of the incubation was monitored by HPLC-MS using SIM mode. Concentrations were
quantified by measuring the area under the peak ([M+H]+) normalized with an internal
standard and converted to the percentage of compound remaining, using the time zero
peak area value as 100%. The natural logarithm of the remaining percentage versus time
data for each compound was fit to a linear regression, and the slope was used to
calculate the degradation half-life.
4.2.5. Analysis by immunodetection of phosphorylated histone 2AX (pH2AX) and
phosphorylated Akt (pAkt) levels
Progeroid HGADFN167 or healthy HGFDFN168 cells were seeded at density of 50000
cells and incubated for 24 h in DMEM medium supplemented with a 15% FBS, until
reaching a 80% of confluence. Then, the culture medium was substituted by fresh
medium with the compound under study at 2 µM or with vehicle (0.1% DMSO in culture
media) and cells were incubated for 17 or 10 days for pH2AX and pAkt analysis,
respectively. Cells were lysed with cold radioimmunoprecipitation assay buffer (50 mM
Tris-HCl pH 7.4, 150 mM NaCl, 1% lgepal) with a mixture of protease and phosphatase
inhibitors (Roche and Sigma-Aldrich, respectively). The lysates were immediately used or 
stored at -20 ᵒC until their use. The protein concentration was determined (DC Protein
Assay Kit, Bio-Rad) and samples with the same amount of protein were diluted in
reductive Laemmli buffer, and denatured at 95 ᵒC for 5 min. Samples were analyzed by
electrophoresis in polyacrylamide gels (4-20% SDS-PAGE, BioRad) and the proteins
transferred to nitrocellulose membranes (GE Healthcare, Amersham). After 1 h of
incubation in blocking buffer (100 mM Tris-HCl pH 8.0, 150 mM NaCl and 0.05% Tween­
20 (TBS-T) with 3% of bovine serum albumin (BSA)), blots were incubated overnight at 4
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ᵒC with the corresponding primary antibody [anti-phospho-histone 2AX (Ser139) (EMD
Millipore, 05-636, 1:1000) and anti-phospho-Akt (Cell Signaling, 4060S, 1:1000)] for
analysis of pH2AX and pAkt, respectively and anti-ERK1/2 (Cell Signaling, 9102S, 1:1000)
as antibody for loading control. Then, membranes were washed (3x) with TBS-T and
incubated with the corresponding secondary antibody conjugated with peroxidase
(Sigma-Aldrich) for 1 h at rt. Proteins were visualized by quimioluminiscence in a Fujifilm
LAS-300 imager and the bands were quantified by densitometry using the program
ImageJ (NIH).
4.2.6. Progerin visualization by confocal microscopy
Progeroid HGADFN167 cells were seeded at a density of 2·104 cells/well over 12 mm
diameter slide covers and were incubated for 24 h at 37 ᵒC in 5% CO2 atmosphere in
DMEM medium supplemented with 15% FBS. Then, the culture medium was substituted
by fresh one with the compound under study at 2 µM or with 0.1% DMSO and the cells
were incubated for 21 days. Cells were fixed with a 4% solution of paraformaldehyde
(PFA, Sigma-Aldrich) and permeabilized with PBS containing 0.1% Triton X-100 (PBS-T,
Sigma-Aldrich). Then, cells were incubated with an anti-progerin antibody (Santa Cruz
Biotechnology, SC-81611, 1:500) in TBS with 3% BSA at rt for 2 h. After that, cells were
washed with TBS (1x) and incubated in absence of light for 1 h with the fluorophore
Alexa Fluor 488 donkey anti-mouse (Thermo Scientific) diluted in TBS with 3% BSA.
Later, cells were additionally washed with TBS (1x) and incubated with Hoechst 33258 (5
µg/mL, Sigma-Aldrich) for 10 min at rt in order to visualize cellular nucleus. Finally, cells
were washed with PBS-T (2x) and the slide cover was carefully mounted with
Immumount (Thermo Scientific). The visualization was carried out using confocal
microscopy (Olympus IX83) equipped with a 60X oil inmersion lens and the appropriate
excitation and emission filters at the cytometry and fluorescence microscopy UCM
facilities. 
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IDENTIFICATION OF NEW MOLECULES PRODUCED
BY THE HUMAN MICROBIOTA

   
 
 
 
 
 
 
 
 
 
 
INTRODUCTION AND OBJECTIVES
 

  
  
     
      
         
         
        
     
     
        
        
             
    
         
      
       
       
       
       
        
     
    
 
1. INTRODUCTION AND OBJECTIVES 
The human microbiota can be defined as an extremely variable and
compartmentalized ecosystem of commensal, symbiotic and pathogenic microorganisms
that lives in our body.1 These populations, formed by bacteria, fungi, parasites and
archaea, are more abundant than our somatic cells and contain more genes than our
human genome.2,3 About a thousand species of bacteria exist in the human body
simultaneously, increasing the number of genotypes over orders of magnitude.4 The
trillions of bacteria that make up the human microbiome are believed to encode
functions that are important to human health. Recent investigations showed that
intestinal microbiota exerts deep effects on many aspects of human health and disease,
which has led to the concept of a human meta-organism consisting on (human)microbial
molecules or derivatized metabolites that integrates the communication between both
prokaryotic and eukaryotic parts to achieve homeostasis (Figure 1). In particular, for
many diseases, there is huge evidence that the microbiota and their metabolites can be
used to explain a great percentage of variance in the relevant phenotypes for a given 
condition, including cancer,5,6 liver cirrhosis,7 diabetes,8,9 obesity,10 cardiovascular
disease,11 inflammatory bowel disease,12 immune system dysfunction,13 and aging.14-16 
Furthermore, replacement of the microbiota of a diseased individual with that of a
healthy individual clearly ameliorates certain diseases.17 These findings strongly support
the hypothesis that metabolites produced by the human microbiota regulate key
biological functions in the host.
   
 
 
         
 
     
        
     
      
            
     
        
       
        
     
      
          
      
    
     
     
     
       
        
          
        
       
Introduction and objectives
Gut microbiota
metabolites
Human host
Modified molecules
Microbial molecules
Human-microbial
co-molecules
Food or
xenobiotics
Figure 1. Relationship between the gut microbiota and the human host.
In this work, we have focused our attention on the link between microbiota 
metabolites and aging. The composition of human microbiota is strongly dependent on
aging, and huge evidences of the differences between the gut microbiota of young and
old people have been described.18 These divergences can be associated with
environmental, host, 19,20 and genetic factors.21 In 2016, Bischoff et al. confirmed the
presence of age-related inflammatory processes and diseases that have been linked to
changes in gut bacteria.22 Hence, alterations in the human microbiota have a direct
effect in human health span and aging.
However, due to the large complexity of the human microbiome and its vast coding
potential, most of the metabolites produced by the microbiota are still to be discovered, 
making the identification of microbiota metabolites a daunting task that has not been
addressed up to date. During the last decade, huge efforts have been made to sequence
isolates of the human microbiota from various body sites, and large genome 
programmes have been funded towards this goal.23,24 Functional metagenomics use
bioinformatics tools and genomic sequence data to infer which genes presumably codify 
for enzymes involved in the biosynthesis of metabolites and to predict their products
based on the identification of conserved biosynthetic domains (Figure 2). The main
limitation of this methodology is that it heavily relies on the development of algorithms 
able to identify sequence homologies and to predict the structure of the metabolites
biosynthesized. In addition, this approach penalizes the identification of new gene
clusters that are more likely to produce new metabolites.25,26 On the contrary, direct
metabolomic methods are specifically tailored to study the metabolites directly and are
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Introduction and objectives
often designed for particular compound classes that are expected to be produced by the
gene(s) of interest. As this approach requires a priori knowledge of the metabolite 
structure, it does not enable a wide breadth of profiling coverage (Figure 2).
Figure 2. Current methodologies used for the identification of microbiota metabolites.
These evidences highlight the importance of the development of new strategies for
the de novo identification of metabolites produced by the human microbiota. Thus, in
the present work, we propose to develop an innovative methodology which will allow us 
to identify microbiota metabolites. This platform is based on the use of tagged
precursors of metabolites of the human microbiota. A scheme of the overall platform is 
depicted in Figure 3.
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Introduction and objectives
Figure 3. Platform designed for the identification of metabolites produced by the human
microbiota.
The development of this strategy implies the following steps:
1. Design and synthesis of tagged precursors 
Step 1
2. Incorporation of tagged precursors in selected strains of bacteria
3. Isolation of the different metabolomes (Step 2)
4. Bioorthogonal reaction with the capture reagent (Step 3)
5. Isolation of the tagged metabolites (Step 4)
6. NMR and MS-based deconvolution and identification of metabolites (Step 5)
Then, the main objective of the present work consists on the setting up and
optimization of all the steps of the platform so that we can confirm its potential to
isolate and identify metabolites in complex bacterial metabolomes. If successful, this 
objective will provide the proof of concept for the widespread use of the platform with a
variety of tagged precursors.
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2. RESULTS AND DISCUSSION 
2.1. Design and synthesis of tagged precursors
Among the diverse precursors that have been described to be substrates of different
27-29enzymes of the human microbiota, such as sugars, amino acids, fatty acids, or
steroids, as an initial proof of concept to set up the platform, we decided to start with
sugars as tagged precursors. These compounds have been selected due to the evidence 
that azido sugars can be recognized by the cellular machinery of some bacteria and
30-35incorporated into the metabolism. The selection of the tag has been made
considering three basic features: small size, abiotic nature, and suitability for
bioorthogonal reactivity. Then, an azide group has been chosen as tag. Hence, a set of
azido sugars has been designed and synthesized considering not only previously
incorporated described azido sugars but also structurally diverse ones (Figure 4): glucose
(1-3) and glucosamine derivatives (4-6), taking into account the preferable consumption
by bacteria of glucose versus other sugars;36-38 galactose (7, 8) or galactosamine analogs
(9, 10), due to their not preferable but effective incorporation;39,40 and a mannosamine
41,42 Inderivative (11), based on its incorporation when used as the only source of carbon. 
addition, these amino sugars are described to be carbon or nitrogen sources for some 
strains of bacteria.43-46 Finally, a representative example of a sialic acid (12) has also
been selected due to their reported incorporation by bacteria.47 The tag has been
introduced in positions 1, 2, or 6 of the sugars in an attempt to determine the possible 
influence of the position of the azide in the incorporation by bacteria. Taking into
account the possible differences in incorporation for peracetylated sugars compared to
their free hydroxyl groups analogues, both of them have been selected.
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Figure 4. Azido sugars used as tagged precursors. The azide group used as tag is shown in red.
Azido sugars 2-8 and 11, 12 were commercially available, whereas glucose derivative 
1 and galactosamines 9 and 10 were synthesized. To obtain 2-azido-2-deoxy-D­
glucopyranose (1), 2-glucosamine was converted into the corresponding azide using in
situ prepared imidazole-1-sulfonyl azide hydrochloride as diazo-donor (Scheme 1). With
respect to azido sugars 9 and 10, their synthesis started by protection of 2­
galactosamine with di-tert-butyl dicarbonate and further peracetylation. Its
deprotection with trifluoroacetic acid (TFA), followed by reaction with chloroacetic
anhydride in basic media, and nucleophilic substitution with sodium azide led to desired
sugar 9. Finally, elimination of the acetyl groups yielded the N-acylgalactosamine 
derivative 10 (Scheme 2).
Scheme 1. Reagents and conditions: a) i. imidazol, ACN, rt, on; ii. 2 M HCl in Et2O; b) K2CO3, 
CuSO4, MeOH, rt, 6 h, 15%.
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Results and discussion
Scheme 2. Reagents and conditions: a) (Boc)2O, NaHCO3, dioxane/H2O, rt, 48 h, 100%; b) Ac2O, 
pyridine, DCM, rt, 18 h, 100%; c) TFA, DCM, rt, 3 h, 100%; d) chloroacetic anhydride, N-methyl-2­
pyrrolidone, DCM, rt, 16 h, 80%; e) NaN3, DMF, 60 °C, 3 h, 52%; f) NaOMe, MeOH, rt, 2 h, 100%.
2.2. Incorporation of tagged precursors in selected strains of bacteria
2.2.1. Screening by 1H NMR 
Once synthesized the tagged precursors, we needed to confirm whether bacteria
from human microbiota can incorporate the selected sugars (1-12, Figure 4). For this 
purpose, the consumption of the tagged sugar was followed by 1H NMR after 24 h of
incubation with bacteria. Towards this end, the optimal concentration of the tagged 
sugar that could be detected in basal peptone yeast broth,30 the culture medium used
for growing the bacteria, was assesed. Since the complexity of the culture medium made
difficult the determination of the signals of the azido sugars, we also analysed by 1H 
NMR the culture medium, and then, by substraction of this spectra from the spectra of
the azido sugars in medium, we were able to detect some signals coming from the 
analyzed sugars (see Figure 5 for a representative spectrum). The analysis of the 1H NMR
spectra showed that, in general, those sugars with free hydroxyl groups (1, 3, 5, and 8) 
could be followed at 100 µM, whereas a concentration of 400 µM was required for the
suitable detection of peracetylated sugars (2, 4, 6, 7, 9, and 11), probably due to
solubility issues. However, sugars 10 and 12 could not be detected under these
conditions because even at the higher concentration tested, significant splitting of the 
signals between anomers was observed, fact that precluded a good observation of the
signals in the 1H NMR spectra. Therefore, sugars 10 and 12 were excluded from the NMR
screening.
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Figure 5. 1H NMR spectra of azido sugar 6. A) Full 1H NMR spectrum of basal peptone yeast broth
as culture medium is shown in red. Spectrum of culture medium containing 400 µM of sugar 6 is
represented in blue and the difference spectrum between azido sugar 6 in culture medium and 
culture medium alone is indicated in green. B) Zoom of the selected range of the spectrum of
panel A showing some representative signals of azido sugar 6.
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Results and discussion
At this point, and once selected the tagged sugars and their concentration for
screening (1, 3, 5, and 8 at 100 µM and 2, 4, 6, 7, 9, and 11 at 400 µM) we needed to
choose representative bacteria from the human microbiota, taking into account their
high diversity and the possible differences in the incorporation process. 
The most abundant bacteria found in the human body are part of four main phyla:
Firmicutes, Actinobacteria, Proteobacteria, and Bacteroidetes.48 Among them, different
strains of each phyla have been described to have a role in the gut microbiota such as: i)
Bacteroides or Prevotella (both belonging to phyla Bacteroidetes), with functions in
polysaccharide decomposition, nutrients absortion, and maturation of endothelial
cells,49 ii) Lactobacillus (from phyla Firmicutes), which is in charge of the production of
some short-chain fatty acids (acetic, propionic, or butyric)49 and even in the production
of neurotransmitters,50 and iii) E. coli (belonging to phyla Proteobacteria), responsible 
for the production of some metabolites implicated in colorectal cancer50 and in the
decomposition of mucins. Furthermore, it has been even reported the substitution of
bacteria from Firmicutes by Bacteroidetes in aging process.51 These evidences together 
with previously described azido sugars incorporation,30,31,33,35,52-54 led us to select B.
fragilis, B. thetaomicron, P. copri, L. rhamnosus, and E. coli for our experiments.
Hence, in collaboration with Dr. Carles Úbeda (Centro Superior en Salud Pública,
Valencia), selected bacteria were grown in the presence of each of the azido sugars at
37 ᵒC in anaerobic conditions, mimicking the gastrointestinal tract. Then, aliquots from
the culture media at time 0 and 24 h were taken and analyzed by 1H NMR following the 
signals of the tagged sugars in order to determine the incorporation of the azido sugar. 
The obtained spectra showed that incorporation was strongly dependent on both the
bacteria and the azido sugar (Table 1). Our results described for the first time the
incorporation of glucose derivatives 1-4 in E. coli, azido glucose, galactose, and mannose
3, 9, and 11, respectively, in B. thetaomicron, sugars 6, 7, and 9 in P. copri, azido
galactose 8 in L. rhamnosus, and derivatives 6 and 11 in B. fragilis. The obtained results
are also consistent with the previous reported incorporation results in the case of azido
sugars 731 and 930,35 in B. fragilis and azido mannose 11 in P. copri.30 
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Results and discussion
Table 1. Incorporation of azido sugars by selected strains of bacteria
Compound B. fragilis B. thetaomicron P. copri L. rhamnosus E. coli
1
2
3
4
5
6 NDa NDa NDa
7 NDa NDa NDa 
8
9
11
Green: incorporation. Red: no incorporation. a ND: not determined.
As representative examples, the spectra obtained for azido sugars 6, 9, and 11 in
two different strains are represented in Figures 6 and 7. When using Ac4GlcNAz (6) as
azido sugar we could observe that the signals that were present at time 0 at 5.33, 
5.94, and 6.02 ppm corresponding to H3, H1β, and H1α, respectively (Figure 6A), 
disappeared after incubation for 24 h with both B. fragilis (Figure 6B) and P. copri
(Figure 6C), which indicated that azido sugar 6 was incorporated by both bacteria. In
the case of Ac4GalNAz (9), the incorporation took place in B. thetaomicron (Figure 7A) 
as shown by the disappearance of the signals of H3 and H4 at 5.37 and 5.43 ppm,
respectively, in the spectrum registered after 24 h of incubation, but not in L.
rhamnosus (Figure 7B) because these signals were still present after 24 h. When
analyzing the spectra corresponding to Ac4MnNAz (11), its consumption was observed
in B. fragilis (Figure 7C), due to the disappearance, after 24 h, of the signal at 5.25
ppm corresponding to H3, whereas this signal persists when 11 was incubated with E.
coli (Figure 7D), indicating that azido mannosamine derivative was not incorporated in
the cellular machinery.
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Figure 6. 1H NMR spectrum of azido sugar 6 in basal peptone yeast broth (A). Overlapped spectra
corresponding to times 0 and 24 h after incubation with B. fragilis (B), and P. copri (C).
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Figure 7. Representative 1H NMR spectra corresponding to times 0 and 24 h for different strains
and azido sugars. Ac4GalNAz (9) is incorporated in B. thetaomicron (A), whereas incorporation
does not take place in L. rhamnosus (B). Ac4ManNAz (11) is incorporated by B. fragilis (C) but not 
in E. coli (D).
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Results and discussion
2.2.2. Cytometry and confocal experiments
To further confirm the results obtained from the NMR screening, the incorporation of
the tagged sugars was assessed by flow cytometry and confocal experiments. Taking
into account that previously described results indicate that azido sugars are at least
partially incorporated in the glycoproteins of the glycocalix of bacteria, this
incorporation can be detected by flow cytometry after click chemistry reaction with a
fluorophore bearing a terminal alkyne. For that purpose, we have carried out these
experiments using the copper free version of the azide-alkyne click chemistry reaction,
trying to avoid the cytotoxicity of Cu (I) catalyst that could have a negative effect in
bacteria. Hence, we selected a fluorophore with a dibenzocyclooctyne group, so that the
reaction can proceed without any other catalyst with high efficiency. Thus,
dibenzocyclooctyne bodipy fluorophore DBCO-FL-PEG4-BODIPY (λexc = 503 nm, λem= 512
nm) was selected.32 The bacteria were incubated for 24 h in basal peptone yeast broth
at 37 ᵒC, and the supernatants removed from the pellet after centrifugation. The 
bacterial pellet was treated with DBCO-FL-PEG4-BODIPY, incubated with the cell­
permeant dye SYTO62 (λexc = 649 nm, λem= 680 nm) and analyzed by fluorescence
activated cell sorting (FACS) and confocal microscopy (Figure 8).
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Figure 8. Study of the incorporation of azido sugars by bacteria using flow cytometry and 
confocal microscopy.
Representative experiments are shown in Figures 9-12. In the dot plots (FL 4-H:
SYTO62, FL 1-H: DBCO-FL-PEG4-BODIPY) we observe that incubation of E. coli or B.
fragilis in the presence of azido sugars 3 or 9, respectively, provided a doubly positive
population for both SYTO62 and bodipy (Figures 9A and 9C, upper right area), thus
confirming the incorporation of these azido sugars. However, in absence of any azido
sugar (Figures 9B and 9D), only SYTO62 positive cells (upper left area) were detected.
The obtained results confirmed the incorporation of selected azido sugars by specific
strains of bacteria.
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Figure 9. Incorporation of azido sugars by bacteria from the human microbiota. E. coli
incorporates azido sugar 3 as indicated in the doubly positive population (upper right region) (A),
which is not observed in the absence of azido sugar 3 (B). B. fragilis incorporates azido sugar 9 as
indicated in the doubly positive population (upper right region) (C), which is not observed in the 
absence of azido sugar 9 (D). The bar graph (E) represents the percentage of fluorescence
intensity of the bodipy positive cells (FL1-H) with respect to the total SYTO62 positive population
after incubation of the cells in the absence or in the presence of the corresponding azido sugar.
Fluorescence intensity corresponds to SYTO62 (FL 4-H) or to DBCO-FL-PEG4-BODIPY (FL 1-H). FACS
experiments were carried out in a 2FACScalibur citometer and shown data correspond to the 
mean ± standard error mean (sem) of two independent experiments. ***, p < 0.0005 (Student´s t
test).
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Results and discussion
Confocal analysis also confirmed the incorporation of these azido sugars. When
bacteria (E. coli or B. fragilis) were grown in the presence of azido sugars 3 or 9, the
green fluorescence appeared (Figure 10A and 10C, respectively), whereas when
incubated in absence of azido sugar, only red staining corresponding to the bacterial
marker SYTO62 was observed (Figure 10B and 10D).
A)
10 μm
C)
10 μm
D)
5 μm
B)
10 μm
Figure 10. Azido sugars 3 and 9 are effectively incorporated by E. coli and B. fragilis, respectively. 
E. coli incorporates azido sugar 3 as pointed out by the presence of green fluorescence (A) which
disappears in absence of the azido sugar 3 (B). B. fragilis is able to incorporate azido sugar 9 as
shown by the green fluorescence (C), which is not observed in the absence of sugar 9 (D). Images
were obtained in a Leica confocal microscope and are representative from two independent 
experiments. Bacterial cells are visualized with SYTO62 (red).
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Results and discussion
Once checked the incorporation of azido sugars in specific strains of bacteria from
human microbiota, we wanted to extend the methodology in a more complex setting.
Thus, human microbiota bacteria coming from a healthy individual was incubated in the 
absence or presence of azido sugar 3 under the conditions previously described and flow 
cytometry and confocal analysis were performed. The incorporation of this sugar by the
human microbiota was confirmed as shown in Figures 11 and 12.
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Figure 11. Incorporation of azido sugar 3 by human microbiota bacteria. Azido sugar is
incorporated as indicated by the doubly positive population (upper right region) (A), which is not
observed in the absence of azido sugar 3 (B). The bar graph (C) represents the percentage of
fluorescence intensity of the bodipy positive cells (FL1-H) with respect to the total SYTO62
positive population after incubation of the cells in the absence or in the presence of azido sugar
3. Fluorescence intensity correspond to SYTO62 (FL 4-H) or to DBCO-FL-PEG4-BODIPY (FL 1-H).
FACS experiments were carried out in a 2FACScalibur citometer and shown data correspond to
the mean ± sem of two independent experiments. ***, p < 0.0005 (Student´s t test).
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A) B)
5 μm250 μm
Figure 12. Azido sugar 3 is effectively incorporated by human microbiota bacteria. The green 
fluorescence observed in the presence of the azido sugar confirms the incorporation (A), whereas
this signal disappears in the absence of azido sugar 3 (B). Images were obtained in a Leica
confocal microscope and are representative from two independent experiments. Bacterial cells
are visualized with SYTO62 (red).
2.3. Isolation of the different metabolomes
Due to the chemical diversity of metabolites that can be isolated from bacteria strains
(polar, non-polar, secreted or non-secreted by bacteria to the medium), we designed a 
separation and extraction process of these metabolomes in order to obtain fractions
enriched in different types of metabolites (Figure 13). First, the pellet of bacteria was
separated from the culture medium by centrifugation, obtaining the first metabolome 
fraction (A) that contained the metabolites secreted by the bacteria to the culture
medium. Then, the pellet of bacteria was extracted with a mixture of
methanol/chloroform/water (2:2:1) to separate the polar and non-polar metabolites.
After evaporation of the solvents of the organic phase, we obtained a second
metabolome fraction (B) formed mainly by non-polar metabolites. The aqueous phase of
the extraction was lyophilized to afford the last metabolome fraction (C) that contained
the more polar metabolites produced by the bacteria.
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Bacteria + Culture Medium
Centrifugation
Culture Medium (A)
Bacteria 
Extraction
 
MeOH/CHCl3/H2O
 
Organic Aqueous
Phase Phase
Non-polar Polar
Metabolites (B) Metabolites (C)
Evaporation of solvents Lyophilization
and resuspension in and resuspension
DMF/H2O 15:85 in PBS
Figure 13. Schematic process of the isolation of the three different metabolomes.
2.4. Bioorthogonal reaction with the capture reagent
The next step consisted on the synthesis of the capture reagents that would allow us
to capture the tagged metabolites by a bioorthogonal reaction. Taking into account the
selection of an azide group as the tag, we decided to apply the copper(I)-catalyzed 
azido-alkyne cycloaddition55 for the capture step. This bioorthogonal reaction can be
carried out in water and in mixtures of water and miscible organic solvents and requires
the presence of a source of copper (I) as catalyst that is formed in situ from Cu (II), due
to the instability of Cu (I) in aqueous solutions. Hence, CuSO4·5H2O is used as a source of 
Cu (II) in the presence of a reducing agent, such as sodium ascorbate or tris(2­
carboxyethyl)phosphine (TCEP). Furthermore, a stabilizing ligand such as
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Results and discussion
tris(benzyltriazolylmethyl)amine (TBTA) is used for the stabilization of the in situ Cu (I)
formed. Thus, we have designed capture reagents with a terminal akyne in order to
carry out this cycloaddition. For isolation of the captured metabolites we have
considered either a biotin group or a resin bead, which can be pulled down using
(strept)avidin beads or directly by centrifugation, respectively. Both moieties were 
separated by an adequate spacer that incorporates a disulfide bond as a cleavable 
sequence so that the metabolite can be softly released from the capture reagent. Hence,
disulfide capture reagents 17 and 18 were designed (Figure 14).
A)
B)
 
Figure 14. A) General structure of capture reagents containing an affinity handle (in green) and a
reactive group (in red) separated by a cleavable spacer (in blue). B) Designed capture reagents.
The synthesis of capture reagents 17 and 18 was carried out by condensation of
amine 19 with biotin or resin-supported carboxylic acid 20, respectively (Scheme 3). The
formation of 18 was checked by cleaving the resin in the presence of an aqueous
solution of TFA and triisopropylsilane (TIS) and confirming the release of the 
corresponding free carboxylic acid 21 by high performance liquid chromatography
coupled to mass spectrometry (HPLC-MS).
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Scheme 3. Reagents and conditions: a) biotin, EDC·HCl, HOBt, DIPEA, DMF, DCM, rt, on, 31%; b)
PEGA resin, PyBOP, Et3N, DMF, rt; c) TFA/TIS/H2O (95:2.5:2.5), rt, 60 min.
Amine 19 was obtained from commercially available cystamine dihydrochloride 
(Scheme 4). Its monoprotection with di-tert-butyl dicarbonate and further condensation
with 6-heptynoic acid using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and
hydroxybenzotriazole (HOBt) as coupling reagents led to amide 23. Later Boc
deprotection with TFA finally provided desired amine 19. Carboxylic acid 20 was
synthesized from commercially available PEGA resin and succinic anhydride (Scheme 4).
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Results and discussion
Scheme 4. Reagents and conditions: a) (Boc)2O, Et3N, MeOH, rt, 1 h, 49%; b) 6-heptynoic acid,
EDC·HCl, HOBt, DCM, rt, on, 56%; c) TFA, DCM, rt, 1 h, 67%; d) DMAP, pyridine, DMF, rt, on,
100%.
The next step consisted on setting up the conditions for the click chemistry reaction
between the azido sugars and the capture reagents 17, 18 that would allow us to
capture the metabolites produced by the bacteria. For this purpose, we selected 2­
azidoglucose 1 as the tagged sugar for reaction with the two capture reagents.
Considering that, after incubation of the corresponding tagged precursor with the
bacteria, we would isolate different metabolomic fractions (A, B, and C in Figure 13) that
could contain tagged metabolites, we need to carry out the click chemistry reaction in
three different media (culture medium for fraction A, DMF/H2O 15:85 for fraction B, and
PBS for fraction C). Hence, the bioorthogonal reaction was optimized in the culture
media (to capture the potential metabolites present in fraction A), in a mixture of
solvents (DMF/H2O, 15:85) in which the non-polar metabolites present in fraction B will
be captured, and in an aqueous medium (phosphate buffered saline (PBS), pH=7.4) to
capture the polar metabolites present in fraction C.
With respect to the conditions for the click chemistry reaction, we had to consider
several aspects. As reducing agents, based on previous work described in the literature,
we selected sodium ascorbate for those cycloaddition reactions performed in media that
contain organic solvents56,57 (fraction B, DMF/H2O, 15:85) and TCEP for those reactions
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Results and discussion
carried out in aqueous solvents58,59 (fractions A and C, culture medium and PBS, 
respectively). The equivalents of CuSO4·5H2O and TBTA, as well as the relative 
equivalents of azido sugar and alkyne (1:10), were chosen based on previously reported 
conditions.30,60 
Hence, the click chemistry reaction was carried out in the three different reaction
solvents during different periods of time to determine the conversion of the reaction,
which was followed by the disappearance of the azide by HPLC-MS. The obtained results
showed that in culture medium and with TCEP, the conversion of the reaction was 
higher than 90% after 3 h and this conversion was even higher in DMF/H2O, 15:85 for
the same time (>99%). However, the reaction was slower in PBS with TCEP, and 16 h
were required to obtain a conversion of 95% (Table 2).
Table 2. Optimization of the click chemistry reaction with capture reagent 17.
Reaction
solvent
Capture
reagent 
(equiv)
CuSO4·5H2O 
(equiv)
Reducing
Agent 
(equiv)
Time
(h)
Conversiona
(%)
Culture 
medium
10 20
TCEP
(20)
3
16
>90
b
DMF/H2O 
15:85
10 1.5
Sodium
Ascorbate 
(1.5)
1
3
16
>99
>99
>99
PBS 10 20
TCEP
(20)
1
3
16
70
70
95
a Determined by HPLC-MS; b Decomposition.
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Results and discussion
Once optimized the reaction conditions of azido sugar 1 with capture reagent 17, we
tested whether compound 18 was more efficacious than 17. For that purpose, capture
reagent 18 was reacted under the conditions previously optimized for different periods 
of time (Table 3). The results showed that the reactions in the culture medium or PBS
maintained the high conversions obtained with capture reagent 17 (>90% after 3 h, and
95% after 16 h, respectively), whereas in DMF/H2O, 15:85 the conversion decreased
from >99% to 80% after 3 h, observing even the decomposition of the formed triazol
with higher reaction times (Table 3). Hence, capture reagent 17 was selected for further
experiments.
Table 3. Optimization of the click chemistry reaction using capture reagent 18.
Reaction
solvent
Time (h) Conversiona (%)
Culture medium
3
16
>90
b
3 80
DMF/H2O 6 80
15:85 8 65
16 26
1 70
PBS 3 70
16 95
a Determined by HPLC-MS; b Decomposition.
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Results and discussion
2.5. Isolation of the tagged metabolites
Once optimized the bioorthogonal reaction that will be carried out to capture the
tagged metabolites, we performed the optimization of the isolation process of captured
metabolites. The conditions for the isolation with streptavidin beads and the reduction
of the disulfide bond were optimized using the resulting biotinyltriazol 24 previously
obtained by the click chemistry reaction of azido sugar 1 and alkyne 17. With respect to
the isolation, we tested a variety of volumes of the aqueous suspension of commercially
available streptavidin beads (100-300 µL). Hence, the resulting samples after click
chemistry reaction were incubated with different volumes of streptavidin beads for 90
min, centrifuged and the supernatants analyzed by HPLC-MS quantifying the 
disappearance of biotinyltriazol 24. The obtained results indicated that incubation with
250 µL of beads was enough for the complete isolation of the biotinyl compound and its
disappearance of the solution. Finally, we set up the conditions for the reduction of the
disulfide bond of the triazol 24 by incubation with DTT confirming the formation of the
resulting thiol 26 by HPLC-MS (Scheme 5).
Scheme 5. Reagents and conditions: a) Streptavidin beads, rt, 90 min; b) DTT, MeOH/H2O (1:1), 
rt, 60 min.
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Results and discussion
2.6. NMR and MS-based deconvolution and identification of metabolites
The final step consisted on the identification of the isolated tagged metabolites. For
that purpose, we carried out the complete methodology in higher scale selecting one 
pair of azido sugar and strain where the incorporation took place. Hence, E. coli was
grown in basal peptone yeast broth medium in the presence of the azido sugar 3 and
after centrifugation and extraction processes, three metabolome fractions (A, B, and C, 
see Figure 13) were obtained. Metabolites were captured in the three different
metabolome fractions using the optimized click chemistry conditions detailed in 2.4.,
followed by isolation with streptavidin beads, metabolite release after treatment with
DTT (see 2.5.), and analysis by MS. In parallel, the same strategy was carried out growing
E. coli without the azido sugar to discard unspecific results. The experiments aimed at
the identification of the captured metabolites have been carried out during a short stay 
in the laboratory of Dr. Jean-Charles Portais from the Platform of Metabolomics and
Fluxomics (Metatoul) in Toulouse, France, a centre with expertise in metabolomics. 
To establish which peaks of the mass spectra come from the captured metabolites
we checked whether they could be identified on the basis of the common fragment ion
A (Figure 15).
Figure 15. General structure for captured metabolites coming from azido sugars. The common 
fragment ion A is shown in red.
To confirm the generality of this fragmentation in this type of structures, the click 
chemistry reaction between azides 1-12 and biotinylated alkyne 17 was carried out.
After isolation of the reaction products with streptavidin beads and release with DTT,
MS analysis confirmed the presence of the triazol containing fragment ion [A + H]+ (m/z
229) as shown by the spectra obtained for sugars 3 and 6 as representative of free and
peracetylated sugars, respectively (Figure 16).
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391.1717
[M+H]+
114.0935
229.1153
m/z400300200100
100
0
%
A)
[M-A-H2O-CH2O]+
[A+H]+
m/z
229.1153
B)
[M+Na]+
638.2109
[M+H]+
616.2294
184.0778
202.0887
350.1939
382.1756
100
0
%
600400200
[M-A-H2O-4Ac+H]+
[A+H]+
[M-A-2H2O-4Ac +H]+
Figure 16. Mass spectra corresponding to captured azido sugars 3 (A) and 6 (B).
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Results and discussion
Then, we performed the MS/MS analysis of metabolome fractions A-C coming from
the incubation of E. coli with azido sugar 3, identifying those peaks that generate in their
fragmentation the characteristic m/z 229 peak. For these analyses, we have used a 
tandem MS technique named MSE. In MSE, the spectometer firstly carries out a MS
analysis where all the ions are transmitted from the ion source through the collision cell
to the mass analyzer using low collision energy so that a minimal fragmentation occurs.
Hence, a precursor ion spectrum is registered in order to identify the parental ions.
Then, all the ions are transmitted from the ion source through the collision cell to the
mass analyzer using higher collision energy values in order to generate the maximum
information from fragment ions, providing a fragment ion spectrum. In our particular
case, as we have previously checked that this type of structures fragment giving the 
common ion m/z 229 (Figures 15 and 16), we searched for those peaks that generate
this characteristic ion in their fragmentation. As representative examples, analyses
coming from metabolome fraction B of E. coli grown in the presence or absence of azido
sugar 3 are shown in Figure 17. These chromatograms represent the total ion current
(TIC) when registering the precursor and fragment ion spectra (Figure 17). When we
search for those peaks containing m/z 229, we can observe the presence of two peaks
with retention times of 7.77 and 9.23 that could come from captured metabolites
(Figure 17A, upper pannel). When comparing with the negative control (Figure 17B, 
upper pannel), we discarded the peak at 9.23 min due its inespecific nature. Then, after
analyzing the mass spectra from the peak at 7.77 min (Figure 18), we determined m/z
391.1717 as the molecular ion due to its high intensity in the parent ion spectrum
(Figure 18A) and its almost complete disappearance in the fragment ion spectrum
(Figure 18B). Analysis of these spectra and a mass of m/z 391.17 suggested the
possibility of the capture of the azido sugar 3 without any transformation. This 
assignment was further confirmed by MSE analysis of the product of the click chemistry 
reaction between compounds 3 and 17 as detailed in Figure 19. The resulting spectra 
(Figures 20 and 21) closely match with the ones obtained previously (Figure 18), result
that suggests that the azido sugar 3 has been incorporated in E. coli but not
metabolized, at least in an appreciable extent.
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A)
m/z  229 extracted
Precursor ion (TIC)
Fragment ion (TIC)
Specific peak
B)
m/z  229 extracted
Precursor ion (TIC)
Fragment ion (TIC)
Figure 17. Chromatograms corresponding to the metabolome fraction B coming from the
incubation of E. coli with azido sugar 3 (A) and in absence of azido sugar as negative control (B).
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m/z400300200100
100
0
%
391.1717
114.0935
133.0785 286.1085
229.1153
152.0845 229.1153
m/z400300200100
100
0
%
391.1717
133.0785
A) B)
[M+H]+
[M+H]+
[A+H]+
[A+H]+
Figure 18. MS spectra corresponding to the TIC chromatograms of metabolome fraction B coming
from the incubation of E. coli with azido sugar 3. (A) Parent ion spectrum. (B) Fragment ion 
spectrum.
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Figure 19. Schematic process of the synthesis of captured azido sugar 3.
Precursor ion (TIC)
Fragment ion (TIC)
Figure 20. Chromatograms corresponding to captured azido sugar 3.
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m/z400300200100
100
0
%
114.0935
229.1153
391.1717
[M+H]+
391.1717
[M+H]+
m/z400300200100
114.0935
229.1153
B)A)
[M-A-H2O–CH2O]+
[A+H]+
[M-A-H2O-CH2O]+
[A+H]+
Figure 21. MS spectra corresponding to the TIC chromatograms of captured azido sugar 3. (A)
Parent ion spectrum. (B) Fragment ion spectrum.
The identification of captured azido sugar 3 in the metabolome of E. coli confirms
that the proposed platform is suitable for the capture, isolation, and identification of
tagged compounds within complex metabolomes. These results validate, as proof of 
concept, the proposed strategy for the identification of metabolites produced by the
human microbiota. This methodology will be extended in our research group to other
tagged precursors such as amino acids or fatty acids aimed at the identification of their 
metabolites.
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3. CONCLUSIONS
In the present work we have developed a strategy based on the use of tagged
precursors for the identification of metabolites produced by the human microbiota.
Using azido sugars as tagged precursors in a variety of strains of bacteria of the human
microbiota we have validated the proposed platform. These results constitute the proof
of concept that the envisioned approach is suitable for the identification of tagged
metabolites within complex metabolomes. This strategy is being extended in our
research group to other tagged precursors (amino acids, fatty acids<) with the final
objective of expediting the identification of new microbiota metabolites and their
subsequent phenotypic study.
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4. EXPERIMENTAL SECTION
4.1. Chemistry
As far as general considerations are concerned, see section 4 of Chapter A.
Additionally, specific synthetic issues related to the present chapter are detailed below.
4.1.1. Synthesis of azido sugar 1
1-(Azidosulfonyl)-1H-imidazol-3-ium chloride. To a suspension of NaN3 (1.00 g, 15.4
mmol) in anhydrous ACN (15 mL), sulfuryl chloride (1.3 mL, 15.4 mmol) was added
dropwise at 0 ᵒC under and the reaction mixture was stirred on at rt. Then, a solution of
imidazol (1.90 g, 29.2 mmol) was added dropwise to the ice-cooled reaction mixture and
stirred at rt for 3 h. The mixture was diluted with EtOAc, washed with H2O and saturated
solutions of NaHCO3 and NaCl, subsequently, dried over Na2SO4 and filtered. Then, a
solution of HCl (2 M in Et2O, 5.8 mL) was added dropwise to the ice-cooled filtrate with
stirring, and the mixture was left stand for 10 min at 0 ᵒC. The precipitate was isolated
by filtration, washed with cold EtOAc and dried to afford the corresponding
hydrochloride in 64% yield (2.10 g). The spectroscopic data are in agreement with those 
previously described.61 
1H-NMR (D2O, ): 7.55 (m, 1H, H5), 7.97 (m, 1H, H4), 9.22-9.30 (m, 1H, H2).
  
 
   
              
        
         
       
       
      
 
         
                
                
         
       
 
       
           
       
         
      
      
           
            
      
    
           
   
       
         
          
       
       
         
 
Experimental section
2-Azido-2-deoxy-D-glucopyranose (1). To a suspensión of 2-aminoglucose 
hydrochloride (646 mg, 3.0 mmol), K2CO3 (981 mg, 7.1 mmol), and CuSO4 · 5H2O (6 mg,
40 μmol) in methanol (15 mL) at rt, 1-(azidosulfonyl)-1H-imidazol-3-ium chloride (755
mg, 3.6 mmol) was added and the reaction mixture was stirred at rt on. The residue was
concentrated under reduced pressure, redissolved in methanol and filtered. The solvent
was removed under reduced pressure to yield azido glucose 1 in 15% yield (92 mg). The 
spectroscopic data are in agreement with those previously described.62 
Rf (DCM/MeOH, 4:1): 0.85. 1H-NMR (CDCl3, ): (mixture of anomer α/β, 1:2): 3.25 (dd, J = 
9.2, 8.3 Hz, 1 H, H2β), 3.44 (dd, J = 10.1, 3.2 Hz, 2H, H6α, H6β), 3.45-3.49 (m, 5H, H2α, H4α, 
H4β, H6α, H6β), 3.70-3.85 (m, 4H, H3α, H3β, H5α, H5β), 4.69 (d, J = 8.1 Hz, 1H, H1β), 5.33 (d, J = 
3.6 Hz, 1H, H1α). MS (ESI, m/z): 206.1 [M+H]+.
4.1.2. Synthesis of azido sugars 9 and 10
1,3,4,6-Tetra-O-acetyl-2-[(tert-butoxycarbonyl)amino]-2-deoxy-D-galactopyranose
(14). Over a solution of 2-galactosamine hydrochloride (141 mg, 0.8 mmol) in a mixture 
H2O/dioxane, 1:1 (8 mL), a solution of di-tert-butyl dicarbonate (188 mg, 0.9 mmol) in
H2O/dioxane, 1:1 (4.5 mL) was added dropwise and the reaction mixture was stirred for
2 days at rt. The solvents were removed under reduced pressure to afford 2-[(tert­
butoxycarbonyl)amino]-2-deoxy-D-galactopyranose 13 in quantitative yield (350 mg),
which was used in the next step without further purification. N-Boc protected amine 13
(310 mg, 1.1 mmol) was partially dissolved in DCM (5 mL) and pyridine (1.8 mL, 22.2
mmol) was added. The mixture was stirred at 0 ᵒC for 30 min and Ac2O (2.1 mL, 22.2
mmol) was added dropwise. The reaction mixture was stirred at rt observing the 
formation of a precipitate. After two hours of stirring, the precipitate disappeared
turning into a yellow solution, and then, H2O was added to the reaction mixture and the
aqueous phase was extracted with DCM. The combined organic layers were dried over 
anhydrous Na2SO4, filtered, and the solvent was removed under reduced pressure. The
obtained residue was redissolved in Et2O and washed with a solution of NaHSO3 (1 M in
H2O) and a saturated solution of NaCl. Then, it was dried over anhydrous Na2SO4, 
filtered, and the solvent removed under reduced pressure. The residue was purified by
chromatography (hexane/EtOAc, 7:3) obtaining peracetylated compound 14 in 51% yield
(250 mg). The spectroscopic data are in agreement with those previously described.63 
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Experimental section
Rf (hexane/EtOAc, 1/1): 0.4. 1H-NMR (CDCl3, ): 1.41 (s, 9H, C(CH3)3), 2.01 (s, 3H, CH3),
2.02 (s, 3H, COCH3), 2.16 (s, 3H, COCH3), 2.17 (s, 3H, COCH3), 4.07-4.14 (m, 2H, 2H6), 4.25
(dd, J = 6.7, 1.1 Hz, 1H, H5), 4.44 (m, 1H, H2), 5.13 (dd, J = 10.9, 2.5 Hz, 1H, H3), 5.41 (d, J = 
3.2, 1.3 Hz, 1H, H4), 6.21 (d, J = 3.6 Hz, 1H, H1α). MS (ESI, m/z): 331.9 [M-2OAc+H] +, 469.9
[M+Na]+.
1,3,4,6-Tetra-O-acetyl-2-amino-2-deoxy-D-galactopyranose (15). To a solution of
sugar 14 (100 mg, 0.2 mmol) in anhydrous DCM (7 mL), TFA (0.9 mL, 11.2 mmol) was
added dropwise at 0 ᵒC and the reaction was stirred within for 3 h. The solvent was 
removed under reduced pressure obtaining amine 15 in quantitative yield as a TFA salt
(m= 114 mg). The spectroscopic data are in agreement with those previously
described.64 
Rf (DCM): 0.35. 1H-NMR (MeOD, ): 1.91 (s, 3H, CH3), 1.96 (s, 3H, CH3), 2.05 (s, 3H, CH3),
2.11 (s, 3H, CH3), 3.98 (dd, J = 11.4, 3.7 Hz, 1H, H2), 4.11 (m, 2H, 2H6), 5.37 (dd, J = 11.4,
3.2 Hz, 1H, H3), 5.52 (dd, J = 3.2, 1.3 Hz, 1H, H4), 6.36 (d, J = 3.6 Hz, 1H, H1α). MS (ESI,
m/z): 370.1 [M+Na]+.
1,3,4,6-Tetra-O-acetyl-2-(2-chloroacetamido)-2-deoxy-D-galactopyranose (16). To a
solution of amine 15 (115 mg, 0.3 mmol) in DCM (3.5 mL) at 0 ᵒC, a solution of
chloroacetic anhydride (119 mg, 0.7 mmol) in DCM (10 mL) and 4-methylmorpholine 
(220 µL, 2.0 mmol) were added, subsequently. The reaction mixture was stirred on at rt
and then diluted with Et2O, washed with solutions of HCl (1 M in H2O), NaOH (1 M in
H2O), and a saturated solution of NaCl, subsequently. The combined organic layers were
dried over anhydrous Na2SO4, filtered, and then concentrated under reduced pressure
to provide derivative 16 in 80% yield (111 mg).65 
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Experimental section
Rf (hexane/EtOAc, 1:1): 0.2. 1H-NMR (CDCl3, ): 2.02 (s, 3H, CH3), 2.03 (s, 3H, CH3), 2.17
(s, 3H, CH3), 2.18 (s, 3H, CH3), 4.01 (s, 2H, CH2Cl), 4.24 (m, 2H, 2H6), 4.28 (ddd, J = 7.6,
6.7, 0.9 Hz, 1H, H5), 4.69 (dd, J = 9.1, 3.8 Hz, 1H, H2), 5.25 (dd, J = 11.6, 1.1 Hz, 1H, H3),
5.44 (dd, J = 3.1, 1.1 Hz, 1H, H4), 6.23 (d, J = 3.8 Hz, 1H, H1α), 6.50 (d, J = 9.1 Hz, 1H, NH).
MS (ESI, m/z): 453.0 [M+Na]+.
1,3,4,6-Tetra-O-acetyl-2-(2-azidoacetamido)-2-deoxy-D-galactopyranose
(Ac4GalNAz) (9). To a solution of chloride 13 (500 mg, 1.1 mmol) in DMF (20 mL), NaN3 
(750 mg, 11.4 mmol) was added and the reaction mixture was stirred for 3 h at 60 ᵒC.
Then, the crude was diluted with H2O and extracted with EtOAc. The combined organic
layers were washed with a saturated solution of NaCl, dried over Na2SO4, filtered, and
the solvent was removed under reduced pressure to yield peracetylated sugar 9 in 52% 
yield (250 mg). The spectroscopic data are in agreement with those previously
described.66 
Rf (hexane/EtOAc, 1:1): 0.4. Mp: 140-142 °C. 1H-NMR (CDCl3, ): 2.02 (s, 3H, CH3), 2.03 (s,
3H, CH3), 2.17 (s, 3H, CH3), 2.18 (s, 3H, CH3), 3.95 (s, 2H, CH2N), 4.08 (m, 2H, 2H6), 4.25
(dd, J = 6.7, 1.1 Hz, 1H, H5), 4.69 (dd, J = 9.1, 3.6 Hz, 1H, H2), 5.25 (dd, J = 11.6, 3.1 Hz, 1H,
H3), 5.45 (dd, J = 3.1, 1.1 Hz, 1H, H4), 6.21 (d, J = 3.6 Hz, 1H, H1α), 6.28 (d, J = 9.1 Hz, 1H,
NH). MS (ESI, m/z): 453.0 [M+Na]+.
2-(2-Azidoacetamido)-2-deoxy-D-galactopyranose (GalNAz) (10): Over a solution of
peracetylated sugar 9 (150 mg, 0.4 mmol) in MeOH (3.5 mL), a solution of sodium
methoxide (1 M in MeOH, 70 µL) was added dropwise. The reaction mixture was stirred 
for 2 h and the solvent was removed under reduced pressure to afford free hydroxyl
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Experimental section
sugar 10 in 100% yield (m= 105 mg). The spectroscopic data are in agreement with those
previously described.67 
Rf (DCM/MeOH, 9:1): 0.3. 1H-NMR (D2O, ): mixture of anomers α/β, 1:1: 3.71 (app d, J
= 6.3 Hz, 2H, H3α, H3β), 3.74 (dd, J = 9.9, 3.3 Hz, 2H, H5α, H5β), 3.90 (dd, J = 9.1, 6.7 Hz, 2H,
H6αβ), 3.95 (dd, J = 9.9, 3.3 Hz, 2H, H6´α,β), 4.04 (s, 4H, 2CH2N), 4.05-4.11 (m, 3H, H2β, H4α, 
H4β), 4.16 (dd, J = 10.9, 3.7 Hz, 1H, H2α), 4.65 (d, J = 8.4 Hz, 1H, H1β) 5.20 (d, J = 3.7 Hz,
1H, H1α). MS (ESI, m/z): 260.8 [M-H]-.
4.1.3. Synthesis of capture reagents 17 and 18
• Synthesis of capture reagent 17
tert-Butyl-(2-[(2-aminoethyl)disulfanyl]ethyl)carbamate (22). To a suspension of
cystamine dihydrochloride (1.00 g, 4.8 mmol) in MeOH (10 mL), Et3N (2 mL, 14.5 mmol) 
and a solution of di-tert-butyl dicarbonate (900 mg, 4.8 mmol) in MeOH (5 mL) were
added. The mixture was stirred for 1 h at rt and the solvent evaporated in vacuo. To the
residue, a solution of NaH2PO4 (1 M in H2O, pH = 4.2) was added and the mixture was
extracted with Et2O to remove di-Boc-cystamine. The aqueous solution was basified (pH
= 9) using a solution of NaOH (1 M in H2O) and extracted with EtOAc. The combined
organic layers were washed with H2O and a saturated solution of NaCl, subsequently,
dried over Na2SO4, filtered, and the solvent removed under reduced pressure to yield
protected amine 22 in 49% yield (594 mg). The spectroscopic data agreed with those
previously described.68 
Rf (hexane/EtOAc, 3:7): 0.2. Mp: 112-113 ᵒC (Lit.69 109-110 ᵒC). 1H-NMR (CDCl3, δ): 1.40 
(s, 9H, 3CH3), 2.72 (t, J = 5.9 Hz, 2H, SCH2CH2NH2), 2.75 (t, J = 5.6 Hz, 2H, SCH2CH2NHCO),
2.97 (t, J = 6.1 Hz, 2H, CH2NH2), 3.40-3.42 (m, 2H, CH2NHCO). MS (ESI, m/z): 253.1
[M+H]+.
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tert-Butyl-N-(2-[(2-aminoethyl)disulfanyl]ethyl)hept-7-ynamide (23). A solution of
EDC (461 mg, 3.0 mmol), HOBt (402 mg, 2.9 mmol), and 6-heptynoic acid (0.3 mL, 2.4
mmol) in anhydrous DCM (20 mL) was stirred for 1 h at rt. Then, a solution of amine 22
(500 mg, 2.0 mmol) in a mixture DCM/DMF, 1:1 (7 mL) was added dropwise and the
reaction was stirred on. The reaction mixture was washed with a saturated solution of
NaHCO3 and the aqueous layer was reextracted with DCM. The combined organic layers 
were washed with a saturated solution of NaCl, dried over anhydrous Na2SO4, filtered,
and the solvent was removed under reduced pressure. The residue was purified by
chromatography (hexane/EtOAc, 6:4) to afford amide 23 in 56% yield (407 mg).
Rf (hexane/EtOAc, 1:1): 0.24. IR (ATR, cm-1): 3301 (CΞCH, NH), 1696, 1652, 1533 (CONH),
640 (S-S). 1H-NMR (CDCl3, δ): 1.44 (s, 9H, 3CH3), 1.51-1.60 (m, 2H, CH2CH2CO), 1.70-1.80
(m, 2H, CH2CH2CΞ), 1.94 (t, J = 2.7 Hz, 1H, CHΞC), 2.20 (td, J = 7.0, 2.9 Hz, 2H, CH2CΞ),
2.25 (t, J = 7.3 Hz, 2H, CH2CO), 2.77 (t, J = 6.7 Hz, 2H, CH2CH2NHBoc), 2.83 (t, J = 6.1 Hz,
2H, CH2CH2NH), 3.44 (q, J = 6.7 Hz, 2H, CH2NHBoc), 3.56 (q, J = 6.1 Hz, 2H, CH2NH), 4.98
(br s, 1H, NHBoc), 6.50 (br s, 1H, NHCO). 13C-NMR (CDCl3, δ): 18.3 (CH2C≡), 24;9
(CH2CH2C≡), 28;1 (CH2CH2CO), 28.5 (3CH3), 36.1 (CH2CO), 37.8 (CH2CH2NHBoc), 38.2
(CH2CH2NH), 38.7 (CH2NH), 39.8 (CH2NHBoc), 68.7 (C≡CH), 80.0 (C(CH3)3), 84.2 (C≡CH),
156.4 (OCONH), 172.9 (CONH). MS (ESI, m/z): 261.1 [M-Boc+H]+.
N-(2-[(2-Aminoethyl)disulfanyl]ethyl)hept-7-ynamide (19). To a solution of
compound 23 (320 mg, 0.8 mmol) in anhydrous DCM (4 mL), TFA (1.3 mL, 16.8 mmol) 
was added dropwise and the reaction mixture was stirred at rt for 5 h. The solvent was
removed under reduced pressure, the residue was redissolved in DCM and basified with
a solution of NaOH (1 M in H2O). The organic layer was extracted with DCM, dried over
anhydrous Na2SO4, filtered and the solvent was removed under reduced pressure to
afford amine 19 in a quantitative yield (240 mg).
Rf (DCM/MeOH/NH3, 8:2:0.1): 0.6. IR (ATR, cm-1): 3295 (C≡CH, NH), 1648, 1552 (CONH),
638 (S-S). 1H-NMR (MeOD, δ): 1.53-1.58 (m, 2H, CH2CH2CO), 1.70-1.80 (m, 2H,
CH2CH2C≡), 2.18-2.23 (m, 3H, CH2C≡CH, C≡CH), 2.25 (t, J = 7.3 Hz, 2H, CH2CO), 2.88 (t, J = 
6.8 Hz, 2H, CH2CH2NHCO), 3.02 (t, J = 6.6 Hz, 2H, CH2CH2NH2), 3.28 (t, J = 6.6 Hz, 2H,
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CH2NH2), 3.50 (t, J = 6.8 Hz, 2H, CH2NHCO). 13C-NMR (MeOD, δ): 18.7 (CH2C≡), 26.0
(CH2CH2C≡), 29.1 (CH2CH2CO), 35.4 (CH2CH2NH2), 36.5 (CH2CO), 38.2 (CH2CH2NHCO), 39.3
(CH2NH2), 39.4 (CH2NHCO), 69.8 (C≡CH), 84.6 (C≡CH), 176.0 (CO). MS (ESI, m/z): 261.1
[M+H]+.
N-(2-[(2-([5-(2-Oxohexahydro-1H-thieno[3,4-d]imidazol-4­
yl)pentanoyl]amino)ethyl)disulfanyl]ethyl)hept-6-ynamide (17). A suspension of biotin
(38 mg, 0.2 mmol), HOBt (21 mg, 0.2 mmol) and activated 4Å molecular sieves in
anhydrous DMF (8 mL) was stirred at 77 ᵒC until a clear solution was obtained. Once
cooled to rt, a solution of EDC (27 mg, 0.2 mmol) in anhydrous DCM (3 mL) was added
dropwise and the mixture stirred at rt for 3 h. Then, a solution of amine 19 (20 mg, 0.1
mmol) and DMAP (200 μg, 20 µmol) in anhydrous DCM (2 mL) was added and the
reaction mixture was stirred for 24 h. Then, the crude was filtered, diluted with DCM,
washed with saturated solutions of NaHCO3 and NaCl, subsequently. The organic layer 
was dried over Na2SO4, and filtered. The solvent was removed under reduced pressure
and the residue was purified by chromatography (EtOAc/MeOH, 9:1, 0.1% NH3) to yield
compound 17 in 31% yield (12 mg).
Rf (EtOAc/MeOH/NH3, 8:2:0.1): 0.4. Mp: 217-220 °C. IR (ATR, cm-1): 3301 (C≡CH, NH),
1692, 1652 (CONH). 1H-NMR (MeOD, δ): 1.43-1.78 (m, 10H, CHS(CH2)3, (CH2)2CH2CΞ),
2.18-2.25 (m, 7H, CH2C≡, C≡CH, 2CH2CO), 2.71 (d, J = 12.7 Hz, 1H, ½CH2Sbiot), 2.83 (t, J = 
6.7 Hz, 2H, CH2S), 2.84 (t, J = 6.6 Hz, 2H, CH2S), 2.94 (dd, J = 12.7, 5.0 Hz, 1H, ½CH2Sbiot),
3.18-3.25 (m, 1H, CHS), 3.49 (t, J = 6.7 Hz, 4H, 2CONHCH2), 4.32 (dd, J = 7.9, 4.4 Hz, 1H,
CHNbiot), 4.51 (dd, J = 7.9, 4.3 Hz, 1H, CHNbiot). 13C-NMR (MeOD, δ): 18.5 (CH2C≡), 25.8
(CH2CH2C≡), 26.5, 28.9, 29.2, 29.5 (CH2CH2CO, (CH2)3CHS), 36.2, 36.5 (2CH2CO), 38.2, 38.3
(2CH2S), 39.2, 39.3 (2CONHCH2), 40.8 (CH2Sbiot), 56.7 (CHS), 61.4, 63.1 (2 CHNbiot), 69.5
(C≡CH), 84.3 (C≡CH), 164.7 (NCON), 174.7, 174.8 (2CONH). HPLC-MS (rt, min): 15.16, 
method A. HRMS (ESI): Calculated for C21H34NaN4O3S3 [(M+Na)+]: 509.1691. Found:
509.1720.
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• Synthesis of capture reagent 18
Solid-supported intermediate (20). Polyethylene glycol polyacrylamide (PEGA) resin
(200 mg, 70 µmol, charge: 0.34 mmol/g resin) was washed with DMF and shaked for 16
h (rt, 120 rpm, THZ thermostatic shaker (Lan Technics)) with a solution of succinic
anhydride (170 mg, 1.7 mmol), pyridine (20 µL, 0.3 mmol) and DMAP (8 mg, 70 µmol) in
DMF (2.7 mL). Then, the resin was washed with DMF and DCM (3x). The formation of
derivative 20 was checked by Kaiser´s test, which showed no presence of amino PEGA
resin.
Capture reagent (18). Resin 20 (70 µmol) was swollen in DMF (700 µL) and PyBOP
(181 mg, 0.3 mmol) and DIPEA (60 µL, 0.3 mmol) were added. Shaking was maintained 
for 20 min (rt, 120 rpm) and a solution of amine 19 (13 mg, 70 µmol) in DMF (1.4 mL) 
was added. The resin was shaken for 40 h (rt, 120 rpm), the reaction mixture was 
filtered off and the resin was washed with DMF, DCM, MeOH, and DMF (2 x 2.5 mL
each) to afford capture reagent 18. In order to check that the reaction has worked, a
small amount of resin was separated and treated with a mixture of TFA/TIS/H2O,
95:2.5:2.5 (0.2 mL) for 1 h (rt, 120 rpm). The reaction mixture was filtered, the solvent
removed and the residue analized by HPLC-MS, observing the peak of m/z = 361.1,
which correspond to the [M+H]+ of carboxylic acid 21.
4.1.4. NMR analysis of tagged precursors in the culture medium. The 1H NMR spectra 
of these sugars in basal peptone broth medium* was carried out at 100, 200, and 400
µM by mixing 180 µL of the corresponding solution of the azido sugar in the culture
medium with 20 µL of deuterated water and then analyzed in a 700 MHz equipment
(Bruker Avance III 700 MHz).
* Basal peptone-yeast broth contains (per liter): 5 g of yeast extract, 20 g of proteose
peptone, 5 g of NaCl, 5 mg of hemin, 0.5 mg of vitamin K1 and 5 g of K2HPO4. Hemin,
vitamin K1, and K2HPO4 were added through a filter after the basal medium had been
autoclaved.
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Experimental section
4.1.5. Optimization of the bioorthogonal reaction and the isolation processes
4.1.5.1 With capture reagent 17
• In culture medium. Azido sugar 1 (2 mM in DMSO, 5 µL), capture reagent 17 (10
mM in DMSO, 10 µL), CuSO4·5H2O (40 mM in H2O, 5 µL), TCEP (40 mM in H2O, 5 µL), and
TBTA (2 mM in H2O, 5 µL), were added to 100 μL of culture medium. The samples were
shaked for 3 h (rt, 120 rpm) and a suspension of streptavidin beads (250 µL) in PBS (500
µL) was added (streptavidin beads were previously centrifuged (rt, 10 min, 12000 rpm)
to remove the glycerol of the commercial solution, washed with PBS (2x), and
suspended in PBS). The mixture was shaked for 90 min (rt, 120 rpm), centrifuged (rt, 10
min, 12000 rpm), and the pellet of beads washed with PBS (2 x 500 µL). Then, the beads
were resuspended in a solution of DTT (50 mM in MeOH/H2O, 1:1, 100 µL), shaked for 1
h (rt, 120 rpm) and centrifuged (rt, 10 min, 12000 rpm). The supernatant was isolated, 
the solvent was removed and the residue was redissolved in 100 µL of MeOH and
analyzed by HPLC-MS. HPLC-MS analysis was done in an Eclipse XDB-C18 column (5 μm,
4.6 mm x 150 mm), together with a guard column (5 μm, 4;6 mm x 12;5 mm) with a flow
of 0.5 mL/min. The gradient mobile phase consisted of A (95:5 water/acetonitrile) and B
(5:95 water/acetonitrile) with 0.1% formic acid as solvent modifier. The gradient is
indicated in Table 4.
Table 4. HPLC-MS method used in the optimization of the click chemistry reaction
t (min) % B
0 0
5 0
12 60
22 100
26 100
30 0
• In DMF/H2O, 15:85. Azido sugar 1 (2 mM in DMSO, 5 µL), capture reagent 17 (10
mM in DMSO, 10 µL), CuSO4·5H2O (3 mM in H2O, 5 µL), sodium ascorbate (3 mM in H2O,
5 µL), and TBTA (2 mM in H2O, 5 µL), were added to 100 µL of DMF/H2O, 15:85. The
samples were incubated for 1 h (rt, 120 rpm) and a suspension of streptavidin beads 
(250 µL) in PBS (500 µL) was added (streptavidin beads were previously centrifuged (rt,
10 min, 12000 rpm) to remove the glycerol of the commercial solution, washed with PBS
(2x), and suspended in PBS). The mixture was shaked for 90 min (rt, 120 rpm),
centrifuged (rt, 10 min, 12000 rpm), and the pellet of beads washed with PBS (2 x 500
µL). Then, the beads were resuspended in a solution of DTT (50 mM in MeOH/H2O, 1:1, 
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Experimental section
100 µL), shaked for 1 h (rt, 120 rpm) and centrifuged (rt, 10 min, 12000 rpm). The
supernatant was then isolated, the solvent was removed, and the residue redissolved in
100 µL of MeOH before analysis by HPLC-MS using the conditions previously described 
and the gradient indicated in Table 4.
• In PBS. Azido sugar 1 (2 mM in DMSO, 5 µL), capture reagent 17 (10 mM in DMSO,
10 µL), CuSO4·5H2O (40 mM in H2O, 5 µL), TCEP (40 mM in H2O, 5 µL), and TBTA (2 mM in
H2O, 5 µL), were added to 100 µL of PBS. The samples were shaked for 16 h (rt, 120 rpm)
and a suspension of streptavidin beads (250 µL) in PBS (500 µL) was added (streptavidin
beads were previously centrifuged (rt, 10 min, 12000 rpm) to remove the glycerol of the
commercial solution, washed with PBS (2x), and suspended in PBS). The mixture was
shaked for 90 min (rt, 120 rpm), centrifuged (rt, 10 min, 12000 rpm) and the pellet of 
beads washed with PBS (2 x 500 µL). Then, the beads were resuspended in a solution of 
DTT (50 mM in MeOH/H2O, 1:1, 100 µL), shaked for 1 h (rt, 120 rpm) and centrifuged (rt,
10 min, 12000 rpm). The supernatant was then isolated, the solvent was removed, and
the residue redissolved in 100 µL of MeOH before analysis by HPLC-MS using the 
conditions previously described and the gradient indicated in Table 4.
4.1.5.2. With capture reagent 18
• In culture medium. Azido sugar 1 (2 mM in DMSO, 5 µL), capture reagent 18 (0.3
mg, charge 0.34 mmol/g), CuSO4·5H2O (40 mM in H2O, 5 µL), TCEP (40 mM in H2O, 5 µL),
and TBTA (2 mM in H2O, 5 µL), were added to 100 μL of culture medium. The samples 
were incubated for 3 h (rt, 120 rpm), centrifuged (rt, 10 min, 12000 rpm) and the
resulting resin was resuspended in a solution of DTT (50 mM in MeOH/H2O, 1:1, 100 µL),
shaked for 1 h (rt, 120 rpm) and centrifuged (rt, 10 min, 12000 rpm). The supernatant
was then isolated, the solvent was removed, and the residue was redissolved in 100 µL
of MeOH before analysis by HPLC-MS using the conditions previously described and the
gradient indicated in Table 4.
• In DMF/H2O, 15:85. Azido sugar 1 (2 mM in DMSO, 5 µL), capture reagent 18 (0.3
mg, charge 0.34 mmol/g), CuSO4·5H2O (3 mM in H2O, 5 µL), sodium ascorbate (3 mM in
H2O, 5 µL), and TBTA (2 mM in H2O, 5 µL), were added to 100 µL of DMF/H2O, 15:85. The
samples were incubated for 1 h (rt, 120 rpm), centrifuged (rt, 10 min, 12000 rpm) and
the resulting resin was resuspended in a solution of DTT (50 mM in MeOH/H2O, 1:1, 100
µL), shaked for 1 h (rt, 120 rpm) and centrifuged (rt, 10 min, 12000 rpm). The
supernatant was then isolated, the solvent was removed and the residue was
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Experimental section
redissolved in 100 µL of MeOH before analysis by HPLC-MS using the conditions
previously described and the gradient indicated in Table 4.
• In PBS. Azido sugar 1 (2 mM in DMSO, 5 µL), capture reagent 18 (0.3 mg, charge 0.34
mmol/g), CuSO4·5H2O (40 mM in H2O, 5 µL), TCEP (40 mM in H2O, 5 µL), and TBTA (2 mM
in H2O, 5 µL), were added to 100 µL of PBS. The samples were incubated for 16 h (rt, 120
rpm), centrifuged (rt, 10 min, 12000 rpm) and the resulting resin was resuspended in a 
solution of DTT (50 mM in MeOH/H2O, 1:1, 100 µL), shaked for 1 h (rt, 120 rpm) and
centrifuged (rt, 10 min, 12000 rpm). The supernatant was then isolated, the solvent was
removed, and the residue was redissolved in 100 µL of MeOH before analysis by HPLC­
MS using the conditions previously described and the gradient indicated in Table 4.
4.2. Biology
4.2.1. Bacterial growth in the presence of azido sugars 1-12. Growing experiments 
were carried out in collaboration with Dr. Carles Úbeda (Centro Superior en Salud
Pública, Valencia). Bacteroides fragilis, Bacteroides thetaomicron, Prevotella copri, 
Lactobacillus rhamnosus, and Escherichia coli were incubated with the corresponding
azido sugar at the adequate concentration (100 µM for free hydroxyl azido sugars 1, 3, 
5, and 8 and 400 µM for peracetylated azido sugars 2, 4, 6, 7, 9, and 11) in basal peptone
yeast broth (10 mL for the incorporation experiments or 100 mL for those carried out in
higher scale) in an anaerobic chamber (Whitley DG250 Anaerobic Workstation) at 37 ᵒC. 
Optical density values were measured (Eppendorf Biophotometer Plus equipment) 
obtaining at 24 h values from 0.3 to 0.8.
4.2.2. Screening by 1H NMR of the incorporation of azido sugars 1-12 in bacteria
strains. Aliquots of 200 µL at time zero and 24 h were taken from the culture medium
and centrifuged (4 °C, 10 min, 12000 rpm, Mikro 220R (Hettich)) to separate the
supernatants from the pellets. 180 µL were taken from the supernatants and then mixed
with 20 µL of deuterated water. The samples were analyzed by 1H NMR in a 700 MHz
NMR equipment (Bruker). 
4.2.3. Analysis by flow cytometry and confocal microscopy of the incorporation of
azido sugars 1-12. The pellet of bacteria after 24 h of growing in the presence of the
tagged sugar was resuspended in a solution of bovine serum albumin (BSA) (0.01% in
H2O, 200 µL). Then, DBCO-FL-PEG4-BODIPY (2 mM in DMSO, 5 µL) was added and the
mixture was shaked for 16 h (rt, 120 rpm, THZ thermostatic shaker (Lan Technics)). After
that time, the sample was centrifuged (rt, 10 min, 12000 rpm), the supernatant was
removed and the pellet was washed with a solution of BSA (0.01% in H2O, 200 µL, 3x).
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Then, the pellet was permeabilized with a solution of PFA (3.7% in H2O, 500 µL), and
incubated for 1 h at 0 ᵒC protected from light. After centrifugation (rt, 10 min, 12000 
rpm), the resulting pellet was washed with a solution of NaCl (0.9% in H2O, 500 µL, 3x)
and resuspended in a solution of NaCl (0.09% in H2O, 900 µL). Then, a solution of
SYTO62 (50 µM in DMSO, 100 µL) was added. The samples were analyzed by FACS using
a 2FACScalibur citometer at the Cytometry and Fluorescence Microscopy UCM facilities.
For confocal experiments, 20 µL of the samples prepared for flow cytometry
experiments were taken, sealed in a slide cover at 0 ᵒC for 16 h and then visualized in a 
confocal microscope (Leica SP-8) at the Cytometry and Fluorescence Microscopy UCM
facilities.
4.2.4. Isolation of the different metabolomes fractions. The suspension of bacteria in
the culture medium was centrifuged (4 °C, 10 min, 12000 rpm) and the pellet separated 
from the culture medium (metabolome fraction A). The pellet was homogenized in
MeOH/CHCl3/H2O, 2:2:1 (200 µL), vortexed (Heidolph REAX), and centrifuged (4 °C, 10
min, 12000 rpm). The two phases were separated and after removal of the organic
solvent under an argon athmosphere and lyophilization (Telstar lyophilizer, Life Science)
of the aqueous phase, the two metabolome fractions corresponding to non-polar
(metabolome fraction B) and polar metabolites (metabolome fraction C), respectively,
were obtained.
4.2.5. Biorthogonal reaction and isolation of the tagged metabolites from azido
sugars 1-12
• Metabolome fraction A. Capture reagent 17 (330 mM in DMSO, 150 µL),
CuSO4·5H2O (1.7 M in H2O, 60 µL), TCEP (1.7 M in H2O, 60 µL), and TBTA (83 mM in H2O,
60 µL), were added to 1 mL of the metabolome fraction A isolated as described in 4.2.4.
Then, the samples were shaked for 3 h (rt, 120 rpm) and a suspension of streptavidin
beads (600 µL) in PBS (1.2 mL) was added (streptavidin beads were previously
centrifuged (rt, 10 min, 12000 rpm) to remove the glycerol of the commercial solution,
washed with PBS (2x), and suspended in PBS). The mixture was incubated for 90 min (rt,
120 rpm), centrifuged (rt, 10 min, 12000 rpm), and the pellet of beads washed with PBS
(2 x 1.2 mL). Then, the beads were resuspended in a solution of DTT (100 mM in
MeOH/H2O, 1:1, 200 µL), shaked for 1 h (rt, 120 rpm) and centrifuged (rt, 10 min, 12000
rpm). The supernatant was isolated, the solvent was removed, and the resulting residue 
was stored at -80 ᵒC until further analysis for structural elucidation.
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• Metabolome fraction B. Metabolome fraction B, isolated as described in 4.2.4.,
was redissolved in DMF/H2O, 15:85 (1 mL) and capture reagent 17 (333 mM in DMSO,
150 µL), CuSO4·5H2O (125 mM in H2O, 60 µL), sodium ascorbate (125 mM in H2O, 60 µL),
and TBTA (83 mM in H2O, 60 µL), were added. Then, the samples were shaked for 3 h (rt,
120 rpm) and a suspension of streptavidin beads (600 µL) in PBS (1.2 mL) was added
(streptavidin beads were previously centrifuged to remove the glycerol of the
commercial solution, washed with PBS (2x), and suspended in PBS). The mixture was
shaked for 90 min (rt, 120 rpm), centrifuged (rt, 10 min, 12000 rpm), and the pellet of
beads washed with PBS (2 x 1.2 mL). Then, the beads were resuspended in a solution of 
DTT (100 mM in MeOH/H2O, 1:1, 200 µL), shaked for 1 h (rt, 120 rpm), and centrifuged
(rt, 10 min, 12000 rpm). The supernatant was then isolated and the solvent was
removed under an argon atmosphere. The resulting residue was stored at -80 ᵒC until
further analysis for structural elucidation.
• Metabolome fraction C. Metabolome fraction C, isolated as described in 4.2.4.,
was redissolved in PBS (1 mL) and capture reagent 17 (330 mM in DMSO, 150 µL),
CuSO4·5H2O (1.7 M in H2O, 60 µL), TCEP (1.7 M in H2O, 60 µL), and TBTA (83 mM in H2O,
60 µL), were added. Then, the samples were shaked for 3 h (rt, 120 rpm) and a 
suspension of streptavidin beads (600 µL) in PBS (1.2 mL) was added (streptavidin beads
were previously centrifuged to remove the glycerol of the commercial solution, washed
with PBS (2x), and suspended in PBS). The mixture was shaked for 90 min (rt, 120 rpm),
centrifuged (rt, 10 min, 12000 rpm), and the pellet of beads washed with PBS (2 x 1.2
mL). Then, the beads were resuspended in a solution of DTT (100 mM in MeOH/H2O, 
1:1, 200 µL), shaked for 1 h (rt, 120 rpm), and centrifuged (rt, 10 min, 12000 rpm). The
supernatant was then isolated, and the solvent was removed under an argon
atmosphere. The resulting residue was stored at -80 ᵒC until further analysis for
structural elucidation.
4.2.6. Analysis of captured metabolites
Analyses of captured metabolites were done by LC-MS. Metabolites were separated
in a Kinetex-C18 column (1;7 μm, 150 mm x 21 mm) with a flow of 0;25 mL/min; The 
gradient mobile phase consisted of A (water) and B (methanol) with 0.1% formic acid as 
solvent modifier. The gradient is indicated in Table 5. MS analyses were carried out in a
Xevo G2-XS QTof spectrometer (Waters) in positive ionization mode from 50 to 1500
m/z and in UV-mode at 254 nm. MS analysis was performed with an ESI source and a 
time of flight (ToF) analyzer. The capillary voltage was set to 0.5 kV and the fragmentor
voltage was set at 10 or 30 eV for parent or fragment ion spectra, respectively. The
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drying gas temperature was 250 ᵒC, the drying gas flow was 10 L/min, and the nebulizer
pressure was 20 psi.
Table 5. HPLC-MS method used in the optimization of the detection of captured tagged 
precursors 
t (min) % B
0 2
2 2
20 100
24 100
24.1 2
30 2
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